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Kynurenine 3-monooxygenase is a FAD-dependent aromatic hydroxylase (FAH) which is a 
widely suggested therapeutic target for controlling the balance of bioactive metabolite 
levels produced by the mammalian kynurenine pathway (KP). Prior to starting this work 
no structural information was known for the enzyme, with studies of the human form 
complicated by the presence of a C-terminal transmembrane helix. The bacterial 
Pseudomonas fluorescens enzyme (PfKMO) lacks the transmembrane region and has 
been previously characterised by Crozier-Reabe and Moran [1, 2]. Therefore PfKMO, 
which shares 32 % sequence identity with the human enzyme, was selected as a target 
for structure solution. Initial substrate bound PfKMO crystals showed poor X-ray 
diffraction. Subsequent growth optimisation and the generation of a C252S/C461S 
PfKMO mutant (dm2) yielded crystals suitable for structure solution. Selenomethionine-
labelled substrate bound dm2 crystals were used to solve the first structure to a 
resolution of 3.40 Å. With just one protein molecule per asymmetric unit, a high solvent 
content was responsible for the poor diffraction properties of this crystal form. The 
overall fold resembled that of other FAH enzymes with a Rossmann-fold based FAD-
binding domain above a buried substrate binding pocket. Interestingly PfKMO possesses 
an additional, novel C-terminal domain that caps the back of the substrate-binding 
pocket on the opposite side to the flavin. Residues proposed to be involved in substrate 
binding were identified and shown to be highly conserved among mammalian KMO 
sequences.  
Subsequently single crystals of substrate-free dm2 PfKMO were obtained and showed 
significantly stronger diffraction due to new lattice packing in an orthorhombic space 
group bearing four molecules per asymmetric unit. The structure was solved to a 
resolution of 2.26 Å and revealed a clear conformational change of the novel C-terminal 
domain. This movement opens a potential route of substrate/product exchange between 
bulk solvent and the active site. The investigation of a set of C-terminal mutants further 
explored the relevance and mechanics of the conformational change. In addition the 
presence of chloride ions in the substrate-free crystal growth solution caused a small 
number of localised subtle alterations to the structure, with a potential chloride binding 
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site identified adjacent to the flavin cofactor. This may have relevance for the observed 
inhibition of PfKMO activity by monovalent anions – a feature widely common to FAH 
enzymes [3]. 
The first discovered KMO inhibitors were analogues of the substrate L-Kyn, however one 
such compound (m-NBA) was recently shown to instigate uncoupled NADPH oxidation 
leading to the release of cytotoxic hydrogen peroxide [1]. A set of substrate analogues 
were tested and characterised for inhibition of PfKMO. The picture was shown to be 
complex as some substrate analogues completely inhibited the enzyme whilst the 
binding of some still stimulated low-levels of NADPH oxidation. Crystallographic studies 
with m-NBA and 3,4-dichlorobenzoylalanine (3,4-CBA) bound revealed indistinguishable 
structures from that of substrate-bound PfKMO. These studies suggest that the analogue 
3,4CBA is a potent PfKMO inhibitor whose therapeutic potential may be re-visited. The 
previous most potent KMO inhibitor whose structure was not analogous to the substrate 
was Ro 61-8048 [4], which unfortunately did not pass pre-clinical safety tests. A novel 
series of 1,2,4-oxadiazole amides based on the structure of Ro 61-8048 was created by 
Gavin Milne (PhD, University of St Andrews) and tested on PfKMO. Rounds of refinement 
led to the discovery and refinement of low nanomolar competitive inhibitors of the 
bacterial enzyme. PfKMO was co-crystallised with each of the four most potent 
compounds forming a third different lattice arrangement, which yielded structures to 
resolutions of 2.15-2.40 Å. The structures displayed conformational changes resembling 
the substrate-free fold possibly caused by displacement of a crucial substrate-binding 
residue, R84.  
Overall the wealth of structural data obtained may be transferable to predictions about 
the structural features of human KMO and to the rational design of therapeutic 
inhibitors. The potent novel inhibitors tested may additionally present a new exciting 
development for the therapeutic inhibition of human KMO. 
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Abbreviations and units 
 
1. Amino acids 
The single and three letter amino acid codes listed below are used. Mutations are described 
by the symbol of the initial amino acid, the residue number and then the new residue 
symbol, e.g. R386T. 
 
Amino acid Three letter code Symbol 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartate Asp D 
Cysteine Cys C 
Glutamate Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
 
2. Nucleotides 
When referring to nucleotide sequences, the single letter abbreviations A, C, G and T are 




3-HAA 3-hydroxyanthranilic acid 
3,4-CBA 3,4 dichlorobenzoylalanine 
o
 Degrees (angles) 
oC Degree Celsius 
 Wavelength 
Å Angstrom 
Axxx Absorbance at xxx nm wavelength 
Axxx Change in absorbance in a set time period 
AP Acute pancreatitis 
ATP Adenosine-5’-triphosphate 
AVH Aklavinone-11-hydroxylase 
B-factor Temperature factor – measure of mobility of atoms within a structure 
ME -mercaptoethanol 
CNS Central nervous system 
Da (kDa) Daltons (kilodaltons) 
DNA Deoxyribonucleic acid 
dm2 C252S/C461S double mutant 
DHPH 2,6-dihydroxypyridine 3-hydroxylase 
DMSO Dimethyl sulphoxide 
DTT Dithiothreitol 
E.coli Escherichia coli 
EG Ethylene glycol 
FAD Flavin adenine dinucleotide 
FAH Class A flavin-dependent aromatic hydroxylase 
g (ng/g/mg/kg) Grams (nano/micro/milli/kilograms) 
GSH Glutathione 
h Hours 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid 
HpxO Urate oxidase 
HS Data for the highest resolution shell 
I/I Measure of the ratio of signal:noise of recorded reflections 
IC50 The concentration of inhibitor corresponding to 50 % enzyme activity 
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IPTG Isopropyl -D-1-thiogalactopyranoside 
KAT Kynurenine aminotransferase 
kcat Measure of the number of turnovers catalysed per second per enzyme 
Km Michaelis-Menten kinetic parameter for substrate affinity 
KMO Kynurenine-3-monooxygenase 
KP Kynurenine pathway 
KYNA Kynurenate 
LB Luria broth 
L-Kyn L-kynurenine 
M (nM/M/mM) Molar (nano/micro/millimolar) 
m (nm/mm) Meter (nano/millimetre) 
mg Milligrams 
MHPCO 2-Methyl-3-hydroxypyridine-5-carboxylic acid oxygenase 
mins Minutes 
m-HBH 3-Hydroxybenzoate hydroxylase 
m-NBA Meta-nitrobenzoylalanine 
MOPEG Methoxy poly-ethyleneglycol 
MPD 3-Methyl-1,5-pentadiol 
MWCO Molecular weight cut-off 
NAD/NAD+ icotinamide adenine dinucleotide 
NADPH/NADP+ Nicotinamide adenine dinucleotide phosphate  
NMDAr N-methyl-D-aspartic acid receptor 
ODxxx Optical density at xxx nm 
pdb Protein databank 
PEGx Poly-ethyleneglycol, average molecular weight of x  
Pf Psuedomonas fluorescens 
p-HBH Para-hydroxybenzoate hydroxylase 
PhH Phenol hydroxylase 
pIC50 Equivalent to value of Log(1/IC50)  
PMSF Phenylmethanesulphonylfluoride 
QUIN Quinolinate 
Rmerge Measure of agreement of multiple measurements of the same reflection 
R Measure of agreement between observed and calculated crystal data 
Rfree As above but for a sub-set of reflections excluded from refinement 
viii 
rmsd Root means square deviation 
s Seconds 
SDS Sodium dodecyl sulphate 
SeMet L-selenomethionine 
TetX Tetracycline monooxygenase 
TLS Translation libration screw-motion 
UV Ultraviolet 
Vis Visible 
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Chapter 1 – Introduction 
1.1 The kynurenine pathway 
1.1.1 Overview of the kynurenine pathway 
Tryptophan is an amino acid that the human body must obtain externally. In mature 
mammals, the cellular tryptophan pool for protein synthesis is mostly maintained by 
protein degradation. This leads to >90 % of dietary tryptophan being catabolised via the 
kynurenine pathway (KP) (figure 1.1), into NAD+, with the rest utilised for the synthesis 
of serotonin or tryptamine. NAD+ is imperative to numerous cellular processes including 
ATP production and poly(ADP-ribose)polymerase activity. The KP is the major route for 
NAD+ synthesis. Along the pathway numerous stable intermediates are generated, 
several of which have physiological and/or pathophysiological implications. This 
combined with the presence of pathway branch points has meant that control of the 
activities of enzymes acting along the pathway has proved crucial for maintaining a 
healthy balance of the metabolites. As a result the KP has been implicated in the 











Figure 1.1. Overview of the 
kynurenine pathway. The major 
route of metabolism is signified by 
unbroken arrows with each number 




1.1.2 Regulation of the ratio of Trp:L-Kyn 
The first step of the KP is the enzymatic cleavage of the indole-ring of tryptophan (Trp) 
into the transient intermediate formylkynurenine (FKyn). FKyn is rapidly converted into 
the first stable intermediate of the pathway, L-kynurenine (L-Kyn). The oxidation of Trp is 
catalysed by the enzymes tryptophan 2,3-dioxygenase (TDO) in the liver and indoleamine 
2,3-dioxygenase 1 (IDO-1) and 2 (IDO-2) extra-hepatically. TDO and IDO may both be 
heme-proteins that catalyse the same reaction however their sequences and structures 
are unrelated with differential properties regarding: substrate selectivity, specific 
inhibition and activation/up-regulation. Certain cytokines and pro-inflammatory 
molecules released during an immune response have been found to stimulate the up-
regulation of IDO-1 expression and activity. The most potent stimulant was found to be 
interferon gamma (IFN-) [5, 6] with stimulation also evident with IFN-tumour necrosis 
factor  (TNF-), lipopolysaccharides,  amyloid  peptide 1-42, human 
immunodeficiency virus (HIV) proteins and interleukin-I[7-11]. IDO activation depletes 
Trp levels and has been shown to be critically involved in the mechanism of antimicrobial 
and antitumoral defence [12, 13]. 
In the past decade it has become clear that inflammation is a primary pathophysiological 
mechanism in many chronic illnesses [14, 15]. Raised levels of pro-inflammatory factors 
and cytokines have been associated with and shown to contribute to the development of 
dementia [16, 17], Alzheimer’s disease (AD) [18, 19] amyotrophic lateral sclerosis [20] 
and major depression [21] among others. The immune-stimulated up-regulation of IDO-1 
reduces serum Trp concentrations by 25-50 %, which raises concentrations of L-Kyn 
whilst proportionally decreasing the amount of Trp available for the generation of 
serotonin [22, 23]. The subsequent decrease in Trp levels has been shown to efficiently 
inhibit T-cell proliferation [24, 25] leading to an implication in the development of 
immunodeficiency and immunotolerance. Lowered Trp and raised L-Kyn concentrations 
have been discovered in patients with end-stage renal disease [26] and ovarian cancer 
[27], and have been directly correlated with decreased levels of CD4+ T cells in HIV 
patients [28-30]. In addition to this, up-regulated IDO-1 was found to be specifically 
associated with neurofibrillary tangles and senile plaques [31] – both hallmarks of the 
pathophysiology of AD – and with severity of chronic kidney disease [32] among others. 
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Inflammatory immunoactivation can also influence the activities of more KP enzymes 
downstream of IDO, as shown in several human cell lines [33-35]. This altered KP 
regulation also affects the balance of levels of other KP intermediates that might be 
influential in pathophysiology, as we will see in the following sections. A complicating 
factor in the study of the KP in models of disease though is the fact that expression and 
activation of the KP enzymes varies between: species, cell types and even throughout 
the development of certain cell lines [35-39]. As a result care must be taken in assessing 
the therapeutic relevance of findings relating to the KP in animal models of disease. Such 
models are still useful to further our broader understanding of the physiological and 
pathophysiological involvements of KP metabolites. 
 
1.1.3 Neurotoxicity versus neuroprotection; QUIN and KYNA 
Interest in KP metabolites was prompted when kynurenate (KYNA) and quinolinate 
(QUIN) were found to act as antagonist and agonist respectively on the excitatory 
glutamate receptor NMDAr in the CNS [40, 41]. NMDAr over-stimulation causes an influx 
of calcium ions that causes disruption of mitochondrial functions and leads to the 
generation of cytotoxic reactive oxygen and nitrogen species (ROS and RNS) [42-44]. This 
process is known as excitotoxicity and ultimately leads to cell death. The question arose 
– could one KP metabolite QUIN contribute to excitotoxicity whilst another KYNA offered 
a counteracting neuroprotective role? With the two metabolites on separate branches of 
the KP, misregulation of the enzymes governing each route and therefore the imbalance 
of these two molecules could be a factor in the pathophysiology of numerous diseases. If 
true this would create a therapeutic opportunity to restore this balance by restricting the 
QUIN-generating route of the KP as discussed extensively elsewhere [45-49].  
 
1.1.3.1 KYNA and neuroprotection 
The biggest query regarding the hypothesis above was surrounding the hoped 
neuroprotective ability of KYNA. At high concentrations, KYNA blocks both the 
glutamate-binding site of the NMDAr, however at low concentrations it can block the 
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allosteric glycine site of the NMDAr as well as the 7-nicotinic acetylcholine receptor 
(7-nAChr) [47]. The IC50 against the 7-nAChr was determined to be only 7 M. The 
strength of KYNA antagonism at the NMDAr has been published as low to high 
micromolar values – for example the IC50 for KYNA competing with glycine was 
determined to be 238 M [50] and around 8 M [51] in separate studies with cultured 
neurons. In the rat brain it was determined that 10-40 M KYNA was required to 
substantially inhibit hippocampal synaptic transmission [52]. Under physiological 
conditions, KYNA is present in the human brain at nanomolar concentrations (up to 1 
M) and in rat brains it was measured at <100 nM [53]. As a result speculation arose as 
to whether KYNA levels in the brain ever reach levels sufficient to significantly inhibit the 
NMDAr and counter the stimulation by QUIN.  
Numerous studies have noted the neuroprotective effect of small increases in levels of 
KYNA with a reduction in locomotor activity, convulsion strength and frequency and 
excitotoxic neuronal damage [54-59]. Using in vivo and ex vivo models, post-ischemic 
brain damage was significantly reduced as a result of two to three-fold increases in KYNA 
concentrations [60, 61]. An increase in KYNA at low nM concentrations directly and 
drastically reduced extracellular brain Glu content in the rat caudate [62]. It has 
therefore been speculated that in fact the local synaptic KYNA concentrations may be 
significantly higher than the overall measurements made from whole tissue 
homogenizations [52]. Therefore in specific areas levels of KYNA may reach sufficient 
levels to show significant inhibition of excitatory amino acid receptors and block synaptic 
transmission. Otherwise it may be possible that KYNA additionally acts via an alternate 
NMDAr-independent mechanism to decrease concentrations of Glu. It has been reported 
that KYNA selectively activates a G-coupled protein receptor (GPR35) [63], which may 
contribute towards the observed reduction of Glu release [64]. 
Decreased levels of KYNA have been associated with the pathophysiology of several 
diseases including major depression [65], Alzheimer’s disease [66] and renal cancer [67]. 
After twenty-two years of following patients who suffered from schizophrenia, those 
who attempted suicide had lower concentrations of KYNA in the CSF (0.8 nM compared 
to 1.7 nM) [68]. Outside of the CNS, KYNA concentrations in the kidney were found to be 
over three-times higher than healthy controls in kidney tumour tissue [67]. Moreover, in 
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vitro experiments showed that high micromolar concentrations of KYNA could 
significantly inhibit proliferation, DNA synthesis and migration of renal cancer Caki-2 
cells. The mechanism of this inhibition was shown to involve KYNA-dependent over-
expression of the cyclin-dependent kinase inhibitor p21 Waf1/Cip1 [69]. So outside of 
the CNS artificially-raised KYNA levels may be beneficial in the therapeutic treatment of 
cancers. 
On the other hand, raised levels of KYNA have also been associated with several diseases 
including: the pathophysiology of schizophrenia [42, 70, 71], the high invasiveness and 
rapid progression of specifically adenocarcinoma among lung cancer patients [72], 
complex partial seizures in epilepsy patients [73] and human cataractous lenses [74]. In 
another example, a study of patients with long-term cognitive impairment associated 
with tick-borne encephalitis discovered dramatically raised levels of KYNA [25]. Sufferers 
had mean and maximum CSF KYNA concentrations of 5.3 nM and around 70 nM 
respectively compared to healthy age-matched controls who averaged 0.99 nM with a 
maximum concentration of 4 nM. Therefore there appears to be a need to maintain a 
balance between too little and too much KYNA depending on the specific subcellular 
location - but particularly in the brain - as recently reviewed elsewhere [75]. 
 
1.1.3.2 QUIN-mediated cytotoxicity 
Studies of the potential dangers associated with QUIN have been more conclusive. QUIN 
has grown into a notorious cytotoxic villain since it was discovered to directly cause 
necrosis upon intracerebral injection [76] and when added to in vitro neuron cultures 
[77]. Raised levels of QUIN have since been shown to directly contribute to cytotoxicity 
in cases of AIDS dementia complex caused by infection with HIV-1 [78-80], Poliovirus 
brain infection [81], cerebral malaria [82], multiple sclerosis [83], cerebral ischemia [84] , 
epilepsy [85, 86], Huntington’s disease [87, 88] and Alzheimer’s disease [89, 90].  
Physiological levels of QUIN have been determined to be nanomolar in the brain [91] and 
nano to micromolar in the CSF [92]. Sub-physiological QUIN concentrations greater than 
150 nM have been shown to be cytotoxic in primary cultures of human neurons [93]. 
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These effects were significantly attenuated by treatment with the NMDAr blockers: 
MK801 and memantine, as well as with the nitric oxide synthase (NOS) inhibitor, L-
NAME. Interestingly it has been suggested that the enzyme responsible for directly 
catabolizing QUIN – QPRTase – is easily saturated at low QUIN concentrations [94]. In 
vitro, QPRTase activity began to saturate at around 300 nM QUIN [95]. This could explain 
the apparent CNS accumulation of QUIN seen in the aforementioned diseases and 
disorders. The most dominant cells in the CNS – astrocytes – are unable to generate 
QUIN as they do not express the enzyme KMO in humans [34]. The majority of QUIN 
within the brain is in fact produced by infiltrating macrophages and immune-activated 
resident microglia. It is believed that the elevated L-Kyn surrounding astrocytes can be 
used by such neighbouring macrophages and microglia to produce extra QUIN, 
particularly during a local inflammatory response [34].  
Raised levels of QUIN are known to be involved in several cytotoxic mechanisms 
including some independent of NMDAr stimulation, as extensively reviewed recently [94, 
96]. Firstly, QUIN has been shown to form a complex with Fe2+, which increased the 
generation of hydroxyl radicals that directly promoted lipid peroxidation and DNA 
damage [97]. Parallel to this, intrastriatal injection of QUIN  in rats was shown to 
stimulate lipid peroxidation within two hours and this correlated with raised 
extracellular levels of hydroxyl radicals [98, 99]. Oxidative stress via free-radical 
generation has emerged as the major route of QUIN-mediated cytotoxicity [100]. 
Antioxidants including melatonin, 6-hydroxymelatonin, selenium, L-carnitine, spermine 
and statins, among others, suppress the destructive consequences of QUIN 
administration, whereas they are ineffective on the cytotoxicity induced by other NMDAr 
agonists and NMDA itself [99-106]. Methods of reducing QUIN concentrations via the 
inhibition of KP enzymes such as KMO may be an effective therapeutic supplement to 




1.1.4 Cytotoxicity mediated by 3-HK  
The KP intermediate 3-HK, which is produced from L-Kyn by the enzyme KMO, has been 
shown to cause cytotoxicity by the generation of ROS. In neuronal hybrid cell line 
cultures, addition of 3-HK to concentrations greater than 100 M was toxic to more than 
85 % of the cells over a period of 24 hrs [107]. A role for oxidative stress – specifically via 
hydrogen peroxide build up and metal ions – was implicated as catalase, glutathione, 
peroxidase or iron chelator (desferrioxamine) treatment significantly attenuated the 
cytotoxicity caused by 3-HK [108]. In a later study, intrastriatal injection of just 50 nM 3-
HK into rat brains induced local tissue damage with greater sensitivity than via injection 
of QUIN [109]. Moreover the potent NMDAr antagonist MK-801 attenuated only QUIN-
induced toxicity whereas the antioxidant N-acetyl-L-cysteine reduced 3-HK induced 
damage. Interestingly co-administration of just 5 nM 3-HK and 15 nM QUIN – levels of 
each harmless by themselves – to rat brains caused substantial neuronal loss [110]. 
Under physiological conditions, 3-HK was shown to form reactive autoxidation products 
whilst also generating cytotoxic hydrogen peroxide and hydroxyl radicals [111]. These 
studies led to the suggestion that 3-HK-mediated cytotoxicity proceeded differently to 
the QUIN NMDAr activation mechanism via the generation of free-radical forming ROS 
and ultimately causes cell death with apoptotic features [112].  
At physiological concentrations, 3-HK has been shown to have beneficial roles in UV 
absorption and as an antioxidant [113-117]. In humans the average serum 3-HK 
concentration under physiological conditions has been measured to be 383 nM [73]. In 
primary cultures of mixed cortical cells, the minimum concentration of 3-HK required to 
cause a significant degree of neurotoxicity was 100 M and just 1 M in relation to 
exposure times of 24 hrs and 72 hrs respectively [112]. Similarly 3-HK concentrations of 
1-100 M caused cell death to primary neuronal cultures from the rat striatum [118]. 
Significantly raised 3-HK levels have been correlated with: vitamin B6 deficiency [119, 
120], the prevalence of increased oxidative stress and cardiovascular disease among 
patients with end-stage renal disease [26], chronic renal insufficiency [121], bacterial 
endotoxin exposure in rat CNS [122], patients with Alzheimer’s disease [123], 
Huntington’s disease [124-127], development of cataracts in human lens [128-131], HIV-
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associated dementia [132], experimental malaria in mice [82] a decline in memory and 
learning in Drosophila [133] and an experimental rat model of multiple sclerosis [83]. 
Acute pancreatitis (AP) involves inflammation of the pancreas which can be mild and 
self-limiting, however in 20% of cases it leads to multiple organ failure with a 30-50% 
mortality rate. In 2008, Mole et al [134] showed the mesenteric lymph to be directly 
involved in the development of acute lung injury in AP. Moreover they showed a 
correlation linking raised mesenteric kynurenine and 3-HK levels to the severity of AP 
lung injury in rats. Raised kynurenine levels were also observed in the plasma of AP 
patients. The cytotoxicity of AP mesenteric lymph on lung HCT116 cells was reproduced 
in vitro with exogenous 3-HK. Whilst the cause of raised 3-HK levels was not established, 
it was suggested that decreasing mesenteric lymph 3-HK levels could be an effective way 
of preventing the development of multiple organ failure in AP patients. 
 
1.1.5 Other bioactive KP metabolites 
The next intermediate generated in the KP after 3-HK is 3-HAA. Under physiological 
conditions, 3-HAA has implications as an antioxidant in rat cerebral cortex [117] and has 
been suggested as a natural regulator of T-cell expansion and activation [135]. At 
different concentrations it significantly inhibited NF-B activation (10-50 M 3-HAA) and 
caused apoptosis (100-500M 3-HAA) specifically among CD4 T-cells. At low g doses, 3-
HAA treatment significantly attenuated the symptoms of experimental asthma in mice, 
linked to the suppression of T-helper cell mediated inflammation. Like 3-HK, 3-HAA can 
be oxidised to generate ROS in the presence of Cu(II) and molecular oxygen [136]. 
Reduced serum 3-HAA levels were associated with epilepsy in a mouse model and in 
patients [137]. This could possibly involve overactive 3-HAA oxygenase converting extra 
3-HAA into the excitotoxin QUIN. A decreased ratio of 3-HAA:AA has been detected in a 
range of disorders as summarised in 2010 [138] and was speculated to be a protective 
response. Moreover AA is an effective competitive inhibitor of 3-HAA oxygenase [35] and 
so its build-up would largely prevent the generation of QUIN to reduce local cytotoxicity.  
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The product of 3-HAA oxygenase is actually a transient intermediate (2-amino-3-
carboxymuconate-6-semialdehyde), which subsequently undergoes a non-enzymatic 
transformation into QUIN. This transient intermediate can also be competitively and 
enzymatically converted into another stable KP metabolite – PIC. Little was really known 
about the biological significance of this molecule a part from its metal chelating 
properties [139]. PIC has shown uncharacterised antagonistic properties towards the 
cytotoxicity of QUIN [140, 141]. High PIC concentrations of 1-4 mM have shown an 
enhancement of macrophage effector functions and anti-viral properties [142]. The 
likelihood of these effects being reproduced in humans is small as physiological PIC 
concentrations have been reported to be thousands of times smaller in the low to mid 
nanomolar range [143]. 
 
1.1.6 Summary of the KP 
In all the KP presents a complex balance of biologically active intermediates with serious 
implications in the pathophysiology of numerous inflammatory diseases (see table 1.1). 
The pathway branches at the stable intermediate L-Kyn with three possible routes. 
Damaging irregularities in intermediate levels could be corrected by the inhibition of 
KMO and subsequently of its associated pathway branch. This would suppress levels of 
the cytotoxic 3-HK and QUIN whilst raising levels of the neuroprotective compound 
KYNA. Normal levels of NAD production can be maintained by the side-branch via the 
intermediate AA. Several reviews have suggested that KMO inhibition may provide a key 
therapeutic tool in the treatment of many of the aforementioned conditions associated 
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1.2 Flavin-dependent aromatic hydroxylases 
1.2.1 Biological flavin cofactors 
The biological flavins – flavin mononucleotide (FMN) and flavin adenine dinucleotide 
(FAD) – have key catalytic and electron transport roles in metabolic pathways. The key 
conserved flavin moiety is a tricyclic isoalloxazine ring, which can exist in several redox 
states. These are illustrated in figure 1.2. Interestingly flavins are able to accept and 
donate either one or two electrons and as such have been utilised in a variety of 
Table 1.1. Summary of the biological and pathophysiological properties of metabolites 
generated by the KP. 
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biochemical processes. Oxidised flavins are photoreducible, with a yellow colour that 
turns to blue for the semiquinone radical and red for the anionic state. When totally 
reduced, flavins are colourless. They also store energy, which is released as high-energy 
electrons upon oxidation due to the stabilisation effect created by the formation of a 
more conjugated aromatic ring system. This process is utilised in the electron transport 
chain in the mitochondria. The different flavin redox states are also crucial to catalysing 
and controlling many metabolic reactions. For example when in the reactive reduced 
state flavins can react with oxygen as will be discussed in the following sections. 
 
                
 
 
1.2.2 Flavoprotein monooxygenases 
In free solution, the reaction between reduced flavins and molecular oxygen generates 
hydrogen peroxide. The rate of reaction however is slow due to the need for oxygen spin 
inversion and the formation of unstable radical intermediates [146]. Molecular oxygen 
has a triplet spin in its ground state with two unpaired electrons whilst organic 
compounds such as flavins are diamagnetic singlets. Therefore in the reaction with 
oxygen, the highly reactive radical species superoxide and flavin semiquinones are 
formed. Flavoprotein monooxygenases/hydroxylases (FHs) have evolved to increase this 
rate of reaction by developing specialised local environments to stabilise particular oxy-
flavin intermediates. As more FHs have been discovered and studied over the past 
Figure 1.2. Different oxidation states of the flavin isoalloxazine 
ring system found in FMN and FAD cofactors. 
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decade, they have been extensively reviewed and categorised [3, 147, 148]. These 
enzymes stabilise either a C4a-peroxyflavin or a C4a-hydroperoxyflavin intermediate to 
catalyse the respective reaction with their substrate(s). The very reactive nature of such 
intermediates is then utilised for varied catalytic tasks including hydroxylation, 
epoxidation, halogenation and more (see figure 1.3). Subsequently water is released to 
return the flavin to the oxidised state prior to the next round of catalysis. Without 
sufficient control over flavin reduction, the C4a-(hydro)peroxyflavin can decay to release 
the strong oxidiser hydrogen peroxide. To prevent this uncoupling of flavin reduction, 
FHs employ two different mechanisms whereby either flavin-reduction is ineffective until 




Figure 1.3. Summary of the different catalytic processes catalysed by flavoprotein hydroxylases [147] 
All FHs non-covalently bind either an FAD or FMN flavin cofactor and most are classed as 
external as they reduce their flavin with electrons from free coenzymes in solution. 
Some rare examples of internal FHs exist where the flavins are reduced by the respective 
substrate, as is the case for lactate monooxygenase [149]. ‘Life’ is complicated for 
external FHs as the reactions they catalyse involve two chemical processes requiring very 
different environments. The first reaction involves flavin reduction and requires flavin 
exposure to solvent. Following from this is the flavin reaction with oxygen and 
subsequent catalysis. The reactive flavin-oxygen intermediate can only be maintained by 
shielding it from solvent. Two-component external FHs use two enzymes to overcome 
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this; with one involved in reducing the flavin cofactor and then transferring it to the 
other for catalysis [148]. Single-component external FHs can coordinate both 
requirements in one enzyme using different conformational states (See section 1.2.3). In 
2006, external FHs were categorised into six sub-classes A-F based on similarity in 
sequence or in structural characteristics [147].  
   
1.2.3 Class A flavin-dependent aromatic hydroxylases 
The enzyme KMO belongs to subclass A of the external FHs, known as flavin-dependent 
aromatic hydroxylases (FAHs). FAHs are encoded by a single gene with one dinucleotide 
binding domain that contains a tightly non-covalently bound FAD cofactor. Flavin 
reduction results in immediate release of NAD(P)+. The intermediate formed is a C4a-
hydroperoxyflavin which catalyses mainly hydroxylation reactions via electrophilic attack 
of an aromatic substrate which typically contains an activating hydroxyl or amino group. 
Flavin reduction is stimulated only upon substrate binding to prevent uncoupled 
degradation of the flavin-oxygen intermediate to release hydrogen peroxide. In para-
hydroxybenzoate hydroxylase (p-HBH) the presence of substrate stimulated the rate of 
flavin reduction by NADPH by a factor of >100,000-fold [150]. Catalysis by FAHs displays 
a marked sensitivity to the presence of small monovalent anions such as Cl-. In p-HBH, 
inhibition by halogen ions was studied in detail and shown to be competitive with 
NADPH and a mixture of competitive and non-competitive with respect to the substrate 
[151]. The strongest inhibition was seen with chloride ions with a Ki of 5.9 mM. The 
much-studied p-HBH is the prototypal FAH from which most of the known FAH structural 
and mechanistic information was elucidated. 
 
1.2.3.1 Structural studies of para-hydroxybenzoate hydroxylase 
The FAH enzyme p-HBH was first purified and studied from three bacterial Pseudomonas 
strains over forty years ago [152-154]. The enzyme was successfully crystallised with 
substrate in 1975 [155], with the resulting structure published in 1979 (depicted in figure 
1.4) [156]. Interestingly this crystal growth was unrepeatable for a further decade until a 
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study on the influence of protein heterogeneity in 1989 [157]. It was discovered that 
strongly diffracting p-HBH crystals could only be generated from purely dimeric protein 
possessing a reduced SH group on residue C116. From this a structure emerged with 
substrate bound to a resolution of 1.9 Å [158]. Since then numerous mutagenic and 
structural studies of p-HBH have elucidated key features of the interactions and 




The major developments that came from studies of p-HBH surrounded the discovery of a 
proposed ‘wavin’ flavin’ conformational change to create the different solvent 
environments required during catalysis. An alternate flavin conformation was first seen 
in the structure of Y222F p-HBH in complex with substrate [159]. The electron density 
(figure 1.5) revealed a mixture of the previously seen ‘in’ and the new, more solvent 
exposed ‘out’ conformation for the flavin’s isoalloxazine moiety. Moreover, in the 
structure of wt p-HBH complexed with a substrate analogue – 2,4-dihydroxybenzoate 
(DOB) - only the flavin’s ‘out’ conformation was seen [160]. Here the out conformation 
of the flavin was stabilised by hydrogen bonds with the added hydroxyl on the substrate 
Figure 1.4. Cartoon representation 
of the structure of p-HBH (pdb code 
1pbe) with FAD (yellow) and the 
substrate (cyan) shown in spheres. 
The protein is split into three 
domains coloured blue, purple and 
red. 
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analogue DOB and the side chain of Y222. Only the flavin appeared to move relative to 
the structure of wt substrate bound p-HBH (figure 1.6). The flavin movement was 
supported by spectroscopic measurements, which showed different spectral changes 
upon the addition of substrate or DOB, and later by Raman spectroscopy [161]. The 
flavin movement in solution was again investigated with a modified flavin cofactor, 6-
azido-FAD, incorporated into p-HBH [162]. The azido group was photoactivated into the 
highly reactive nitrene group by visible light. When the flavin occupied the ‘out’ 
conformation this group could react with water whereas in the ‘in’ position it reacted 
and covalently cross-linked with the protein. In the absence of substrate the cross-linked 
yield was 80 % compared to 66 % with substrate and only 17 % when DOB was present. 
Further studies of the cross-linked protein showed that with the flavin fixed in the in 
position, both substrate exchange and reduction by NADPH occurred at a substantially 
decreased rate. In all these results correlated well to strongly confirm the 
crystallographically-observed flavin movement and imply its role in substrate entry and 
NADPH-mediated flavin reduction. 
 
                   
 
Figure 1.5. Electron densities for the 
two flavin conformations – in (blue) 
and out (yellow) in the Y222F p-HBH 
mutant (pdb code 1dob) as taken 
from Gatti et al., 1994 [159]. 







As FAH enzymes use external NADPH to reduce the flavin, there is no well-defined 
NADPH binding site. Instead NADPH transiently docks at the surface of the enzyme and is 
immediately released after flavin reduction. As a result, no native structures with NADPH 
bound have been obtained to date. In 2002, a NADPH-bound pHBH structure (figure 1.7) 
was obtained using a R220Q mutant form of the enzyme [163]. This substitution 
favoured the open conformation of the enzyme and dramatically diminished the 
substrate binding affinity. As a result the first substrate free pHBH structure was also 
obtained with this mutant. It was postulated that upon substrate binding the flavin 
swings out and the NADPH bends into a folded conformation to bring the isoalloxazine 
and nicotinamide moieties into close contact. A lot of the residues interacting with 
NADPH in the structure (including R44, F161, H162 & R269) had previously been shown 
to be important in NADPH binding from mutagenesis studies [164-167]. In contrast 
though, Y38 and R42 had also been implicated in the binding of the 2’-PO4 of NADPH 
Figure 1.6. Two flavin conformations seen in the structures of 
substrate-bound (blue) and DOB-bound (yellow) wt p-HBH. The 
substrate analogue stabilises the flavin out conformation via 
the formation of two hydrogen bonds. Created using PyMol 
Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC. 
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[168, 169] whereas they were close but didn’t directly interact in the presented 
structure. This left doubt as to whether the presented mutant enzyme’s NADPH binding 





1.2.3.2 Structural information from other FAHs 
In addition to p-HBH, numerous FAH crystal structures have recently emerged including 
those of: phenol hydroxylase (PhH) [170], 2-methyl-3-hydroxypyridine-5-carboxylic acid 
oxygenase (MHPCO) [171], RebC [172], , 2,6-dihydroxypyridine 3-hydroxylase (DHPH) 
[173], aklavinone-11-hydroxylase (AVH) [174], m-hydroxybenzoate hydroxylase (m-HBH) 
[175], tetracycline monooxygenase (TetX) [176], two aromatic polyketide hydroxylases 
(PgaE and CabE - [177]), urate oxidase (HpxO) [178] and two FAD-dependant 
monooxygenases with unknown substrates (PQSL - [179] and phzS - unpublished). The 
structures share low sequence identities averaging at 10-20 % but with conservative 
rmsd values of 2.0-3.5 Å2.  
Figure 1.7. Surface view of the R220Q mutant p-HBH structure (pdb code 1k0j) 
with NADPH (magenta sticks) bound in a groove adjacent to the FAD-binding site. 
Figure created using PyMol. 
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As can be seen in figure 1.8, the structures in fact share very similar overall folds with 
highly conserved structural elements for the two domains decribed for p-HBH. Some FAH 
enzymes possess additional thioredoxin-like C-terminal domains with no known 
functional roles. The conserved first two domains comprise up to around 370-400 
residues with the C-terminal extensions ranging from a further 20-250 residues. In all 
cases the flavin cofactor is tightly bound in a superimposable cleft near the surface of the 
enzymes with the respective substrate bound in a buried pocket beneath the 
isoalloxazine moeity. The previously mentioned different flavin conformations are 
represented in different FAH structures but are not dependent simply upon the 
presence/absence of substrate. In some cases, binding of the substrate immediately 
appears to cause flavin movement to the out position. Where this does not happen it is 
possible that the actual docking of NADPH directly causes the flavin movement. In such 
cases this still must only be allowed to happen in the presence of substrate to prevent 











From these structures and from studies of p-HBH, three conserved motifs were 
discovered for the identification of FAHs [166]. In all FAH enzymes the motifs are present 
in relatively similar locations in terms of primary sequence and three-dimensional 
structure. The first motif is conserved among the majority of single-component 
flavoenzymes, however the second and third motifs are typically only found among the 
FAH subclass. As can be seen in table 1.2, all three are conserved in the sequence of 
human KMO. 
Figure 1.8. Cartoon representation of published FAH crystal structures with FAD (yellow) and the respective 
substrate (blue) shown in spheres. The structures are arbitrarily split into three domains in blue, purple and red 
respectively to show the similarity in the fold of the first two domains but the variation in the layout of the 
third, C-terminal domain. The respective pictures represent: row 1 = TetX (pdb code: 2y6q), MHPCO (3gmc), 
PQSL (2x3n), DHPH (2vou), row 2 = p-HBH (1pbe), HpxO (3rp7), PhzS (3c96), row 3 = CabE (2qa2), PgaE (2qa1), 








1.3 Kynurenine 3-monooxygenase (KMO) 
 
1.3.1 Overview of KMO 
KMO catalyses the hydroxylation of L-kynurenine into 3-hydroxykynurenine whilst 
consuming external NADPH and molecular oxygen. It has been classified as a member of 
the FAH family of enzymes due to the presence of the three aforementioned highly 
conserved motifs and from mechanistic studies [1]. KMO is a key player in the 
mammalian kynurenine pathway and acts in certain degradation pathways present in 
some species of bacteria and fungi. All KMO proteins are between 437-513 residues long 
with the eukaryotic sequences all appearing to contain a C-terminal trans-membrane 
helix. Whilst no KMO structures had been solved prior to this investigation, the enzyme 
had been purified and studied from several sources.  
 
 
Motif Location* Function Human KMO sequence 
VhhhGsGhhGhhhs Near N-terminus Binding ADP moiety 
of FAD - -fold 
[180] 
VAVIGGGLVGSLQA 
chhhssDGxcSxhR ~ position 150-200 In contact with 
riboflavin moiety of 
FAD 
DLIVGCDGAYSTVR 
hhLhGDAAHxxxPxxGxGxN ~ position 300 Important to FAD 
and NADPH binding 
CVLLGDAAHAIVPFFGQGMN 
Table 1.2. Description of the three conserved sequence motifs found among FAH enzymes and the relative 
sequence composition in human KMO. h = any hydrophobic residue, s = any small residue (G/A/C/S), c = any 
charged residue and x = any residue. Residues underlined are strictly conserved. The human KMO sequence 
residues that are not bold and in italic font do not fit with the generalised motif. *The motif location is relative 
to the amino acid sequence.  
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1.3.2 Studies of mammalian KMOs 
Kynurenine 3-monooxgenase (KMO) was first isolated in a partial purification from rat 
liver mitochondria in 1957 [181]. The enzyme was shown to convert L-kynurenine (L-Kyn) 
into 3-hydroxykynurenine (3-HK) in the presence of NADPH and O2. An experiment with 
18O confirmed that the oxygen atom incorporated into the product came from 
atmospheric oxygen and not from water. A further decade passed until further 
characterization confirmed that the enzyme was exclusively localised in the outer 
mitochondrial membrane (OMM) in preparations from rat liver [182] and that it required 
flavin adenine dinucleotide (FAD) [183]. In 1969, KMO from rat liver mitochondria 
solubilised and partially purified with ammonium sulphate fractionation was shown to be 
independent of OMM cytochromes and also able to utilise NADH for catalysis [184]. By 
1975, a complete yet complex purification procedure was developed to isolate pure 
solubilized rat liver KMO [185]. It was concluded that addition of 1 % Triton X-100, 1 mM 
DTT and 5 mM FAD stabilised the enzyme during purification, that the protein was pure 
with a rough molecular weight of 200 kDa, and that the coenzyme FAD was easily 
dissociable. Further advances in chromatography simplified the procedure as it was 
found that the enzyme successfully bound to NADP-agarose but not to L-kynurenine or 
AMP coupled columns [186]. Characterization of the enzyme was still proving difficult 
though due to its membrane association, apparent oligomerization in solution and co-
purification with haem-containing cytochromes. As a result assessments of the 
monomeric molecular weight and flavin content of KMOs had been wildy variable. 
Almost two decades passed until real progress was seen in the characterization of 
mammalian KMO enzymes. At this stage PCR amplification and DNA sequencing were 
becoming phenomenal tools in developing the understanding of enzymes and their 
relationships. Firstly in 1997, DNA encoding human liver KMO was isolated from 
hybridization screening using a probe containing exon 2 of Drosophila melanogaster 
KMO [187]. After sequencing the 2.0 kb gene was predicted to encode for a 486 residue 
protein with a molecular mass of 55.7 kDa. Transfection of the DNA in human embryonic 
kidney fibroblast cells resulted in successful expression of active enzyme, verified by 
tests on crude cell homogenates. A Km for L-Kyn of 13.0  3.3 M was determined and, 
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as before, the majority of specific KMO activity was seen in the mitochondrial fraction. A 
similar approach was later used with hybridised human KMO involving transfection and 
expression with COS-1 cells (expression cell line derived from monkey kidney tissue) and 
the addition of a cleavable glutathione S-transferase (GST) tag [188]. The GST tag 
provided greater expression levels of soluble human KMO. In 1998, pig liver KMO was 
fully purified to obtain the first absorption spectra without contamination by 
cytochromes (displayed in figure 1.9) [189, 190]. It was finally established in these three 
studies that the enzyme was a simple flavoprotein with an experimental monomeric 
molecular weight of around 49-59 kDa and one FAD molecule bound per monomer. The 
native enzyme was still present as an oligomer with an apparent molecular weight of 
around 300 kDa based on gel filtration. An interesting finding from the investigation with 
GST tagged human KMO was that normally NADPH oxidation by KMO in the absence of 
substrate did not occur except when the product 3-HK was present. This suggested that 
the product stimulated uncoupled NADPH oxidation with hydrogen peroxide formation, 
presenting a possible cause for the apparent in vivo neurotoxicity associated with 
elevated 3-HK levels (see section 1.1.4). 
  
 
In 2010, a series of truncation/mutation studies showed that the C-terminal region of pig 
liver KMO was involved in targeting the enzyme to the outer mitochondrial membrane 
and was required for enzyme activity [191]. A series of C-terminal truncates were 
created with 10, 20, 30 and 50 residues removed respectively, as shown relative to the 
Figure 1.9. Absorbance spectra of fully 
purified pig liver KMO as taken from 
Uemura et al., 1998 [189] with native 
and reduced KMO-FAD peaks shown 
inset. 
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amino acid sequence in figure 1.10. Interestingly the intracellular localization of the 
truncates – determined by fluorescence microscopy – varied depending on the length of 
the truncation. The wt and C10 truncate were both localised solely in the mitochondria 
whereas all the longer truncates were localised in the cytosol. This provided strong 
evidence that the highlighted hydrophobic patch between residues -25 and -47 (relative 
to the C-terminus) contained a transmembrane helix. The fact that the C20 truncate 
was also localised in the cytosol suggested that either:  
i) the transmembrane region extended past position -20, which was unlikely 
due to presence of arginines  
ii) a mitochondrial membrane targeting signal was present in between positions 
-20 and -10. It has emerged that tail-anchored OMM proteins generally 
contain a signalling sequence including a positive patch of residues after the 
hydrophobic trans-membrane region [192]. This has been shown to be 
essential to the OMM targeting of Tom20 [193], a splice-isoform of vesicle-
associated membrane protein-1 [194] and cytochromes b5 [195] among 
others. Therefore the two consecutive arginines at position -18 in pig liver 
KMO were speculated to be responsible. 
To determine whether the two arginines were in fact essential to the OMM targeting of 
pig liver KMO they were both substituted by serine. Subsequently the protein was 
localised mainly in the cytosol but with some still visible in the mitochondria. This 
indicated that the two positive residues were involved, although not solely responsible, 
in the mitochondrial targeting of the enzyme. Both arginines are conserved in the human 
enzyme although rat KMO contains a serine in the second position. 





The truncations also affected the enzyme activity with 100 % expression-corrected 
activity up to truncate C20 and then 160 % for C30 and just 10 % for C50 (For 
Figure 1.10. The relative sequence location of the introduced truncations to pig KMO as 
taken from Hirai et al., 2010 [191]. Basic residues are labelled by a plus sign and the 
potential transmembrane region is highlighted in grey. 
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summary see figure 1.11). The key information from this was that truncation to 
completely remove the transmembrane region effectively inactivated the enzyme. 
Soluble fully active enzyme could, however, be obtained from the removal of just the 
sequence up to the RR targeting signal as with the C20 truncate. So in summary it was 
discovered that the C-terminal residues of pig KMO were linked to the enzyme activity 
and contained an OMM-localised transmembrane helix with a similar arrangement and 
signalling sequence to tail-anchored OMM proteins. The discoveries were thought to be 





1.3.3 Studies of KMOs from other eukaryotic sources 
Whilst studies of mammalian KMOs were under way, KMO activity was also detected in 
various insect tissue preparations [196], in Drosophila melanogaster [197], Anopheles 
stephensi [198], Aedes aegypti [199], the Mediterranean flour moth Ephestia kuhniella 
[200] and the red bread mould Neurospora crassa [201]. As with mammalian KMOs 
these insect and fungal KMOs showed an association with the outer mitochondrial 
membrane based on specific activity location and electron microscopy. The studies from 
Anopheles stephensi and Aedes aegypti involved purified and characterised recombinant 
Figure 1.11. Schematic representation, subcellular localisation and enzymatic activity of the pig 
KMO constructs, taken from Hirai et al., 2010 [191]. The predicted transmembrane region is 
highlighted by hatched boxes and no activity was determined for the FLAG-attached SS form, 
KMO-FLAG (N.D.). 
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KMO where similar features were again seen with: pH optima of 7.0-7.5, narrow 
substrate specificity, monomeric molecular weights of around 55 kDa, binding of FAD 
and preference of NADPH over NADH as a coenzyme. An interesting side-story 
developing in the study of insect KMOs was the discovery that a mutation in the KMO 
gene was linked to development of a white-eye phenotype in Aedes aegypti [202, 203]. 
Going back to the work on recombinant KMO from the same species it was 
demonstrated that this mutant gene contained a 3’ deletion translating to the loss of 
residues 373-427 near the C-terminus of the protein [199]. This mutant form of the 
enzyme was inactive but it was speculated that this might be because the deletion 
disrupted a predicted long -helix. Whatever the reason this was further evidence that 
the C-terminus of KMOs had some relevance to the enzyme’s catalytic activity. 
 
1.3.4 Studies of bacterial KMOs  
A small number of bacteria possess limited pathways for tryptophan catabolism that 
include KMO. Critically, sequence analysis shows that these bacterial forms of KMO do 
not appear to contain any predicted transmembrane regions. In 2007 a bacterial KMO 
from Psuedomonas fluorescens strain 17400 (PfKMO) was cloned and expressed in E.coli 
with a high yield of soluble protein [2]. PfKMO was purified with great success using a 
process of: streptomycin sulphate precipitation, ammonium sulphate fractionation and 
anion exchange chromatography. With the absence of a transmembrane region, the 
protein was soluble without the need for any detergents and so it could be characterised 
to a further extent than any previously studied KMO. Despite this, there were still a few 
minor difficulties that had to be overcome. Firstly no activity was detected when normal 
expression protocols involving addition of IPTG and growth at 37 oC were used but this 
was resolved by slower cell growth at 22 oC for 16 hours without induction with IPTG. It 
was thought that either the rate of folding or instability of the enzyme was restricting 
the production of active protein, particularly during overexpression with the inducing 
agent. The second, possibly related, problem involved the rapid loss of the purified 
enzyme’s activity over time in the absence of reducing agent. Over a period of 30 hrs at 4 
oC, up to 90 % of the enzyme activity was lost with the majority recovered by addition of 
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dithiothreitol (DTT), a strong reducing agent. PfKMO contains six cysteine residues and it 
was shown that this loss of activity correlated with the oxidation of two of these residues 
based on a DTNB-based assay for free thiol groups (Figure 1.12). SDS-PAGE confirmed 
the reversible dimerization of PfKMO over time depending on the presence of reducing 
agent. Therefore during purification and storage of the enzyme a reducing agent was 
required to prevent aggregation via disulphide bridge formation. 
 
   






The Michaelis-Menten kinetic parameters for PfKMO were calculated and displayed in 
table 1.3 and it was shown that the enzyme had maximal activity at pH 8.0-8.5 and 
maximal stability at pH 6.0–7.0. The KMO-FAD-L-Kyn complex had a dissociation constant 
of 17.4  1.4 M and of 133  6 M at 5 and 25 oC respectively. The first real detailed 
mechanistic picture of KMO was then revealed in a second study on the bacterial 
enzyme [1] that firmly confirmed the association of KMO with the FAH enzyme family. As 
seen with other FAHs, NADPH oxidation in the absence of substrate was largely 
prohibited with subsequent flavin reduction occurring over long time intervals (around 
5000 s). The process was stimulated 103-fold in the presence of L-Kyn. The reaction 
Parameter Value at 5 
o





) 1.27 ± 0.002 4.9 ± 0.1 





) 0.10 ± 0.02 0.08 ± 0.01 





) 0.15 ± 0.01 0.053 ± 0.004 





) 0.029 ± 0.003 0.008 ± 0.003 
Figure 1.12. Graph taken from Crozier & 
Moran 2007 [2] showing loss of PfKMO 
activity (○) over time relative to the 
number of free thiols/monomer (□).  
Table 1.3. Michaelis-Menten kinetic 
constants determined for PfKMO at pH 
7.5, adapted from Crozier & Moran 2007 
[2]. 
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catalysed by PfKMO was shown to consist of several observable steps as summarised in 
the proposed mechanism in figure 1.13. For each transition the rate constant was 
measured using stopped-flow spectrophotometry and it was found that product release 
was the rate-limiting step. Building on previous observations on the sensitivity of KMOs 
to the presence of anions [188, 199, 200], it was shown that PfKMO activity was sensitive 
to low concentrations of anions. Absorbance spectra confirmed that binding of anions 
directly influenced the flavin, with spectral changes similar to those seen in the presence 
of the product 3-HK. It was suggested that the occupancy of the flavin’s multiple 
positions was sensitive to local electrostatic changes as caused by the binding of anions 
in the proximity of the active site.   
 
 
Figure 1.13. Summary of the proposed PfKMO 
catalysed reaction mechanism split into the 
reductive and oxidative half-reactions. The rate 
and equilibrium constants measured are 
labelled for each step. Taken from Crozier-
Reabe et al., 2008 [1]. * denotes measurement 
in 6 mM NaCl. 
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1.4 Inhibition of KMO 
1.4.1 Discovery of KMO inhibitors  
Partially purified yeast KMO was inhibited by –keto acid analogues of branched chain 
amino acids, pyruvate and -ketoglutarate [204] with Ki values in the low millimolar 
range. The keto acid analogues were found to show non-competitive inhibition with 
respect to both L-Kyn and NADPH whereas pyruvate and -ketoglutarate were mixed-
type inhibitors. Unfortunately such levels of inhibition were not reproduced when the 
compounds were tested on partially purified rat liver KMO [205]. The first potent KMO 
inhibitors synthesised: o-, m- & p-nitrobenzoylalanine (NBA), were analogues of the 
substrate L-kynurenine [54, 206]. The compound m-NBA in particular seemed to be a 
very potent competitive inhibitor, with an IC50 of 0.8 M against KMO from resuspended, 
homogenised rat organs. Going further, administration of m-NBA to rats showed 
anticonvulsant activity against electroshock-induced seizures and increased the brain, 
blood and liver concentrations of both KYN and KYNA [54, 206]. Another group explored 
more manipulations of substrate analogues to develop a stronger inhibitor in the shape 
of 3,4-dichlorobenzoylalanine (3,4-CBA or FCE 28833). This compound showed similar, 
yet more potent benefits in rats compared to m-NBA and had an IC50 of 0.2 M [207]. 
Further variations of substrate analogues with similar levels of inhibition were 
characterised by Giordani et al., 1998 [208] and Drysdale et al., 2000 [209]. Again these 
compounds showed promising therapeutic potential by preventing IFN- induced 
synthesis of QUIN in primary cultures of human monocyte-derived macrophages [209]. 
Recently however, the therapeutic potential of substrate analogues was dismissed when 
it was shown that they actually cause uncoupled flavin reduction by NADPH which leads 
to the generation of cytotoxic hydrogen peroxide [1]. Thus, such inhibitors have been re-






Shortly after the discovery of substrate analogue inhibitors, the search for more specific 
and more potent KMO inhibitors moved on to novel and more complex organic 
compounds. In 1997, screening of a chemical library based on bioisosters of the L-Kyn 
carboxyl group rapidly identified a sulphonamide as a good starting scaffold [4]. 
Subsequently a series of N-(4-phenylthiazol-2-yl)benzenesulfonamides (figure 1.15) were 
synthesised and shown to be promising high-affinity competitive inhibitors of KMO. Of 
those tested in vitro on KMO from rat kidney mitochondria, the strongest compounds 
had low IC50 values of 20-40 nM, which were up to 10 times lower than the substrate 
analogues. A selection of the compounds was tested ex vivo on different homogenised 
organs after oral administration in both rats and gerbils. In all cases strong inhibition was 
seen and with significantly greater potency than 3,4-CBA when directly compared. The 
ED50 values determined for the two strongest inhibitors in the different organ tissues 
ranged between 0.5-5.5 mol/kg compared to 22-222 mol/kg for 3,4-CBA. Finally, 
administration of one of the compounds (Ro 61-8048) to rats was also shown to increase 
the extracellular hippocampal fluid concentration of KYNA by 7.5 times at a dose of 100 
mol/kg. Subsequently Ro 61-8048, which contained a 3-NO2 R’ group and a 3,4-OMe R’’ 
Figure 1.14. Summary of the molecular structures of the range of substrate analogue KMO inhibitors 
synthesised and tested compared to the substrate L-Kyn. The 4-phenyl-4-oxo-butanoic acid series of 
compounds were synthesised by Giordani et al. 1998 [208], whilst both the 4-aryl-4-oxo-but-2-enoic 
series were synthesised by Drysdale et al. 2000 [209]. 
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group, was used in several studies to further investigate the therapeutic potential of 
inhibiting KMO.  
             
 
 
Since this discovery an alternate unrelated group of specific KMO inhibitors has 
emerged. In 2012 a natural product lanthellamide A (figure 1.16) – isolated from the 
Australian marine sponge lanthella quadrangulata – showed relatively potent inhibition 
of KMO [210]. The IC50 from in vitro assays with rat KMO was determined to be 1.5 M 
for the inhibition of 3-HK production. The inhibition was specific for KMO as only weak 
inhibition of KYNase was detected at concentrations of up to 1 mM lanthellamide A. 
Moreover co-administration of L-Kyn and the inhibitor in the hippocampus of 
anesthetised rats caused up to a peak three-fold increase in extracellular KYNA levels 
over L-Kyn only controls. Due to its recent discovery, little is known about the wider 
therapeutic potential of lanthellamide A and any possible related compounds. 
 
   
 
Figure 1.15. Comparison of the structure of the series of novel KMO inhibitors synthesised 
by Rover et al. 1997 [3] with that of the substrate L-Kyn. 
Figure 1.16. Structure of the marine sponge 
natural product that was found to inhibit 
KMO by Feng et al. 2012 [210]. 
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1.4.2 Therapeutic effect of KMO inhibition in models of disease 
One of the questions surrounding the therapeutic potential of KMO inhibitors was 
whether QUIN synthesis could continue regardless via KMO-independent pathways? In 
mice, large doses of m-NBA & Ro 61-8048 increased blood and brain KYNA whereas they 
only decreased QUIN levels in immune-stimulated animals [211]. It was suggested that 
during an immune response raised QUIN levels were achieved as a result of upregulation 
of the KMO branch, whereas anthranilic acid hydroxylation was normally sufficient to 
generate QUIN under normal conditions. These data were encouraging: minimising the 
effect of KMO inhibitors in healthy cells whilst significantly reducing pathophysiological 
levels of QUIN. Research involving induced rat and gerbil brains showed that the two 
KMO inhibitors protected against induced brain lesions [61]. The percentage of lesioned 
neurones reduced from around 90 % to 10% in the presence of the inhibitors and again a 
significant increase in the concentration of KYNA was noted. Ro 61-8048 has also been 
shown to offer partial protection against induced convulsions both extending the time 
before first convulsion and reducing the total number of convulsions in rats [212]. Aside 
from the main focus of controlling the ratio of QUIN:KYNA, there has also been cases 
where inhibition of KMO has been targeted for direct reduction of its reaction product 3-
HK. It was thought that an excessive accumulation of 3-HK in the eye lens was linked to 
cataract formation [131]. In mitochondrial extracts from the rabbit iris and lens, Ro 61-
8048 inhibited KMO activity and subsequently 3-HK production with IC50 values of 0.1 & 
1.0 M respectively (compared to 1.3 & 7.0 M for m-NBA) [131].  
There have been several examples of KMO inhibition resulting in observed 
neuroprotective qualities and raised KYNA levels [49, 60, 61, 144, 213-216]. There are 
mixed reports however as to whether the level of increase in [KYNA] caused by KMO 
inhibition is sufficient to reduce activity of EAA receptors and thus to suppress 
excitotoxicity. One group found evidence against the notion by studying anaesthetised 
rats where NMDAr depolarisation was measured after direct administration of QUIN, 
KYNA and the KMO inhibitor Ro 61-8048 [214, 217] . Whilst KMO inhibition with 100 
mg/kg Ro 61-8048 increased the basal [KYNA] 11 times to around 30 nM, there was no 
evidence of an associated reduction in NMDAr response. Another study found that 
addition of 30-100 M m-NBA or 1-10 M Ro 61-8048 to hippocampal slice cultures 
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reduced post-ischemic neuronal death after 30 mins of exposure to oxygen and glucose 
deprivation [60]. KYNA levels increased but to only 50 nM, considered to be below the 
concentration needed to significantly affect EAA receptors. Due to the observed 
protective effect being counteracted by addition of 3-HK or QUIN, the authors proposed 
that KMO inhibition offered neuroprotection in this case by reducing the local synthesis 
of these two metabolites. A couple of years later it was found that local application of 
30-100 nM KYNA to rats was enough to significantly decrease the concentration of GLU 
in the caudate and cortical dialysates but had no effect in the hippocampus [218]. 
Further, administration of 4-40mg/kg Ro 61-8048 increased the concentration of KYNA in 
dialysate collected from cortex, caudate and hippocampus but only reduced the 
concentration of GLU in the basal ganglia. A complex picture was emerging whereby 
raised KYNA levels to the extent seen with inhibition of KMO seem to be able to suppress 
NMDAr activity in some selective regions of the CNS. It was still not clear whether the 
definitive neuroprotective properties associated with KMO inhibition were directly 
linked to increased KYNA, reduced QUIN and/ or reduced 3-HK levels.  
 
1.5 Characterising enzyme-catalysed reactions 
1.5.1 Michaelis-Menten kinetics 
The Michaelis-Menten equation (equation 1.1) describes the relationship between 
substrate concentration and the rate of an enzymatic reaction. Michaelis-Menten 
kinetics applies to all enzyme-catalysed reactions represented by scheme 1.1 and does 
not apply for reactions where there is cooperative or allosteric binding of the substrate 








   
 
 
Equation 1.1. Michaelis-Menten 
relationship. V = initial reaction rate,           
[S] = concentration of substrate. 
Scheme 1.1. Generalised reaction scheme defined by 
Michaelis-Menten kinetics. E = Enzyme, S = Substrate,            
P = product, k = rate constants. 










The Vmax is the maximum rate of reaction obtained with infinite substrate and is variable 
with respect to the enzyme concentration. The Michaelis-Menten constant kcat (turnover 
number) represents the Vmax per enzyme active site and reveals a particular enzyme’s 
maximal rate of turnover per unit time. Another important constant in the 
characterisation of an enzyme is the Km value for a respective substrate. The Km is the 
substrate concentration required to achieve 50% of kcat, which in reality reveals how 
tightly the substrate is bound in the active site. The efficiency of an enzyme is estimated 
by calculating the second order rate constant kcat/Km. The Michaelis-Menten constants 
for an enzyme can be determined experimentally from a plot of the initial reaction rate 
(v) against substrate concentration, as shown in figure 1.17. 
 
                     
 
 
1.5.2 Enzyme inhibition 
The activity of an enzyme may be inhibited by a molecule in one of the following ways: 
i) Competitive inhibition – whereby the inhibitor reversibly competes with the substrate 
for binding in the active site. With increasing [inhibitor] Vmax is unchanged but Km is 
increased as only substrate binding is affected. 
Figure 1.17. Example of Michaelis-Menten plot for the determination 




ii) Uncompetitive inhibition – whereby the inhibitor binds to the enzyme-substrate 
complex to prevent catalysis. Km and Vmax are both lowered with increasing inhibitor. 
iii) Mixed inhibition – whereby the inhibitor binds both to the free and to the substrate-
bound enzyme with different binding affinities. Inhibitor binding affects binding of the 
substrate. The inhibitor binds in a site other than the substrate binding site either within 
the active site or at an alternate location (allosteric site). Both Km and Vmax are increased 
in the presence of inhibitor. 
iv) Non-competitive inhibition – a form of mixed inhibition where the inhibitor binds only 
to the enzyme-substrate complex. With increasing inhibitor concentration Km is 
unchanged, but Vmax is reduced. 
v) Irreversible inhibition – whereby the inhibitor binding is irreversible, usually due to the 
formation of a covalent adduct with the enzyme. Binding can be competitive or 
uncompetitive.  
Each type of inhibition can be distinguished experimentally due to their different effects 
on the apparent Vmax and Km. The Lineweaver-Burke plot of 1/v against 1/[S] can be used 
to distinguish between different types of inhibition as illustrated in figure 1.18. The data 
fit to a straight line defined by equation 1.2, with the y intercept providing 1/Vmax and 
the x intercept giving -1/Km.  
                
 
 






The Lineweaver-Burke plot is effectively a double-reciprocal plot of kinetic data, 
therefore it significantly amplifies the influence of errors within the data. More accurate 
plots to determine the Ki and identify the type of inhibition are plots of 1/v and of 
[substrate]/v versus [inhibitor] [219]. A summary of the characteristic plots observed 
with different types of inhibition is shown in figure 1.19. 
 
Figure 1.18. Lineweaver-Burke plots in the presence of increasing concentrations of 





1.6 X-ray crystallography of proteins 
1.6.1 X-ray diffraction  
There are two major techniques for determining the three dimensional structure of a 
protein – X-ray crystallography and NMR-spectroscopy. NMR-spectroscopy has the 
advantage of allowing the characterisation of a protein in solution, however the 
technique is typically limited to polypeptides of <30 kDa. As a result X-ray crystallography 
has remained a powerful method for observing the 3-D structure of proteins regardless 
Figure 1.19. On the left plots of 1/v against [inhibitor] and on the right 
plots of [substrate]/v against [inhibitor] for different types of inhibition. 
Taken from Cornish-Bowden, 1974 [219]. 
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of their size. The technique utilises the phenomenon of diffraction. Diffraction occurs 
when the path of a wave is regularly distorted upon encountering an object of similar 
size to the respective incident wavelength. The size of covalent bonds in proteins is 1.2-
1.5 Å and matches to wavelengths in the range of X-ray radiation (0.1-100 Å).  
Bragg diffraction was discovered when patterns of diffracted spots (reflections) were 
observed upon passing a beam of X-rays through a crystalline solid. Bragg diffraction was 
quantified using an understanding of trigonometry, which lead to the derivation of 
Bragg’s Law (equation 1.3). This showed that the positions of reflections were related to 
the interplanar spacing between each repeating unit cell in the crystal. Reflections are 
only recorded from constructive (in phase) diffraction from identical waves generated 
from parallel sets of symmetrical planes in the crystal lattice (see figure 1.20). The 
equation showed that this constructive diffraction at each interplanar distance (d) only 
occurs from waves that impinge at angles (θ) that give integer values for n. Therefore as 
a crystal is rotated different sets of reflections are recorded so that information about 
the whole 3-D structure within the repeating crystal lattice is collected. An important 
consequence of this process is that the formation of ordered, homogenous protein 
crystals is essential to achieving strong diffraction for complete structure solution. The 
mechanism of data collection and analysis will be addressed in the following sections.  
 




Figure 1.20. Diffraction of X-rays by parallel sets of repeating planes in a crystal lattice 
results in Bragg diffraction and collection of a reflection.  
Equation 1.3. Bragg’s Law  
n = an integer,  = X-ray wavelength, d = interplanar 
spacing,            = incident angle of wave 
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It is important to remember that the protein structure determined is still just a model; a 
static representation of the average position of each atom from >1013 protein molecules 
within a crystal. The structural model generated may be missing some of the amino acid 
residues of a polypeptide sequence, typically the terminal residues which are usually the 
most disordered. It is also important to ensure that the modelled structure of the 
crystalline protein is a true representation of the aqueous/functional structure of the 
protein. There are two main pieces of evidence for this. In the majority of cases, the 
structure of a protein in solution from NMR spectroscopy is very similar to the structure 
obtained from X-ray crystallography. Also many crystallised enzymes are still catalytically 
active, albeit at a reduced rate of turnover due to reduced accessibility of the active site 
or limited conformational flexibility. 
 
1.6.2 Growth of protein crystals 
Protein crystallisation is a form of ordered aggregation at super-saturating 
concentrations of the protein and may be facilitated by precipitants such as salts, 
solvents and/or PEGs. Initially the solution contains a precipitant concentration that is 
lower than that required to precipitate the protein. The controlled evaporation of water 
from this solution slowly raises the concentration of both the protein and precipitant 
increasing the likelihood of precipitation. The diffusion of water is controlled by vapour 
diffusion techniques. In hanging drop vapour diffusion (h.d.v.d), an aliquot of protein 
solution is mixed with an aliquot of precipitant solution on a cover slip. The cover slip is 
then placed and sealed over a well containing just the precipitant solution. In sitting drop 
vapour diffusion (s.d.v.d) the drop is set up in a raised well above the precipitant solution 
and the chamber is sealed by sticky tape. In both cases the rate of diffusion and the 
initial concentration of precipitant and protein greatly influence the potential to form 
good quality crystals. These methods provide a simple way of screening various 
crystallisation conditions whilst also allowing some control of the rate of diffusion from 
the protein drop. 
There are two aspects to crystal formation - nucleation and growth. Crystal nucleation is 
the event of protein molecules associating together in an ordered arrangement. Crystal 
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growth then proceeds as new protein molecules are added to the site of nucleation. 
Crucially, as protein molecules start coming together, the protein concentration starts 
falling and so does the occurrence of further nucleation. Figure 1.21 describes the region 
where nucleation occurs and shows the metastable zone, where crystal growth, but not 
nucleation, occurs. So, to summarise, the conditions begin to the left of the solubility 
curve, then the concentrations rise until the nucleation zone is reached and this is 
followed by a fall in protein concentration to enter the metastable zone. Protein crystals 




, 2005 [220] 
The nucleation zone depicted figure 1.21 is deceivingly large. In reality, as 
supersaturation is reached, uncontrolled aggregation/precipitation of the protein 
molecules occurs more often than not. It is important that this transition towards 
supersaturation occurs slowly to give the protein the highest chance to associate in a 
controlled and ordered way. For different proteins, different pH, temperature, 
Figure 1.21. Graphical representation of the effect of varying [Protein] or an adjustable parameter 
(such as pH or [precipitant]) on protein solubility. Taken from N.E. Chayen, 2005 [220]. 
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precipitants and concentrations (of protein and the precipitants) may be required to 
allow the formation of crystals. The purity and homogeneity of a protein solution is 
directly linked to the likelihood of forming good quality crystals. Not all proteins will 
easily form diffracting crystals and the ability to do so is largely dependent on the 
sequence and structural composition of the protein. For example, membrane proteins 
can be notoriously difficult to crystallise because of their general tendency to aggregate 
quickly in solution. This is mostly due to large hydrophobicity of trans-membrane 
domains, which have evolved to associate with the hydrophobic fatty acid chains found 
on the interior of cell lipid membranes.  
Protein crystals are typically 50 % water with the surface of the protein coated by water 
molecules. Therefore the actual forces holding a crystal together are mostly hydrogen 
bonds between the protein amino acid residues and solvent molecules. This makes 
protein crystals much more fragile than crystals of small molecules. The large proportion 
of solvent creates an additional problem when freezing protein crystals. Protein crystals 
are typically flash-frozen in liquid nitrogen prior to being exposed to an X-ray source to 
protect the crystals from damage by the X-rays themselves. During freezing, the solvent 
molecules can form small ice crystals which disrupt the ordered lattice of the crystal. A 
clue to this can be seen by the appearance of solid rings on the X-ray diffraction images, 
however this can be simply down to ice on the surface of the crystal. Therefore protein 
crystals are typically soaked in mother liquor supplemented by a cryoprotectant such as 
EG, glycerol or MPD. The cryoprotectant displaces some of the water molecules to buffer 
against ice formation. 
 
1.6.3 Techniques for improving crystal quality 
Protein crystallisation is frequently the bottleneck in the structure solution process. 
Some proteins are unsuitable for crystallization either through not forming crystals or by 
forming crystals with only poor diffraction properties. Several strategies have emerged 
to counteract this to allow the solution of previously unattainable protein structures. 
These strategies include post-crystallisation treatments such as annealing, chemical 
cross-linking, dehydration and seeding as well as pre-crystallization engineering of the 
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protein itself such as the removal of flexible regions or mutagenesis of surface residues. 
Often the required strategy depends on the problem itself, however in most cases this is 
hard to elucidate and so all approaches should be considered. 
i) Seeding 
The most common post-crystal treatments initially explored involve types of seeding. 
Seeding involves the introduction of a nucleating agent into the crystallization mix to 
provide a seed to facilitate crystal growth. The seed itself can be heterogenous or 
homogenous. The most basic approach, which is applicable to situations where crystals 
have not been obtained, is to stroke across the crystallization drops with a hair or 
whisker during tray set up (streak seeding). It is thought that streak seeding leaves 
various nucleants in the drop from which crystals can grow where they otherwise would 
not have formed. Any hair/whisker can be tried – it was presented that some 
researchers routinely use their own human hair (unpublished, CCP4 northern protein 
structural workshop, Carlisle, Aug 2011). At the same conference, Dr Allan D’Arcy 
(Novartis) described that any solid material can be tried for seeding, from amorphous 
precipitates to microcrystals. Further, when crystallization conditions cannot be found, 
such crystalline material is added to the crystallization drops in sparse-matrix screening. 
Here ideally the seed comes from a previous drop with the protein of interest but a 
heterogeneous crystalline material from a different protein source can also be tried.  
In the event that crystals can be obtained but of poor quality, homogenous seeding 
offers a powerful and reasonably successful tool. This involves the introduction of either 
whole crystals (macroseeding) or broken up crystal fragments (microseeding) into the 
crystallization drop to effectively grow second generation crystals. Without the need to 
nucleate, the original conditions can be refined to favour slow crystal growth from just 
the added homogenous seeds. Typically the precipitant concentration is lowered slightly 
to avoid new nucleation events. In this process the right seed concentration is essential 
as it determines the amount of crystallization sites in the drop. Typically serial dilutions 
of the seed crystals/crystal fragments are made and tested and can be stored as aliquots 
at -20 to -80 ⁰C for future use. To create a microseed solution, a drop containing crystals 
of any size is selected and 10 l of stabilizing solution is added. The crystal/s are 
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physically broken up either by pipetting up and down or by using a specialised mixing 
tube. The seed solution is then microcentrifuged at full speed to remove large crystal 
fragments and only leave the small stable crystal cores which act as effective 
microseeds. Subsequently serial ten-fold dilutions are made using the stabilising 
solution. The stabilising solution used can be the original mother liquor itself, usually 
with the precipitant concentration slightly raised. These techniques are also regularly 
used to obtain crystals of the SeMet-labelled form of a protein using a heterogenous 
seed from crystals of the respective native protein. 
ii) Post-crystal annealing and dehydration 
On some occasions poor crystal diffraction occurs as a result of a high lattice solvent 
content. In some cases two techniques have been found to counteract this and improve 
the crystal’s diffraction power: annealing and dehydration. Annealing involves the 
exposure of the crystal to brief bursts of extreme temperatures. One way of doing this is 
by ‘annealing on the loop’ where the cryostream is removed from a mounted crystal 
with one or multiple exposures lasting 1-5s. Also a more subtle approach is where frozen 
crystals are soaked back into the cryoprotectant solution and then re-frozen. Either way 
annealing is thought to improve the crystal lattice packing by forming a more 
energetically favourable and ordered state. Successful cases of annealing are highlighted 
in the review of post-crystallisation treatments by Heras & Martin [221], which includes 
the improvement of the resolution achieved from crystals of DmpFG [222] and arsenate 
reductase [223] from around 6.0 Å to 2.1 and 2.3 Å respectively.  
Crystal dehydration is a technique again aimed at improving crystal lattice packing but as 
a direct result of reducing the crystal solvent content. Crystals are exposed to a higher 
precipitant concentration for a length of time before being flash-frozen and tested for 
diffraction. The exposure can consist of soaking the crystal in a solution of mother liquor 
supplemented with extra precipitant for between 5s to several days. A more gentle 
dehydration involves simply replacing the reservoir solution with one with a higher 
precipitant concentration and the drop is then left to re-equilibrate over several hours to 
days. In both cases a series can be set up with increasing precipitant concentration to 
discover the optimum point before the crystals are damaged. Success stories of 
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dehydration are again reviewed by Heras & Martin [221] and include DsbG where the 
resolution improved from around 10.0 Å to 2.0 Å [224]. 
iii) Post-crystal cross-linking 
Some crystals are particularly fragile and can suffer irreversible damage during handling 
including upon ligand soaking, cryoprotection and/or cooling. A technique that has been 
shown to improve crystal strength is the chemical cross-linking of lysine side-chains in 
protein crystals using glutaraldehyde [225, 226]. The technique is not widely used due to 
a tendency to reduce the diffraction quality of crystals. This can be due to the formation 
of varying chain lengths in the cross-links [227]. It was recently reported that an 
improvement in the success of chemical cross-linking was achieved by gently introducing 
the gluteraldehyde into the crystal drop using vapour diffusion [228]. 
iv) Protein engineering to improve crystal contacts 
Unlike with small molecule crystallography, the crystallisation of protein molecules is 
inherently challenging due to their long chain lengths and high flexibility. It has been 
estimated that fewer than one in four single-domain prokaryotic proteins will yield 
crystals suitable for X-ray analysis using commercial screens [229, 230]. Protein 
engineering has provided a powerful tool for the successful crystallisation of numerous 
proteins which were otherwise resistant to the formation of a regular crystal lattice. The 
aim is usually to modify/remove surface features that inhibit the formation of stable, 
homogenous crystal contacts. More specifically high entropy patches are targeted to 
minimise the energy barrier associated with the formation of a regular crystal lattice out 
of protein molecules in solution. The full range of protein engineering strategies 
available has been extensively reviewed elsewhere [231]. These include: 
-  surface entropy reduction (SER) – this involves the mutation of residues with 
high entropy side chains (Lys, Glu & Gln) into low entropy residues (Ala, Ser, Thr, 
Tyr) [232].   
- Cysteine mutation – cysteine residues are able to form covalent disulphide 
adducts, which can cause aggregation and hinder crystallisation. The mutation of 
cysteines for serines has widely been utilised in the successfull growth of 
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diffracting protein crystals such as with mitogen-activated protein (MAP) kinase 
p38, foot-and-mouth disease virus 3C protease [234] and an RNA-binding 
protein, She2p [235], among others. 
- Truncation/loop removal – Often, the N- and C- termini of proteins are flexible 
and disordered in many protein structures. As such their removal by truncation 
of the protein can increase the likelihood of crystallisation. Additionally flexible 
loop regions or even whole domains may also hinder the formation of stable 
crystal contacts and can be removed by cloning or by limited proteolysis [236]. In 
limited proteolysis the protein is incubated with a small amount of trypsin 
(around 50:1 of protein:trypsin) for a short time period (1-24 hours) either prior 
to or during the growth of crystals.  
 
1.6.4 X-ray data collection  
When collecting X-ray data for a crystal, to obtain all the information about the 3-D 
composition of the repeating crystal lattice unit (the unit cell) reflections must be 
recorded over different points of the surface of the crystal. Therefore the crystal is 
incrementally rotated by 0.2-2.0 o oscillations with full sets of reflections collected at 
each stage of rotation. Due to the symmetrical nature of the different Bravais lattices 
that can be formed, often as little as a 45 o wedge may be sufficient to obtain a complete 
dataset. Collecting more data than the minimum required for the space group is 
beneficial to improve the signal:noise (intensity) of reflections which are measured more 
than once. Care must be taken to avoid introducing radiation damage and so data 
quality/resolution must be balanced with the collection of a complete homogenous data 
set. Each image of reflections is indexed and integrated by computer programs (such as 
MOSFLM) to record the position and intensity of every spot. At the start of this process 
the pattern of spot positions observed is determined by the crystal symmetry/space 
group with the distance between spots inversely proportional to the unit cell 
dimensions. One value to keep an eye on during indexing is the mosaicity that is a 
measure of the minimum angle of rotation over which an individual reflection is 
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observed. It essentially reveals the regularity of the molecular packing within a crystal 
and as such the lower the data the better the quality of data that will be obtained. 
There are three commonly used X-ray sources in protein structure determination: i) X-
ray tubes/cathode-ray tubes, ii) rotating anode tubes and iii) particle accelerators 
(synchrotron sources). With X-ray tubes, electrons from a hot cathode filament are 
accelerated by electrically charged plates and collide with a water-cooled anode made of 
a specific metal. The rearrangement of electrons within the metal emits characteristic X-
ray wavelengths with K and K peaks specific to the metal. X-ray absorbing material is 
used to guide and filter the majority of the K radiation towards the crystals. Typically 
copper and sometimes molybdenum, with average K radiation wavelengths of 1.54 and 
0.71 Å respectively, are used to probe atomic structures. The output of X-ray tubes is 
limited by the amount of heat that can be dissipated from the anode by water. To 
overcome this, rotating anode tubes were created whereby the metal is rapidly spun to 
spread the incoming electrons over a larger surface area. Now most in house X-ray 
sources involve adaptions of rotating anode tubes with a maximum resolution limit 
achievable limited by the wavelength of the K radiation. 
In recent years the field of high resolution protein structure solution has been greatly 
advanced by the development of synchrotron radiation sources. These involve giant 
rings lined with powerful magnets with electrons circulating close to the speed of light. 
When the path of the electrons is bent by the magnets, high energy synchrotron 
radiation is emitted as X-rays. The X-rays are focused into powerful monochromatic 
beams with tuneable wavelengths and beam sizes. Synchrotron facilities offer increased 
levels of radiation energy (smaller X-ray wavelengths) than conventional copper anodes 
for higher resolution data collection. The process is also much faster with whole datasets 




1.6.5 Structure solution 
Each reflection formed can be described as the result of a complicated wave, which is 
defined by the summation of many different simple waves. The function that describes 
this complicated wave for a reflection with indices h,k,l is the structure factor Fhkl. The 
structure factors for all measured reflections are converted into a function of the 
electron density () present at different real lattice coordinates (x, y, z) by the Fourier 
Transform described by equation 1.4. To build an electron density map from a complete 
set of measured reflections, three sets of information are needed about the contributing 
waves: the amplitude, the frequency and the phase. The amplitude is proportional to the 
square root of the reflection intensity and the frequency is that of the X-ray source, 




Equation 1.4. Fourier transform for calculating the electron density from the summation of the 
structure factors of each reflection. V = unit cell volume in Å,  = electron density, h,k,l represents the 
reflection indices and x,y,z represents the real unit cell coordinates. 
 
There are ways to get around this though and calculate values for the phase so that 
crystal structures can be solved. Firstly atoms with large numbers of electrons (heavy 
atoms) can be regularly introduced into the crystal lattice either by soaking or by 
protein-labelling. At a source x-ray wavelength near the respective atom’s characteristic 
absorption edge, these heavy atoms absorb the incoming radiation and re-emit it as a 
new wave with altered amplitude and phase. This is known as anomalous scattering. As a 
result of this scattering the symmetry-related reflections known as Friedal pairs have 
completely different phases whereas for just the un-labelled protein they would possess 
exactly opposite values (i.e +1 and -1). The change in intensity measured due to the 
effect of heavy atoms is known and can be looked up for each element at the source 
particular wavelength. By drawing the reflections as vectors with length relative to 
intensity and direction relative to the phase, the difference between measured 
intensities with and without anomalous scattering can be used to calculate the phases. 
Once the electron density can be calculated it is typically viewed as a map on graphics 
(x,y,z) = 1/V Σ Σ Σ Fh,k,l e
[-2 i(hx + ky + lz)]
   h   k   l 
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programs such as Coot [237]. To reduce the bias of the model in the electron density 
output a 2Fo-Fc map is usually displayed to aid model building/editing. A map of Fo-Fc is 
may also be shown to highlight significant discrepancies between the model and the 
observed data. Here positive areas (typically coloured green) represent regions where 
something is missing from the model and negative areas (typically coloured red) 
represent regions where the model contains additional atoms whose positions are not 
justified by the observed diffraction data. 
There are two ways of collecting the different datasets at the different required beam 
wavelengths, the first is using two different crystals (one heavy and one native) in 
multiple isomorphous replacement (MIR). One problem with MIR is that the heavy 
crystal must be isomorphous with the native one but heavy atom binding may cause 
structural changes within the crystal. Therefore a more reproducible approach is known 
as multiwavelength anomalous dispersion (MAD) where multiple datasets are collected 
with different incident X-ray wavelengths from a single, heavy atom bound crystal. The 
technique utilises the measured different absorption/fluorescence patterns of each 
heavy metals at particular X-ray wavelengths. For this purpose the heavy atom is 
regularly introduced into the crystal by selenomethionine labelling of the protein during 
expression and translation in the host cells. At high resolution the phases can be solved 
from just one dataset in single-wavelength anomalous dispersion (SAD). 
In addition the phases can be estimated using molecular replacement (MR) with the 
program Molrep. This requires a suitable template model from a structurally similar 
protein structure. The atom coordinates of the model are used to calculate a set of 
phases initially which are combined with the measured intensities from the diffraction 
data. For this to work, the model structure must be superposed over the exact location 
and orientation of the target protein in the unit cell of the collected dataset. To make 
this task easier the orientation and position searches are conducted separated in 
Molrep. A Patterson map which is calculated without phase information as the Fourier 
transform of just the reflection intensities rather than the reflection structure factors, is 
used to identify the correct orientation of the model. The map displays a pattern of 
peaks which represent the interatomic distance vectors of all the atoms in the unit cell. 
Following this, the correctly orientated model is translated through the measured unit 
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cell until an output is found where the model-calculated reflection amplitudes align with 
the observed measured amplitudes. This is measured by the R factor (R) (equation 1.5). 
 
1.6.6 Structure refinement and validation 
Typically the resolution from measured X-ray data is insufficient to allow free placement 
of the individual atoms of the protein molecule. Therefore model building/editing is 
strictly restrained by known plausible values for particular bond angles and lengths. The 
fit of the progressive structural model to the experimental electron density is refined and 
assessed by refinement programs such as Refmac 5 [238]. As part of this assessment a 
value for the R factor (R) is determined and this typically finalises around ten times the 
value of the high resolution limit (i.e. for a 2.2 Å resolution dataset, an R value of around 
22 % or 0.22 could be expected). The problem with the R factor is that the values used to 
determine it are biased during refinement as the program tries to fit the data to the 
model. To counter this, an Rfree value is also determined using a small (~ 5 %) set of 
relections that are excluded from the refinement process. The Rfree will always be slightly 
higher than the R value, however the two should never diverge too far from each other 
in a good model. Translation libration screw-motion refinement (TLS) [239] can be a way 
of providing a better fit between the model and the observed diffraction data, lowering 
the values of R and Rfree. It works by breaking the protein up into connected rigid body 






In addition to atomic coordinates, the final model also contains an associated 
temperature factor (the B-factor) for each atom. The B-factor is a measure of the mean 
area of displacement of an atom from its identified coordinates in Å2. This is determined 
by the definition of the electron density surrounding the atom and indicates its flexibility 
within the crystal structure. Therefore flexible protein regions such as surface loops can 
R =    F
o
   -   F
c
 
   F
o
 
Equation 1.5. Definition of the R-factor (R). Fo 
represents the amplitudes observed with the 
diffraction data whereas Fc represents the calculated 
amplitudes based on the model structure.  
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be typically identified by areas with relatively high B-factors. For lower resolution 
datasets the average B-factor of atoms is naturally going to be significantly higher than 
for the same structure solved at a higher resolution.  
 
1.7 Aims of this work 
This investigation was stimulated on the back of the initiation of collaboration between 
Mr Damian Mole (University of Edinburgh centre for inflammation research, Queen’s 
medical research institute), Dr Scott Webster (BHF centre for cardiovascular science, 
Queen’s medical research institute), Dr Nigel Botting (School of chemistry, St Andrews 
University, R.I.P) and Dr Chris Mowat. The main research goal was the development of 
effective KMO inhibitors for potential therapeutic use. To achieve this several separate 
research areas were combined: i) the organic synthesis of new compounds, ii) in vitro 
and ex vivo testing of compounds on the activity of human KMO, iii) ex vivo testing of 
compounds in models of pathophysiology and iv) structural characterization of the active 
site and inhibitor binding. The research undertaken in this investigation under the 
supervision of Dr Chris Mowat, primarily concerns area iv). 
The first and most critical aim was to solve the 3-D structure of a KMO to obtain a 
detailed picture of the enzyme’s active site and potential ligand interactions. Mammalian 
KMOs have been shown to contain a C-terminal transmembrane region that has made 
them difficult targets for in vitro isolation and characterization. To achieve our goals, the 
bacterial PfKMO was selected as the most promising candidate for study due to its 
previously known solubility and successful purification. Following the successful study of 
this enzyme the determined bacterial structure could be used as a model for the 
prediction/solution of the structure of the human enzyme. Also the screening and 
characterization of new compounds as potential KMO inhibitors could be quickly 
undertaken with PfKMO in in vitro assays. Additional aims dependent on the success of 
the project would include solving the structure with the novel compounds and published 
inhibitors bound to facilitate the rational design of KMO inhibitors. In studying the 
bacterial enzyme, it will be essential at all times to assess the suitability and 
transferability of PfKMO as a model for the study of human KMO. 
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Chapter 2 – Materials & Methods 
 
2.1 Cloning and mutagenesis 
2.1.1 Cloning primers 
Primers were manually designed, checked for formation of secondary structures with the 
online server OligoAnalyzer (Integrated DNA technologies) and purchased desalted from 
Sigma-Aldrich or Invitrogen. A list of all the primer sequences used during cloning in this 
project is shown in table 2.1. 
 
 Primer Sequence 5’-3’ (Restriction sites/mutations) 
1 T7 Promoter TAATACGACTCACTATAGGG 
2 T7 Terminator GCTAGTTATTGCTCAGCGG 
3 PfKMO_NTerm_Nde_F GAAGGAGATATACATATGACTGCTACAGACAACGC 
4 PfKMO_CT_Trunc1_451_R AAGCTTTCAGGTCACTTCGTGCTCCAC 
5 PfKMO_CT_Trunc2_434_R AAGCTTTCAGTTGGCCACTGCGAATTTCAG 
6 PfKMO_CT_Trunc3_409_R AAGCTTTCAGAAGGTGACCATGCTGTAACGC 
7 PfKMO_C168S_F GATGGCAGCAACTCGGCGGTGC 
8 PfKMO_C252S_F CAGCCCGTCTTTTGCGCAACTGG 
9 PfKMO_C453S_R_Xho GGATCTGCTCGAGTCAGCACAGGTGGCTCAAGGGTGGCAGGCTGCGGGTC 
10 PfKMO_C461S_R_Xho GGATCTGCTCGAGTCAGCTCAGGTGGCTC 
11 PfKMO_dm2_R_Xho GGATCTGCTCGAGTCAGCTCAGGTGGCTCAAGGGTGGCAGGCTGCGGGTC 
12 PfKMO_E372T_F GGAAAACTACGTGACGATGAGCAGTAAAGTGG 
13 PfKMO_Y382F_F CCACCTTCTTGCTGGAGCGCGAAC 
14 PfKMO_R386K_F CACCTACTTGCTGGAGAAAGAACTGG 
15 PfKMO_R386T_F CACCTACTTGCTGGAGACCGAACTGG 
16 PfKMO_LOOP1_R GATCACCTTGGTTTGGCAGGAACAACGTCACC 
17 PfKMO_LOOP1_F CAAACCAAGGTGATCCGTCTTTTGCACAAACTGGTG 
   





Table 2.1.  List of primer sequences used during the investigation. Mutated bases are highlighted 
in magenta with restriction sites (NdeI, HindIII & XhoI) in cyan. 
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2.1.2 Polymerase chain reaction (PCR) 
The recombinant WT PfKMO gene incorporated into the vector pET17b was constructed 
and kindly donated by Dr Graham R. Moran (University of Wisconsin-Milwaukee, USA). 
This plasmid contained ampicillin resistance and utilised the T7 RNA polymerase 
transcription system. Mutations within 30 bp of the gene termini were introduced on the 
respective flanking primer in a 50 L PCR. Prior to setting up PCRs, 0.2 mL thin-wall PCR 
tubes, 1.5 mL eppendorfs and all pipette tips were sterilised in an autoclave at 120 oC for 
20 mins. All PCR reaction components (see table 2.2) excluding the polymerase were 
assembled in a sterile 0.2 mL thin-wall PCR tube, vortexed to mix and placed in a thermo 
cycler express PCR machine (Thermo Fisher). Cycling conditions consisted of a step at 96 
oC for 2 mins followed by 25 cycles of 96 oC for 1 min, 50-60 oC for 1 min and 72 oC for 1.5 
mins before a final step at 72 oC for 5 mins. For every PCR run, the cycle was paused 
upon entering the first annealing step and the polymerase was added directly into each 
tube before continuing. The polymerase was not initially added with the rest of the 
reaction mixture due to its 3’-5’ exonuclease activity which was capable of digesting the 
single stranded primers. Templates, primers and annealing temperatures for each PCR 
are listed in table 2.3. 
 
Reaction Component [Final] 
Vent DNA polymerase (3U/L) 1.5 U/PCR 
10x ‘Thermopol Reaction buffer’ 1x 
dNTPs (2.5 mM)  250 M 
Template DNA – plasmid extraction ≈ 1 ng/L 
Forward primer (10 M) 0.4 M 
Reverse primer (10 M) 0.4 M 
EB (10 mM Tris-HCl, pH 8.5) up to 50 L 
 
Mutant Mutations Introduced Template plasmid Primers Tm (
o
C) 
C453S C453S WT – p17b 3 + 9  
C461S C461S WT – p17b 3 + 10  
dm1 (C453S/C461S) C453S/C461S WT – p17b 3 + 11  
dm2 (C252S/C461S) C461S C252S – p17b 3 + 10  
Trunc_409 CT-truncation after pos. 409 WT – p17b 3 + 6  
Trunc_434 CT-truncation after pos. 434 WT – p17b 3 + 5  
Trunc_451 CT-truncation after pos. 451 WT – p17b 3 + 4  
Table 2.2. Final solution components 
for each 50 l PCR reaction. 
Table 2.3. Template, primer and annealing temperatures used to construct each mutant PfKMO form. 
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2.1.3 Megaprimer PCR 
Mutations within the PfKMO gene were introduced using the megaprimer technique 
which involved two separate PCR amplifications. The first PCR was set up as directed in 
section 2.1.2 amplifying from a primer containing the required mutation to the reverse 
flanking primer. The PCR product was run on a 1 % (w/v) agarose gel and purified via gel 
extraction (See section 2.1.5). The amplifed gene segment bearing the desired mutation 
served as a ‘megaprimer’ to complement the forward flanking primer in a second round 
of PCR (PCR 2). Contents of a typical reaction mixture for the second PCR are shown in 
table 2.4. Addition of a small amount of Mg2+, commonly used to lower DNA annealing 
temperatures, was found to slightly enhance the second PCR if initial yields were low. 
Cycling conditions were designed to intially extend only from the megaprimer for a few 
cycles before lowering the annealing temperature to allow the flanking primer to bind. 
An intial step at 96 oC for 2 mins was followed by 4 cycles of 96 oC for 1 min, 75 oC for 45 
s and 68 oC for 45 s before 26 cycles of 96 oC for 1 min, 60 oC for 1.5 min and 72 oC for 1 
min. The PCR concluded with a step of 5 mins at 72 oC. Templates, primers and annealing 
temperatures for each individual PCR are specified in table 2.5. 
 
PCR 2 Reaction Component [Final] Volume (L) 
Vent DNA polymerase (3U/L) 1.5 U/PCR 0.5 
10x ‘Thermopol Reaction buffer’ 1x 5 
dNTPs (2.5 mM)  250 M 5 
Template DNA – plasmid extraction ≈ 1 ng/L 1 
Forward primer (10 M) 0.4 M 2 
Purified ‘megaprimer’ - 15 
MgSO4 (25 mM) (0/0.5 mM) (0/1) 







Table 2.4. Final solution components for each 50 l PCR2 reaction. 
The purified megaprimers were at different concentrations based 










C168S C168S WT-p17b 7 + 2 3 
C252S C252S WT-p17b 8 + 2 3 
R386T/C461S R386T C461S-p17b 15 + 10 3 
R386T dm2 (R386T/C252S/C461S) C252S R386T/C461S-p17b 8 + 10 3 
E372T dm2 (E372T/C252S/C461S) E372T dm2-p17b 12 + 2 3 
Y382F dm2 (Y382FC252S/C461S) Y382F dm2-p17b 13 + 2 3 
R386K dm2 (R386K/C252S/C461S) R386K dm2-p17b 14 + 2 3 
2.1.4 Overlap extension PCR for loop exchange 
 
2.1.4 Overlap extension PCR 
The potential loop region HHQSPAAQPAS (aa 240-250) was mutated to PNQGD using 
overlap extension PCR as summarised in figure 2.1. Two initial PCRs A + B were set up as 
outlined in section 2.1.2. PCR A amplified from the N-terminal flanking primer (primer 3) 
to a reverse primer with a terminal overhang containing the new sequence (primer 16). 
PCR B then amplified from a forward primer (primer 17) bearing the complementary 
overhang to that generated in A to a reverse flanking primer (primer 11). The products 
were run on a 1 % (w/v) agarose gel, excised and purified (see section 2.1.5) and 
combined in a final overlap extension PCR as detailed in table 2.6. The cycling conditions 
were as described for PCR 2 in section 2.1.3.  
 
 
Table 2.5. Template, primer and annealing temperatures used to construct each mutant PfKMO form. 
Figure 2.1. Schematic 
overview of the overlap 
extension PCR process. PCR A 
and PCR B generate two 
separate halves of the gene 
(green) with complimentary 
overlapping ends containing 
the new altered sequence 
(red). These then combine in 
the final step to recreate the 
whole gene. Non-coding 
plasmid regions are shown in 
black with the original target 
sequence in grey. 
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Overlap extension PCR Component [Final] Volume (L) 
Vent DNA polymerase (3U/L) 1.5 U/tube 0.5 
10x ‘Thermopol Reaction buffer’ 1x 5 
dNTPs (2.5 mM)  250 M 5 
Template - PCR A product  - 5 
Template - PCR B product - 5 
F flanking primer 3 (10 M) 0.2 M 1 
R flanking primer 11 (10 M) 0.2 M 1 









‘LOOP1 dm2’  
(HHQSPAAQPAS->PNQGD/C252S/C461S) 
dm2-p17b 3 + 16 17 + 11 
 
 
2.1.5 Agarose gel electophoresis 
Agarose gel electrophoresis is a technique used to separate DNA based on its size. The 
separation properties of a gel were varied by changing the concentration of agarose. 
Typically 0.7 % (w/v) agarose gels were used for plasmid DNA (5-8 kb) whereas 1.0 % 
(w/v) agarose gels were used for PCR products (up to 1.5 kb). Molecular biology grade 
agarose (Fisher) was dissolved in 50 mL TAE buffer (40 mM Tris-acetate pH 8.0, 1 mM 
EDTA) with 2 mins heating in a microwave. After a couple of minutes cooling at room 
temperature, ethidium bromide was added to a concentration of 0.5 g/mL. The edges 
of the gel tank were initially sealed with 1 mL of the molten agarose before the rest was 
poured in and combs were added to form wells. The gel was left for 20 minutes to set 
and then covered with TAE buffer prior to the gentle removal of combs. Samples were 
mixed with the appropriate 6x loading buffer (see table 2.8) and 5-20 L was loaded into 
the wells of the gel alongside 5 L of 1kb full scale DNA ladder (Fisher). A steady current 
of 50-80 A with a voltage of around 80-100 V was applied to the gel until the DNA had 
migrated sufficiently far. DNA was visualised with UV irradiation in a sealed box. The 
target DNA bands of the correct expected size were excised and purified using a 
Table 2.6. Final solution 
components for final 50 l 
recombination reaction.                              
Table 2.7. Template, primer and annealing temperatures used to construct the mutant. 
PfKMO form. 
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PureLink™ gel extraction kit (Invitrogen) with a final elution volume of 40 L of the 
supplied elution buffer.  
 
6x Loading Buffer (made with distilled water) DNA range (kb) 
0.25 % w/v Bromophenol blue, 40 % w/v sucrose > 0.5 
0.25 % w/v Xylene cyanol, 40 % w/v sucrose < 2.0 
   
 
 
2.1.6 Restriction digestion and ligation 
All 50 L of each completed PCR was split across two adjacent wells on a 1 % (w/v) 
agarose gel and the products excised and purified (See section 2.1.5). The respective NEB 
restriction buffer and 40 U of each NEB restriction endonuclease were added, briefly 
vortexed and incubated in a water bath at 37 oC for 4 hours. The plasmid vectors pET17b 
(Amp resistance, no tag) and pET28b (Kan resistance, N-terminal hexa-His tag) extracted 
from cell cultures (see section 2.1.8) were digested similarly. The digested reactions 
were loaded onto a 0.7 % (w/v) agarose gel and the appropriate insert and vector DNA 
bands were gel extracted prior to ligation. Some digested PCR products were simply 
incubated at 70 oC for 10 mins to denature the restriction endonucleases prior to ligation 
– this saved time and resources at the cost of a slightly reduced cloning efficiency. 
Ligation reactions were set up as 10 L mixtures in sterile 1.5 mL eppendorfs, briefly 
vortexed and incubated at 4 oC overnight for 16-20 hours. 
 
2.1.7 Transformation of chemically competent hosts 
Ligation reactions were directly used to transform chemically competent BL21(DE3) cells 
(Stratagene) using the heat shock method. The competent cell stock was thawed on ice 
and to a 50 L aliquot of cells 4 L of ligation reaction or 0.5 L of plasmid solution was 
added. After 30 mins on ice, the mixture was incubated at 42 oC for 20 s before being 
transferred back into the ice bath for 2 minutes. Addition of 0.75 mL of SOC media (see 
Table 2.8. DNA loading buffers for gel electrophoresis with rough 
usable size range for the target DNA band.                             
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section 2.2.1) preceeded incubated at 37 oC for 1 hr. An aliquot of 50-100 L was spread 
onto LB agar (see 2.2.1) plates containing the respective antibiotic for screening and 
incubated at 37 oC for at least 16 hours. Individual colonies were selected and restreaked 
onto fresh agar plates. For long-term storage, a loop full of restreaked cells were gently 
suspended in a 1 mL cryo-vial (Nunc) containing 900 L of LB (see 2.2.1) and 100 L of 
DMSO and stored at -80 oC for up to a year. 
 
Occasionally when low yields of insert/vector were experienced, initial transformation of 
ultra-competent NEB5 cells with ligation reactions was required. Subsequently 
successful clones were transferred into BL21(DE3) cells for expression and protein 
production. For production of SeMet labelled protein, clones were moved into the 
methionine auxotroph B834(DE3) pLys S. When transferring a successful clone to a 
different E.coli strain, the transformation protocol was the same except that 0.5 mL of 
the purified plasmid (see section 2.1.8) was used in place of the ligation reaction. 
 
2.1.8 Extraction of plasmids and Sanger sequencing 
Restreaked transformants were used to inoculate 10 mL of LB plus the respective 
antibiotic and grown for 16 hours at 37 oC in an orbital incubator at around 200 rpm. 
After harvesting cells at 3-4000 g for 10 mins plasmids were extracted and purified using 
a QIAprep spin miniprep kit (Qiagen). Pure plasmids were eluted with 40 L of elution 
buffer into sterile 1.5 mL eppendorfs. The Genepool facility carried out BigDye reactions 
and Sanger sequencing for two samples from each clone. To prepare samples, 5 L of 
pure plasmid (≈ 500 ng) was mixed with 1 L of 3.2 M T7 promoter primer for one 
sample and with 1 L of 3.2 M T7 terminator primer for the second. Typically 700-950 
bp of sequence could be read from each flanking primer and combined to provide the 




2.2 Cell Growth and Protein Production 
2.2.1 Media 
All media/agar used was sterilised by autoclaving at 120 oC for 20 mins and used within 
two days. Antibiotics were added to media/agar at 1x concentration after autoclaving 
but once the solution had cooled down to below 50 oC. When at a similar temperature, 
roughly 25 mL of sterile agar was poured into each Petri dish and allowed to set before 
being stored at 4 oC. Prior to use, agar plates were dried for an hour in a 37 oC incubator. 
The media recipes used during the study are summarised in table 2.9. 
 
LB media Tryptone 10 g/L, Yeast extract 5 g/L, NaCl 8 g/L  (pH 7.0) 
LB agar LB media + Agar 15 g/L  
SOC media 
Tryptone 20 g/L, Yeast extract 5 g/L, NaCl 0.58 g/L, KCl 0.19 
g/L, MgCl2 10 mM, Glucose 20 mM (pH 7.2) 
10x M9 Minimal salts 
(Autoclaved) 
NH4Cl 20 g/L, KH2PO4 60 g/L, Na2HPO4 (anhydrous) 136 g/L 
1000x Metals mix 
(Filter Sterilised) 
0.05 M FeCl3.6H2O, 0.02 M MnCl2.4H2O, 0.02 M ZnSO4.7H2O, 
4 mM CoCl2.6H2O, 4 mM NiCl2.6H2O 
1000x Vitamins mix 
(Filter Sterilised) 
1 mg/mL Riboflavin, Niacinamide, Pyridoxine 
monohydrochloride & Thiamine. 
100x Amino acid mix 1 
(Filter Sterilised) 
4 mg/mL amino acids: Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, 
His, Ile, Leu, Lys, Pro, Ser, Thr, Val 
100x Amino acid mix 2 
(Filter Sterilised) 
4 mg/mL aromatic amino acids: Phe, Trp, Tyr  
(pH 8.0 with NaOH) 
Minimal media 
*glucose autoclaved 
separately as 20 % (w/v) 
1x M9 minimal salts, 1x metals mix, 1x vitamins mix, 1x amino 
acid mix 1, 1x amino acid mix 2, 0.4 % (w/v) D-glucose*, 2 mM 
MgSO4, 40 mg/L L-SeMet (pH 7.2) 
1000x Amp 60 mg/mL Ampicillin 
1000x Chloramphenicol 25 mg/mL Chloramphenicol dissolved in ethanol 
1000x Kan 50 mg/mL Kanamycin  
 
Table 2.9. Media and antibiotic recipes for cell growth. 
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2.2.2 Growth of BL21(DE3) cultures for protein production 
Starter cultures of 10 mL LB plus Amp (pET17b clones) or Kan (pET28b clones) were 
inoculated with the respective frozen DMSO cell stock and grown for 24 hours at 37 oC, 
with shaking at 200 rpm. Each starter culture was used to inoculate separate 1.0 L 
baffled shake flasks containing 1.0 L of LB plus the respective antibiotic. The cultures 
were subsequently incubated for 15-17 hours at 22 oC with shaking at 180 rpm. At the 
end of incubation the A600nm was recorded of a mixture of 50 L of cells with 950 L of 
H2O. Multiplication by the dilution factor of the mixture gave the OD of the culture. 
Cultures were harvested by centrifugation for 45 mins at 30000 g at 4 oC when they 
reached an OD of 1.0-2.0. The cell pellets were stored at -20 oC until required.  
 
2.2.3 Growth of B834(DE3) pLys S cultures 
B834(DE3) pLys S cells were grown in minimal media supplied with all amino acids except 
methionine and to allow production of SeMet labelled PfKMO. Starter cultures were 
grown in LB media plus Amp/Kan and chloramphenicol (pLys S) as described in section 
2.1.3. Subsequently each starter culture was used to innoculate 1.0 L of minimal media 
(see section 2.2.1) containing the required antibiotics. The cultures were initially grown 
at 30 oC with shaking at 180 rpm until an OD of 0.6-1.0. At this point IPTG was added to 
0.1 mM, the temperature lowered to 22 oC and the cultures were grown for a further 4 
hours. The cells were then harvested as described in section 2.2.2.  
 
2.3 Protein Isolation and Purification 
2.3.1 Purification buffers 
The composition of the buffers used during this investigation is described in table 2.10. 
During purification of protein for crystallography, HPLC grade water was used to make 
the S-75 buffer. All buffers were made fresh for each purification and stored at 4 oC. DTT 




Resuspension Buffer 20 mM HEPES pH 7.5 
 10 mM NaCl 
  1.0 mM DTT 
100x PMSF 0.2 M PMSF dissolved in ethanol 
Q-Seph Elution Buffer 20 mM HEPES pH 7.5 
  110 mM NaCl 
  1.0 mM DTT 
Ammonium Sulphate Buffer 20 mM HEPES pH 7.5 
  75 % saturated ammonium sulphate 
  1.0 mM DTT 
G-25 Buffer (Assays) 20 mM HEPES pH 6.8 
  10 mM NaCl 
 1.0 mM DTT 
S-75 Buffer (Crystallography) 20 mM HEPES pH 6.8 
  150 mM Na acetate 




2.3.2 Cell lysis 
Frozen cell pellets were thawed at room temperature and resuspended to a 
concentration of 1 g per 10 mL of resuspension buffer plus 1x PMSF. Aliquots of 
resuspended cells of 30-50 mL were lysed by sonication on ice with 6 rounds of 20 s 
pulses. The lysate was clarified by 4 oC centrifugation at 30000 g for 50 mins and the 
insoluble pellet discarded. The supernatant containing soluble proteins, nucleic acids and 
other cytosolic compounds was filtered using a 0.22 m syringe filter. The filtered crude 
protein solution was used immediately for purification. 
 
Table 2.10. Purification buffer compositions. 
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2.3.3 Purification of PfKMO for assays 
The filtered crude protein solution was loaded onto a 60 mL FPLC Q-sepharose 26/10 
column pre-equilibrated with resuspension buffer. The flowthrough of unbound proteins 
was discarded. The column was then washed with Q-sepharose elution buffer which 
contained 110 mM NaCl. After 100 mL of washing, PfKMO and free FAD would 
consistently elute as a yellow band with absorbance peaks at 280, 375 & 450 nm. 
Fractions of 5 mL elute were collected in test tubes using an automatic fraction collector. 
Fractions with absorbance at 450 nm were assayed for PfKMO activity as described in 
section 2.5.1. Those fractions containing activity greater than a A340/min of 0.500 were 
pooled. 
The pooled Q-sepharose eluate was slowly brought to 50 % ammonium sulphate 
saturation by addition of ammonium sulphate buffer with constant, but very gentle, 
stirring. After 10 mins of equilibration, the solution/suspension was centrifuged at 20000 
g for 15 mins to pellet pure, precipitated PfKMO. The supernatant was discarded. 
Pelleted PfKMO, visibly yellow, was incubated for 10 mins in G-25 buffer and then gently 
resuspended by inversion. A total volume of around 60 – 80 mL of G-25 buffer was used, 
with roughly 15 mL per pellet. The pooled solution of resuspended enzyme was 
concentrated to <5 mL using Millipore 30 kDa MWCO spin columns centrifuged at 1,000 
g. Concentration was performed as quickly as possible to minimise precipitation of 
PfKMO due to residual ammonium sulphate from the previous step. 
The concentrated solution was filtered with a 0.22 m syringe filter and loaded onto a 
pre-equilibrated 20 mL G-25 column to remove residual ammonium sulphate. The 
column was pre-equilibrated with G-25 buffer. The yellow, PfKMO band was followed 
and collected in a sterile plastic bijou tube. The concentration of PfKMO was estimated 
(see section 2.4.2) and the protein solution was diluted to 10 M using G25 buffer, with 
the addition of glycerol to a final concentration of 5 % (v/v). The PfKMO solution was 
aliquotted out into 1 mL cryovials and flash-frozen in liquid nitrogen. The protein was 
then stored at -80 oC until required. 
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2.3.4 Purification of PfKMO for X-ray crystallography 
For protein purified for X-ray crystallography, an additional size-exclusion 
chromatography step was added to the purification protocol described in section 2.3.3. 
This step not only improved protein purity but more importantly it improved the 
homogeneity of the PfKMO solution, separating monomeric protein from higher 
molecular weight aggregates. The protein solution eluted from the G-25 column was 
concentrated to a volume of approximately 1 mL and injected onto a 280 mL HiLoad 
26/10 S-75 FPLC column pre-equilibrated with S-75 buffer. The absorbance at 280, 363 & 
450 nm of the eluted solution was monitored throughout. The yellow protein peak that 
eluted at the volume expected for monomeric 50 kDa PfKMO was collected as 1 mL 
fractions with an automated fraction collector. The expected volume was determined 





Figure 2.2. Calibration curve for S-75 chromatography showing the volume of 
eluate corresponding to the log(molecular weight) for several standard proteins. 
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Fractions with the smallest ratio of A280nm:A450nm, representing the ratio of total 
protein:PfKMO, were pooled. The protein concentration was estimated (see section 
2.4.2) and the solution was then concentrated with 30 kDa MWCO spin columns to the 
concentration required for crystallography, typically 5-15 mg/ml. It was observed that 
substrate-bound crystal forms required greater protein concentrations than substrate-
free forms to grow crystals. During concentration, the protein solution was diluted with 
S-75 buffer dilution buffer to dilute the Na acetate from 150 mM to around 20-30 mM. 
For the growth of L-Kyn soaked crystals, L-Kyn was dissolved in S-75 dilution buffer 
(typically as a 10 mM stock) and added to the protein solution to a final concentration of 
1 mM. Aliquots of 25 or 50 L were flash-frozen and stored at -80 oC. Addition of glycerol 
prevented crystal formation at the protein concentrations tested. 
 
2.4 Analysis of enzyme concentration and purity 
2.4.1 SDS poly-acrylamide gel electrophoresis (SDS-PAGE)    
SDS-PAGE is a method for separating proteins based on their molecular weight. The 
anionic detergent SDS denatures the proteins in the sample and binds to the polypeptide 
chain at regular intervals to apply a negative charge. The protein solution is boiled in 
order to help completely denature the proteins in the sample. During electrophoresis a 
current is passed through the gel so that negatively charged SDS migrates towards the 
anode. The longer the polypeptide chain, the slower the migration through the gel so 
that chains are effectively separated based on their size. Comparison with standard 
known molecular weight proteins allows the estimation of molecular weight based on 
distance migrated in a set time period. 
20 L of protein solution was mixed with 20 L of 1 NuPAGE sample buffer in an 
eppendorf tube and left in boiling water for 5 minutes. Up to 20 L was loaded into the 
wells of a pre-poured 12 % NuPAGE bis-tris gel (Invitrogen) alongside 5 L of Seeblue 
Plus 2 (Invitrogen) molecular marker. The gel was pre-placed and then run in 1 NuPAGE 
MOPS running buffer (Invitrogen). A voltage of 150 V (120 mA, 60 W) was applied for 
approximately one hour until the dye front reached the bottom of the gel. The gel was 
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then removed and soaked in Coomassie blue stain (40 % methanol, 10 % acetic acid, 1 % 
Coomassie brilliant blue) with agitation for 20-25 mins. The stain was removed and the 
gel was left in hot water or in destain (50 % water, 40 % methanol, 10 % acetic acid) until 
blue protein bands were clearly visible. 
 
2.4.2 Spectrophotometry 
When Crozier & Moran purified PfKMO in 2007 [2] they calculated the extinction 
coefficient () for KMO-bound FAD at 450 nm to be 12300 M-1cm-1 at pH 7.0. Throughout 
the investigation, this value was used to estimate the concentration of the PfKMO in 
solution by manipulating the equation A = cL (A = absorbance,  = extinction coefficient, 
c = concentration & L = path-length, i.e. width of cuvette). The 250-800 nm absorption 
spectra of protein purification samples using a quartz cuvette was recorded to identify 
fractions containing PfKMO. Such spectra also provided an instant estimation of the 
purity of PfKMO by measuring the ratio of A280:A450, with values < 7.0 indicating a 
suitable purity for crystallographic study.  
 
2.5 PfKMO kinetic analysis 
2.5.1 Measuring the rate of turnover 
Figure 2.3 shows the UV-vis absorbance spectrum of each of the substrates L-kynurenine 
and NADPH, and the products 3-HK and NADP+ of PfKMO turnover. Notably the 
absorbance peak of 3-HK is only slightly blue-shifted by 17 nm from that of the starting 
compound, L-kynurenine. On the other hand, generation of NADP+ results in complete 
loss of the large absorbance peak seen with NADPH. The UV-vis spectra in figure 2.4 
show the change in absorbance over time during typical PfKMO catalysis with excess 
substrates. There are two visible changes occurring, the large fall at 340 nm as NADPH is 
oxidised and a relatively small increase between 380-450 nm due to conversion of L-







To quantify PfKMO-catalysed turnover of L-kynurenine, NADPH oxidation was measured 
by monitoring the absorbance change at a single wavelength of 340nm for a 1mL 
reaction mixture in a quartz cuvette. The typical 1x assay buffer consisted of 20 mM 
HEPES pH 8.0 unless stated otherwise. The enzyme was added last to initiate the 
reaction (with gentle inversion to mix) and the absorbance was recorded for one minute. 
The reaction rate was measured from the initial, linear absorbance change (the first 5-30 
s depending on enzyme/substrate concentrations). In this timescale the pseudo-steady-
state hypothesis is valid and the reaction obeys Michaelis-Menten kinetics. Morevover, 
the second substrate NADPH was present in excess and did not limit the overall reaction 
rate. Where use of excess substrates are detailed, 250 M NADPH and 200 M L-
Figure 2.3. UV-vis absorption 
spectra for the substrates and 
products involved in the 
reaction catalysed by KMO. 
 
Figure 2.4. Absorbance spectra 
taken at regular time intervals 
during a reaction of PfKMO with 
excess L-kynurenine and 
NADPH.  
The red arrow indicates the fall 




The blue arrow shows the 
increase in absorbance as 3-HK 





kynurenine were the concentrations used. Generally, turnover was measured with 0.1 
M pure PfKMO or 50 L of crude protein samples (during purification). The rate of 
absorbance change per minute was converted into turnover (s-1) using equation 2.1. For 
negative controls, the rate was measured in the absence of L-kynurenine and in the 
absence of enzyme before commencing a set of assays. All reactions were conducted at 









2.4.2 Determination of kinetic constants kcat and Km 
 
The rate of turnover of PfKMO over varying concentrations of L-kynurenine was 
measured to determine the catalytic constants kcat and Km. The standard assay buffer 
was 20 mM HEPES pH 7.5, 2 mM DTT, 10 mM NaCl. Excess NADPH (250 M) was present 
and the concentration of L-kynurenine was varied from 0-250 M (> 15 different values). 
The final concentration of PfKMO present in each assay was 0.1 M. The kcat and Km were 
determined from a Michaelis-Menten curve fitted to a plot of turnover against 
concentration of L-kynurenine, using Origin 8 graphing software (OriginLab Corporation). 
Each set of assays was run three times to ensure the data were reliable, with final values 
for the kinetic constants determined from the averages of the separate runs. A plot from 
a single run with dm2 PfKMO is shown in figure 2.5. The error within measuring the 
initial rate data due to background noise/pipetting variations was estimated to be 
around 1-15 % depending on the extent of the absorbance change being measured. 
 
Equation 2.1. Converting change in absorbance into a value for NADPH turnover.  











2.5 Investigating Inhibition of PfKMO 
2.5.1 Screening potential PfKMO inhibitors 
Initially 20 mM stocks of each compound were made up with water or with DMSO 
depending on solubility. Stocks were stored at -20 oC in between uses. Screening 
involved testing the rate of turnover of 50 M L-Kyn by 0.1 M PfKMO in the presence of 
0.5-100.0 M of each inhibitor. This was assayed as described in section 2.4.1 and 
compared to turnover in the absence of inhibitor (replaced with water/ DMSO) which 
was measured in triplicate to get an accurate average. The relative percentage inhibition 
was calculated for each compound relative based on the measured turnover numbers.  
 
Figure 2.5. Michaelis-Menten plot for dm2 PfKMO showing the relationship between the rate of 
turnover and substrate concentration. The R
2
 value and determined kinetic constants for the plot 
are displayed. 
 
R2 = 0.99 
Km = 11.0 ± 0.5 M 




2.5.2 96-well plate-based compound screening 
As a greater number of compounds were arriving to be tested the need for a high-
throughput 96-well plate screen arose. For this purpose a SpectraMax M5 multimode 
plate reader (Molecular Devices) was set to 25 oC with a 2 s plate mixing period before 
commencing data recording. For data collection, a multipipette was used to start the 
reaction in a whole column of eight wells simultaneously by addition of the substrate, L-
Kyn. The reaction was run for three minutes with A340 values measured every 8s for each 
well. In addition before substrate was added the absorbance change was similarly 
recorded for two minutes to check the background rate of uncoupled NADPH oxidation 
and the A600 was measured to check for compound precipitation. Following the assay, 
the A340 was plotted for each well and the reaction rate calculated from the initial linear 
period. The background rate was then subtracted before the percentage inhibition was 
determined relative to uninhibited controls. The first row of wells on the plate contained 
the negative controls, where the inhibitor was replaced by water or DMSO depending on 
the solvent used to suspend the compounds being tested. The final reaction components 
are detailed in table 2.11. DMSO was limited to 3 % v/v to balance compound solubility 







2.5.3 Characterisation of PfKMO inhibitors 
The turnover of PfKMO was measured over 6-9 concentrations of L-kynurenine (in the 
range 0-200 M) and repeated in the presence of increasing concentrations of a 
potential inhibitor compound. Typically 5-7 inhibitor concentrations were selected in 
addition to a set of reactions with no inhibitor (substituted by water/DMSO).  As a rough 
Component  Volume [Final] 
NADPH (2.5 mM) 25.0 l 250 M 
Inhibitor (333.3 M) 7.5 l 10 M 
Assay buffer (34.25 mM HEPES pH 8.0) 182.5 l 25 mM 
KMO (2.5 M) 10.0 l 0.1 M 
L-Kyn (0.5 mM) 25.0 l 50 M 
 (250 l)  
Table 2.11. Final reaction 
components each well of the 
96-well plate for inhibitor 
screening. 
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guide a concentration of inhibitor that showed 20 % inhibition in screening would be 
around the Ki value for that compound. This provided a suitable middle concentration 
when choosing the range of inhibitor concentrations to be tested. Typically a broad 
range of substrate concentrations with a relatively narrow range of inhibitor 
concentrations provided the best data.  
Both substrate and inhibitor concentrations were made up using dilution series from 
initial stocks. Inhibitors were diluted with whichever solvent was used to initially dissolve 
the respective compound. Sufficient buffer was made for the whole experiment and pre-
incubated in 30 mL falcon tubes in a 25 oC water bath at least 30 mins before data 
collection commenced. NADPH and the enzyme were kept on ice during the entire 
experiment and concentrations were tested in a random order to minimise the influence 
of enzyme denaturation during proceedings. The final reaction components are 








Data were plotted for each kynurenine concentration with 1/v (y-axis) against [inhibitor] 
(x-axis). Each series of kynurenine concentrations generated straight lines of best-fit that 
intersected at -Ki on the x-axis and 1/kcat on the y-axis.  Due to experimental error within 
the data, the lines generally did not all intersect perfectly at just one location. Therefore, 
all the intersection points were considered and the average value used to estimate the Ki 
value. Standard deviation of all the intersections provided an estimate for the error of 
the Ki. The type of inhibition was determined from a plot of [S]/v (y-axis) against 
[inhibitor] (x-axis) as described in section 1.5.2. Each set of assays were repeated three 
times, each with newly made buffer, NADPH, substrate stocks and inhibitor stocks and a 
fresh aliquot of enzyme to determine an accurate, average Ki value. An example of the 
two plot types is displayed in figures 2.6 and 2.7 from assay data obtained with the 
inhibitor GM769. 
Component  1 x (Final conc.) 
NADPH (10 mM) 25 L 250 M 
L-Kyn (stocks) 20 L varied 
Inhibitor (stocks) 20 L varied 
KMO (10 M) 10 L 0.1 M 
Assay buffer (section 2.5.1) 925 L  
Table 2.12. Final reaction 
components for absorbance-












Figure 2.6. Dixon plot of 1/v 
against concentration of the 
inhibitor GM769 for 
different concentrations of 
substrate. The Ki was 
determined from the 
average of all measured 
intersection points between 
the lines of best fit. 
Figure 2.7. A plot of [S]/v 
against concentration of the 
inhibitor GM769 for different 
substrate concentrations. The 
relatively parallel nature of 
the best-fit lines suggests 
competitive inhibition. 
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2.6 Enzyme Crystallisation for Structure Determination 
2.6.1 Crystallisation by vapour diffusion  
Crystallisation trials with purified PfKMO were set up using 24-well Linbro trays 
(Hampton research/Molecular Dimensions) and siliconised cover slips. Paraffin oil was 
used to grease the rims of the wells to generate effective seals with the cover slips. 
Either 500 L or 1000 L of different reservoir solutions was added to each well. On each 
cover slip, 1 L of reservoir solution was pipetted into a 1 L drop of protein solution. 
The cover slip was then inverted and placed over the respective well. Trays were sealed 
in aluminium foil to prevent photo-bleaching of the FAD cofactor and were incubated at 
4oC or 17oC. The sealed drops were observed under a light microscope daily for 4 days 
and subsequently on a weekly basis.  
 
Initial screening with PfKMO involved setting up hanging drop vapour diffusion (h.d.v.d) 
trays with two drops per cover slip – one with PfKMO and one with PfKMO pre-soaked 
with 1mM L-kynurenine. Commercially-available Hampton Research screening kits (HR2-
110, HR2-112, HR2-107, HR2-109, HR2-114, HR2-116 and HR2-126), with a range of 
different ready-made solutions were used to search for conditions that grow crystals. 
Trays were incubated at 4 oC or 17 oC. Sitting drop vapour diffusion (s.d.v.d) trays were 
also used during the growth of inhibitor-bound crystals. This involved the addition of 1 l 
of both protein and reservoir solution in to a raised well above 500 l of reservoir 
solution. Each well was sealed with clear tape. 
 
2.7.2 Crystal growth using micro-seeding  
Microseeding was combined with crystallisation screening trials and optimisation 
attempts to promote the growth of single crystals. To prepare the hetero-seed solution, 
a native substrate bound dm2 crystal was crushed, transferred to 100 l of stabilising 
solution (0.1 M HEPES pH 7.0, 20 % v/v PEGMME 550, 10 % v/v 2-propanol) and micro-
centrifuged to pellet large crystal fragments. The remaining supernatant was transferred 
to a new eppendorf and used to create serial dilutions via the transfer of 10 l of seed 
solution into 90 l of stabilising solution. During crystal growth the the different dilutions 
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were tried for the growth of single regular crystals. Dilutions were stored at -20 oC for re-
use over a period of a few months. The procedure was also incorporated into 
commercial vapour-diffusion screening but failed to yield new conditions for the growth 
of PfKMO crystals. 
 
2.7.3 Flash-freezing crystals and data collection 
Single protein crystals were removed from their drop by mounting in loops and flash-
frozen in liquid nitrogen. To prevent the formation of damaging ice crystals, protein 
crystals were soaked in a cryoprotectant solution before freezing. The cryoprotectants 
initially explored were the mother liquor plus 10 or 20 % (saturation) ammonium 
sulphate, (w/v) ethyleneglycol, (w/v) xylitol, (w/v) MOPEG or (v/v) glycerol. Ultimately, 
complete cryoprotection was achieved with short 5-10s sequential soaks in mother 
liquor plus 10 % and then plus 20 % ethylene glycol (EG). Alternatively some crystals 
benefitted from addition of 1 l of the cryoprotectant (mother liquor plus 20 % EG) to 
the crystal drop prior to soaking in the cryoprotectant. Frozen crystals were either 
immediately screened for diffraction using the in-house x-ray generator or stored in a 
Dewar vessel full of liquid nitrogen. For the collection of complete datasets, crystals 
were taken to several beamlines at the Diamond Light Source synchrotron in Oxford.  
Initially crystals were screened to test their diffraction by collecting three single images 
90o apart using minimal beam intensity. Different edges of the crystal or at times whole 
crystal grid scans were used to identify the strongest diffracting region. Subsequently 
complete datasets were collected using a rotation range based on the strategy output 
from imosflm. Fine slicing with 0.2 or 0.3 o rotations per image provided the best data 
when matched with an equal exposure (in seconds per degree). A reduced beam 
intensity was used for the collection of a first dataset before higher intensities were 
attempted on neighbouring patches of the crystal. Large (>0.2 mm3), substrate and non-
substrate effector bound crystals required the maximal available beam intensities to 
maximise the resolution. Often the crystals displayed asymmetrical diffraction properties 
requiring testing of multiple angles to identify the most profitable region to collect. After 
collection, images were indexed and integrated with imosflm [240], tested for the best 
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Laue group with Pointless [241] and scaled with Scala [242] during which a random 5 % 
of the reflections were separated for the calculation of Rfree during refinement. 
Inspection of the output log graphs and removal of images with high Rmerge values (whilst 
maintaining complete datasets) helped to improve data quality. The process was 
coordinated with the CCP4 program suite [242].  
 
2.7.4 Data collection with selenomethionine labelling  
Selenomethionine (SeMet) labelled protein in a multiwavelength anomalous diffraction 
(MAD) experiment was used to solve the first PfKMO structure. This involved the 
collection of four complete datasets using different regions of the same crystal. Different 
X-ray wavelengths were used as determined by a fluorescence scan of the mounted 
crystal controlled by the program CHOOCH [243]. An output scan for the SeMet crystal is 
displayed in figure 2.8. The four wavelengths chosen, known as: peak, inflection, high 
energy remote (HER) and low energy remote (LER), were selected by the X-ray 
wavelength corresponding to: the peak f’’ energy, the peak f’ energy, a value in the post-
peak plateau and a value in the pre-peak plateau. Each dataset was separately indexed 
and integrated and separately scaled with anomalous pairs separated for merging 
statistics. 
 
Figure 2.8. CHOOCH output displaying fluorescence scan with f’’ (above) and f’ (below) absorption at 
each X-ray energy. The peak and inflection values are labelled. The data were collected from the 
SeMet dm2 substrate-bound crystal used for final data collection at synchrotron beamline I04. 
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3.1.1 KMO from Pseudomonas fluorescens 
Eukaryotic KMOs have been shown to contain a C-terminal trans-membrane helix that 
anchors them on to the outer mitochondrial membrane [182, 191] (see section 1.3). It is 
widely known that any proteins with such membrane binding domains are intrinsically 
more difficult to study in vitro due to solubility issues. Whilst there are many detergents 
available these days for successfully purifying membrane proteins, there is still a large 
bottle-neck when it comes to trying to grow crystals suitable for X-ray diffraction and 
structure solution. With bacterial forms of KMO showing reasonable sequence similarity, 
but crucially lacking this C-terminal trans-membrane region, they offered a potentially 
easier route towards KMO structure solution. Therefore KMO from Pseudomonas 
fluorescens (PfKMO) was selected for this investigation as this form had previously been 
cloned and was readily purified and extensively characterised by Crozier-Reabe & Moran 
[1, 2]. PfKMO shares 32 % identity and 51 % sequence similarity with the entire human 
KMO protein as determined using an Emboss needle pairwise alignment (See appendix 
section 1.1 for full alignment). It is 461 residues long with a pI of 6.20 and functions as a 
monomeric 50.7 kDa class A flavin-dependent aromatic hydroxylase (FAH). 
 
3.1.2 FAH crystallization 
As highlighted in section 1.2, there have been numerous FAH crystal structures that have 
been solved in recent years, and these are summarised in Table 3.1. A diagram depicting 
the 3-D structures of each of the enzymes was shown in section 1.2.3.2. Each has a 
similar 3-D fold with conserved structural elements corresponding to the FAD and 
substrate binding domains. At the C-terminus of the enzymes the conservation breaks 
down, often with extensions consisting of whole new domains. Typically the shorter C-
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termini simply seal the back of the substrate binding pocket from bulk solvent. The larger 
C-terminal extensions found in PhH, m-HBH, AVH, RebC, PgaE and CabE form a 
thioredoxin-like fold [170, 172, 174, 175, 177]. This third domain has no known function 
in the FAHs except occasional involvement in dimerization. From alignments constructed 
using the EMBOSS needle pairwise alignment tool, the most similar sequences to PfKMO 





Some of the structures present direct visualization of each of the two flavin 
conformations required during catalysis. Interestingly there is no conserved pattern 
between the flavin conformation and the presence/absence of substrate but the flavin is 
most commonly found in the in orientation. In four of the thirteen cases both substrate 
free and substrate bound forms of the respective enzyme have been obtained, each with 
no evident changes in the crystal lattice. The size and structure of the aromatic 
substrates varies in each case but they are always bound in a buried pocket between 
        PfKMO alignment* 
FAH pdb Ligand Flavin Res. (Å) Lattice Res. Dom. % ID/cons Score 
PQSL 2x3n None Mixed 1.75 P 21 21 21 399 2 23/32 227 
MHPCO 3gmb None In 2.10 C 2 379 2 22/35 227 
 3gmc Substrate In 2.10 C 2     
AVH 3ihg Substrate Out 2.49 P 63 535 3 19/28 185 
TetX 2xdo None In 2.09 P 1 378 2 21/33 182 
 2y6q Substrate 1 In 2.37 P 1     
 2y6r Substrate 2 In 3.10 P 1     
phzS 3c96 None Out 1.90 P 21 21 2 402 2 20/29 160 
p-HBH 1pbe Substrate In 1.90 C 2 2 21 394 2 20/32 159 
PhH 1pn0 Substrate Mixed 1.70 P 21 665 3 16/25 142 
HpxO 3rp6 None In 2.20 P 21 21 21 384 2 18/29 135 
 3rp7 Substrate In 2.04 P 21 21 21     
CabE 2qa2 None In 2.70 P 65 2 2 489 3 17/27 117 
PgaE 2qa1 None In 1.80 F 2 2 2 491 3 21/33 113 
DHPH 2vou None In 2.60 P 32 2 1  397 2 19/32 111 
m-HBH 2dkh Substrate Out 1.80 P 32 2 1 639 3 16/27 92 
RebC 2r0c None Out 1.80 P 21 529 3 18/26 89 
 2r0g Substrate In 2.37 P 21     
 2r0p Substrate Anal. Out 2.10 P 21     
Table 3.1, A summary of current FAH crystal structures and their sequence similarity to PfKMO. Res. 
= number of residues in chain, Dom. = number of domains in each single polypeptide chain structure. 
% ID/cons = % identical residues and % conserved residues, score = alignment strength assigned by 
program. 
*EMBOSS needle pairwise alignment used for whole sequences relative to the length of the largest 
sequence. For references and full protein identification see section 1.2.3.2. 
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domains 1 and 2. The substrate carbon that is hydroxylated by each enzyme is 
superimposable, positioned 4-5 Å from the flavin C4a atom responsible for forming the 
catalytic hydroperoxy intermediate. 
 
3.1.3 Structural information from other L-kynurenine catabolizing 
enzymes 
As displayed in section 1.1, the kynurenine pathway can diverge down three possible 
routes at the stable intermediate L-Kyn. Of course one route proceeds via KMO but this 
leaves two other enzymes that utilise L-Kyn as a substrate – kynureninase (KYNase) and 
kynurenine amino transferase (KAT). Whilst the enzymes are functionally and structurally 
unrelated to KMOs, information about how these enzymes bind L-Kyn may be useful in 
the understanding of L-Kyn binding in KMOs. Mammalian KATs I, II, III and IV are capable 
of catalyzing the transamination reaction that transforms L-Kyn into KYNA and belong to 
the class of fold-type I pyridoxal 5-phosphate (PLP)-dependent enzymes. Crystal 
structures of KAT enzymes with L-Kyn bound have recently emerged including those of 
human KAT II at 1.95 Å resolution [244], mouse KAT III at 2.8 Å resolution [245] and 
mouse KAT IV at 2.4 Å resolution [246]. The key protein-substrate binding interactions in 
each are displayed below in figure 3.1. Interestingly, some of the substrate interactions 
and even the substrate orientation vary between each form of KAT. In each active site 
though, there are conserved Asn and Arg side chains that form crucial interactions to 



























KYNase is also a PLP-dependent enzyme that catalyses the hydrolytic cleavage of 3-HK into 3-
HAA and L-Ala. Bacterial and some fungal KYNases preferentially cleave L-Kyn over 3-HK to 
give AA and L-Ala. Crystal structures have been solved of bacterial forms of KYNase, but 
unfortunately not with L-Kyn bound. The only KYNase crystal structure with a ligand bound is 
of the human enzyme with 3-hydroxyhippuric acid (3XH) - an inhibitory analogue of 3-HK – 
bound, which is at a resolution of 1.70 Å [247]. The active site from this structure is displayed 
below in figure 3.2. As might be expected, there is again a conserved arginine side-chain that 
forms a salt bridge with the ligand’s carboxyl tail. In human KYNase additional interactions 
with the carboxyl group are formed by the side-chain of a serine and a histidine residue. 
Whilst the substrate binding sites of KYNase and the KAT enzymes may not allow direct 
Figure 3.1. Residues and potential 
interactions in the substrate binding 
sites from crystal structures of: 
Human KATII (pdb 2r2n) 
Mouse KATIII (pdb 3e2z) 
Mouse KAT IV (pdb 3pd6) 
Protein residues are shown in green 
and the substrate L-Kyn is shown in 
cyan sticks. Relevant interatomic 
distances (excluding hydrogen) are 
labelled. 
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modelling of the respective L-Kyn binding environment in KMO, they may be useful when 
assessing the selectivity of KMO inhibitors that are competitive with regards to L-Kyn 
binding.       
 
          
 
3.1.4 Aims 
The main and initial aim of this work was to solve a KMO crystal structure using the bacterial 
form from Pseudomonas fluorescens. The enzyme was to be produced in E.coli expression 
strains and purified without a tag using the protocols developed by Crozier & Moran [2]. 
Following successful purification, conditions were to be found and refined for the successful 
growth of strongly diffracting PfKMO crystals. If possible, structures of both the substrate 
bound and substrate free forms of the enzyme were to be solved. More than just solving the 
3-D structure, the aim was to significantly develop the structural understanding of the 
enzyme and assess the relevance of this information to human KMO. Moreover, knowledge 
of structural information regarding KMO enzymes and the key interactions involved in 
substrate binding would help the rational development of novel KMO inhibitors for 
therapeutic use. 
 
Figure 3.2. Residues and potential 
interactions in the substrate binding 
site from the crystal structure of 
Human KYNase (pdb 3e9k) 
Protein residues are shown in green 
and the competitive inhibitor 3XH is 
shown in violet sticks. All relevant 
interatomic distances labelled. 
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3.2 PfKMO – Structural insights from bioinformatics 
3.2.1 Insights from in silico structure prediction tools 
The webservers XtalPred [248], SERp [249] and foldIndex [250] were used to predict the 
possible likelihood of success of PfKMO and human KMO crystallization and to predict 
potentially hindering features of their amino acid sequences. XtalPred uses analysis of 
patterns from protein sequences that either lead to successful or failed attempts at 
crystallization. SERp analyses protein sequences to identify patches of consecutive high 
entropy residues that are unfavourable and could hinder the formation of crystal 
contacts. Without structural knowledge there is no guarantee that patches identified will 
be positioned on the protein’s surface to actually affect crystallization. Finally FoldIndex 
looks at the physicochemical properties of local groups of residues to identify potential 
areas of the sequence that are likely to be disordered. The output results from each 
were compared to values obtained from the current range of successfully crystallised 
FAH enzymes. The data are displayed in table 3.2.  
XtalPred analysis of the PfKMO sequence placed it in the lowest crystallization class, 
which represents sequences most suitable for crystallization. As can be seen from 
analysis of the FAH sequences, this assigned class is not definitive as the crystal structure 
of two enzymes (PhH & m-HBH) that were placed in class 4 out of 5 were solved to 
resolutions of 1.70 and 1.80 Å respectively. Despite these anomalies it was still pertinent 
to note that the sequence of human KMO was placed in the highest, most unsuitable 
class, which was likely to be due to the presence of a transmembrane region. The 
biophysical analysis of the PfKMO sequence revealed no major abnormalities relative to 
the crystallised FAH enzymes. Human KMO did though possess relatively high pI, 
instability index and GRAVY hydrophobicity values. High entropy residues did not appear 
to be a major problem for potential crystallization of KMO, although it only takes a few 
strategically positioned to disrupt the formation of a favourable crystal contact. 
Interestingly both KMO sequences had a relatively high percentage of helices, which may 
reflect a prediction of the nature of the unconserved C-terminal residues of the enzyme. 
In all the bioinformatics analysis was not conceived to directly discover whether PfKMO 
could be crystallised. Importantly though it revealed that there were no obvious 
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problems within the amino acid sequence of PfKMO that needed addressing before 
starting the investigation.  
 
 Results for crystallised FAH enzymes   
Analysis Lowest - highest values Average PfKMO Human KMO 
Crystallization class1 1 (optimal) – 4 (diff.) 2 (suboptimal) 1 (optimal) 5 (very diff.) 
Isoelectric point 4.9 – 6.8 5.7 6.2 9.2 
N residues 378 – 665 413 461 486 
Instability index 24.7 – 42.7 36.1 34.5 42.2 
GRAVY index -0.52 – -0.08 -0.23 -0.16 -0.08 
Predicted Disordered  0 – 6 % 2 % 2 % 3 % 
Predicted Coil  34 – 49 % 41 % 41 % 34 % 
Predicted Helix 29 – 39 % 33 % 39 % 44 % 
Predicted Sheets  22 – 27 % 25 % 20 % 22 % 
Residues = K, E, Q  8.4 – 18.8 % 12.9 % 12.6 % 13.2 % 
SERp outcome2 3 – 7 patches  
(2.4-7.64) 
4 patches  
(4.0) 




FoldIndex: unfoldability3 0.064 – 0.190 0.147 0.176 0.189 
                    charge 0.006 – 0.045 0.022 0.017 0.027 
                    phobic 0.442 – 0.491 0.474 0.483 0.491 







Table 3.2. Biophysical predictions and analysis from amino acid sequences using XtalPred, SERp and 
foldIndex servers. Results for sequences of FAH enzymes with solved crystal structures (including all those 
listed in Table 3.1) were collated with lowest, highest and average values displayed. For comparison the 
results based on the sequences of PfKMO and human KMO are also displayed. The data is colour coded 
with low values (or more promising values) in green, medium in blue and high (or more unsuitable values) 
in red. Values outside the observed range for FAH enzymes are bold with yellow highlighting. 
1
 Predicted propensity of sequence features towards successful crystallization, scale of 1 = optimal to 5 = 
very difficult. 
2
 SERp server identifies patches of consecutive high entropy residues in the sequence that may hinder 
formation of stable crystal contacts. The value in parenthesis represents the lowest and highest scores 
assigned to selected patches with higher values indicating more harmful patches. 
3
 The unfoldability value represents the average from all of the residues; a high value represents a greater 
propensity to being folded whereas a low values represents a greater likelihood that a residue is 
disordered. 
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3.2.2 Insights from primary sequence alignments  
A colour-coded alignment of the sequence of PfKMO with the sequences of known FAH 
enzymes revealed only strong conservational blocks around the three FAD-binding 
motifs GxGxxG, DG and GD as shown below in figure 3.3. As with the other FAH enzymes 
these motifs were present in relatively similar sequence locations indicating that PfKMO 
may have a similar overall fold. Moreover the conserved proline just after the final motif, 
which has been shown to stack with the flavin ring when in the ‘in’ position, is also 
present in the sequence of PfKMO. With 461 residues, PfKMO is longer than some of the 
two domain enzymes of length 380-400 aa, however it is not as long as the three-domain 
FAH enzymes of length 529-635. Moreover, the C-terminal 80 residues of PfKMO do not 
share any sequence similarity with the longer FAH enzymes. As a result the enzyme may 
possess a third, C-terminal domain but one that is unlikely to resemble those evident in 
some of the current FAH structures. 
 
PfKMO      -------------------------MTATDNARQVTIIGAGLAGTLVARLLAR-----NG 
p-HBH      ------------------------------MKTQVAIIGAGPSGLLLGQLLHK-----AG 
PhH        ------------------------MTKYSESYCDVLIVGAGPAGLMAARVLSEYVRQKPD 
PQSL       ---------------------------MTDNHIDVLINGCGIGGAMLAYLLGR-----QG 
MHPCO      ---------------------MANVNKTPGKTRRAEVAGGGFAGLTAAIALKQ-----NG 
RebC       --------------------------MNAPIETDVLILGGGPVGMALALDLAH-----RQ 
phzS       ----------------------------MSEPIDILIAGAGIGGLSCALALHQ-----AG 
DHPH       ---------------------------MSPTTDRIAVVGGSISGLTAALMLRD-----AG 
AVH        ---------------------------MNDHEVDVLVVGAGLGGLSTAMFLAR-----QG 
m-HBH      MQFHLNGFRPGNPLIAPASPLAPAHTEAVPSQVDVLIVGCGPAGLTLAAQLAA----FPD 
HPXO       --------------------------------MKAIVIGAGIGGLSAAVALKQ-----SG 
TetX       --------------------------MNLLSDKNVAIIGGGPVGLTMAKLLQQ-----NG 
PgaE       ------------------------------MDAAVIVVGAGPAGMMLAGELRL-----AG 
CabE       ------------------------------MDASVIVVGAGPAGLMLAGELRL-----GG 
                                               : * .  *   .  *          
PfKMO      Q-R-LTLSNVSGERLEKRFHLLIGADGCNSAVRQAMASVVDLGEHLE----------TQP 
p-HBH      PYVT---FERDGERLRLDCDYIAGCDGFHGISRQSIPAERLK-VFER------------- 
PhH        NYRLP-EGKEAGEIETVHCKYVIGCDGGHSWVRRTLGFEMIG-E---------------- 
PQSL       R-HAIDQVRL-NDGRVLRPRVVVGADGIASYVRRRLLDID-----VE----------RRP 
MHPCO      GRLT--L----QTGEVLEADLIVGADGVGSKVRDSIGFKQDRWVSKDGLIRLIVPRMKKE 
RebC       ATITD-LRTGA--TRAVHARYLVACDGASSPTRKALGIDAPP-R---------------- 
phzS       GRVLIGARDGHGKPQALGADVLVGADGIHSAVRAHLHPDQRP---------------LSH 
DHPH       ETVQMRFSDG----TKAEANWVIGADGGASVVRKRLLGIEPT-----------------Y 
AVH        AGVTA-RLAGPDGEYDLRAGYLVGADGNRSLVRESLGIGRYG-H---------------- 
m-HBH      ---RC-DAAHAGQIETVQARYVVGCDGARSNVRRAIGRQLVG-D---------------- 
HPXO       DGVTVWFTDG----SSASGDLLIAADGSHSALRPWVLGFTPQ---------------RRY 
TetX       KKWTLTFEN----KPSETADLVILANGGMSKVRKFVTDTEV----EE----------TGT 
PgaE       AGVTV-EVRGPEGKHTLRAAYLVGCDGGRSSVRKAAGFDFPG-T---------------- 
CabE       DHVVV-EVEGPDGPRSLTTRYVVGCDGGRSTVRKAAGFDFPG-T---------------- 





PfKMO      GQAVLLGDAAHPMVPFHGQGMNCALEDAVALAEHLQSAADNASAL----AAFTAQRQPDA 
p-HBH      GRLFLAGDAAHIVPPTGAKGLNLAASDVSTLYRLL-LKAYR-EGRGELLERYSAIC---- 
PhH        ERVFIAGDACHTHSPKAGQGMNTSMMDTYNLGWKLGLVLTG-RAKRDILKTYEEERQPFA 
PQSL       DNVAMLGDAIHNVHPITGQGMNLAIEDASALADALDLALRDACALEDALAGYQAERFPVN 
MHPCO      GKVALVGDAAHAMCPALAQGAGCAMVNAFSLSQDLEEGSS----VEDALVAWETRIRPIT 
RebC       GRVFLTGDAAHTLSPSGGFGMNTGIGSAADLGWKLAATLRG-WAGPGLLATYEEERRPVA 
phzS       GRITLLGDAAHLMYPMGANGASQAILDGIELAAALARNAD----VAAALREYEEARRPTA 
DHPH       GRVLLIGDAAVTPRPHAAAGGAKACDDARTLAEVFTKNHD----LRGSLQSWETRQLQQG 
AVH        GRVFLAGDAAKVTPPTGGMSGNAAVADGFDLAWKLAAVLQG-QAGAGLLDTYEDERKVAA 
m-HBH      PRVFIAGDACHTHSPKAGQGMNFSMQDSFNLGWKLAAVLRK-QCAPELLHTYSSERQVVA 
HPXO       GRVALLGDAGHSTTPDIGQGGCAAMEDAVVLGAVFRQTRD----IAAALREYEAQRCDRV 
TetX       LPITMIGDAAHLMPPFAGQGVNSGLVDALILSDNLADGKFN--SIEEAVKNYEQQMFIYG 
PgaE       GRVILAGDSAHIHLPAGGQGMNTSIQDAVNLGWKLGAVVNG-TATEELLDSYHSERHAVG 
CabE       GRVLLAGDSAHVHLPAGGQGMNVSVQDSVNLGWKLAAVVSG-RAPAGLLDTYHEERHPVG 





Even without structural information about KMO, much detailed information can be 
derived from alignments of known KMO sequences. Such alignments can trace the 
evolutionary divergence of the enzyme and can locate which areas of the sequence have 
been selectively protected from this process. A number of residues were strictly identical 
among all tested sequences of KMO. Looking at the KMO sequences alone, however, it is 
impossible to distinguish functionally important residues from conserved residues with 
only structural relevance (hydrophobic patches etc). Therefore the addition of structural 
information from FAH structures can help locate which of the KMO conserved residues 
are well positioned to partake in substrate binding. The full alignment is shown in 
appendix section 1.2 with the residues that directly interact with the flavin cofactor and 
respective substrate separately highlighted (in yellow and green respectively) on each 
FAH sequence. On the aligned PfKMO sequence, residues that are conserved among all 
KMOs are highlighted blue. Barring some sporadic patches there were a few aligned 
segments of sequence that contained the majority of the respective substrate binding 
residues for the FAH enzymes. The major block is shown below in figure 3.4, which 
comprises a lot of the residues that line the β-sheet platform at the bottom of the 
substrate binding pocket. As can be seen there are several conserved KMO residues that 
align in relation to these and may therefore include several key substrate binding 
residues. In all a refined pool of forty-two conserved KMO residues potentially 
populating the substrate binding pocket was generated. 
Figure 3.3. Shows three sections taken from a multiple sequence alignment of PfKMO with 
the sequences of the FAH enzymes whose structures have been solved. Blocks containing 
globally conserved FAH motifs are outlined by the three boxes. The alignment was generated 
with clustal omega and is colour-coded based on the biophysical properties of the amino 
acids.  
For full alignment see appendix sextion _. 
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PfKMO           PNALHIWPHGDYMCIALPNLDRSFTVTLFLHHQSPAAQPASPCFAQLVDGHAARRFFQRQ 269 
p-HBH           SHELIYANHPRGFALCSQRSATRSRYYVQVPLTEK----------VEDWSDERFWTELKA 245 
PhH             --CAIHSAESGSIMIIPREN-NLVRFYVQLQARAE--KGGR----VDRTKFTPEVVIANA 317 
PQSL            ----LYVDSQGGLAYFYPIGFDRARLVVSFPREEA--RELM----ADTRGESLRRRLQRF 251 
MHPCO           IDMWNFWPRVQRILYSPCNENELYLGLMAPAADPR----------GSSVPIDLEVWVEMF 249 
RebC            LFFFLMLSSSLRFPLRALDGRGLYRLTVGVDD-------------------ASKSTMDSF 255 
phzS            DEHWSRLVAYPISARHAAEGKSLVNWVCMVPSAAVGQLDNEADWNRDGRLEDVLPFFADW 269 
AVH             G-WYYLHHPEFKGTFGPTDRPDRHTLFVEYDP------DEG----ERPEDFTPQRCVELI 269 
m-HBH           --VAIQSEQ-GNVLIIPREGGHLVRFYVEMDK-LD--ADER----VASRNITVEQLIATA 297 
 
Figure 3.4. A portion of a sequence alignment between PfKMO and FAH enzymes whose 3-D 
structures have been solved. For each FAH structure, residues interacting with FAD are highlighted 
yellow and those interacting with the respective substrate are in green. For PfKMO residues conserved 
across all sequences of KMO are highlighted in cyan.  
For full alignment see appendix section 1.2.                                                                            
 
The evolution and divergence of KMO sequences also provides clues as to which residues 
are more likely to be located on the surface with no functional significance. Separate 
multiple sequence alignments were created for mammalian, insect, fungal and bacterial 
KMO sequences with conserved residues from each compared. The overall results are 
summarised in appendix section 1.3. This information can help further develop an 
understanding of the potential structural layout of the enzyme and can have further uses 
including: helping in the actual building and validation of a structural model and in 
identifying potential residues to substitute by site-directed mutagenesis for the 
improvement of crystal contacts. To enhance the reliability of these data only KMOs that 
were structurally similar to each other were considered. Therefore PfKMO was aligned 
with all bacterial KMOs and not eukaryotic KMOs that were known to have additional 
transmembrane regions. For every residue in the alignment a percentage identity and 
percentage hydrophilicity were recorded. Logically any residue with low conservation 
but a high frequency towards hydrophilic substitutions was considered as a potential 
candidate and this accounted for 47/461 residues.  
 
3.2.3 Prediction of PfKMO secondary structure  
The PfKMO amino acid sequence was fed through numerous secondary structure 
prediction servers including: APSSP2, Baldig, GOR4, HNN, Psipred, Jnet and SSpro. The 
results were aligned and compared to assess the consistency of the predictions. In all the 
results showed relatively strong agreement with only small discrepancies regarding the 
start/stop position of predicted α-helices. The prediction of β-sheets was slightly more 
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troublesome in certain sequence areas but on the whole the predictions were similar. 
From these a consensus prediction was derived and compared to the known secondary 
structural elements of some published FAH structures (see appendix section 1.4). 
Interestingly, up to residues 370-390 there was a strong correlation between the 
locations of α-helixes and β-sheets in all the FAH sequences despite very limited 
sequence conservation. The blocks of secondary structure with the strongest 
conservation were those involved in the FAD-binding core of the proteins – residues 1-80 
& 300-360. Otherwise a lot of the β-sheets were less rigidly conserved and often 
intertwined with several sequence insertions. The consensus prediction for the 
secondary structural layout of PfKMO fitted very well with those from the aligned FAH 
structures, but again only up until around residue 370. For the C-terminal residues of 
PfKMO, the consensus prediction did not match any of the other larger FAH enzymes and 
predicted a largely helical arrangement. In summary, secondary structure prediction 
programs seemed to potentially predict the location of such structural elements in the 
sequence of PfKMO with reliable consistency. If the predictions are accurate then they 
suggest that the enzyme may possess a similar structural layout to the conserved first 
two domains seen in other solved FAH structures. The C-terminal 80-90 residues 
however may extend into a novel third domain relative to the current FAH structures.   
 
3.2.4 Prediction of PfKMO tertiary structure  
The amino acid sequence of PfKMO was fed into the homology-based protein tertiary 
structure prediction servers: I-TASSER [251], SWISS-MODEL [252], Phyre [253], and 
LOOPP [254]. A sample of the models can be seen below in figure 3.5. Every model that 
was constructed by the servers was based on the structure of one of the aforementioned 
published FAH structures. As a result of this each model was biased towards the 
respective template. This meant that different areas of different models appeared to be 
modelled better, i.e. were denser with secondary structure. Half of the models finish 
between residues 373-416 with only the I-TASSER models covering the whole 461 
residue sequence. Where predicted, the C-terminal residues were often disordered 
strands or had little secondary structure and with few common consistencies. In the full 
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models the C-terminal 90 residues always started from the bottom of the long kinked α-











Figure 3.5. Cartoon representation for a sample of the PfKMO tertiary structure models 
generated by the: I-TASSER, SWISS-MODEL, Phyre and LOOPP servers. The residues are coloured 
blue through to red going from the N- to the C-terminus with FAD shown in yellow spheres. 
 
Figure 3.6. Surface representation showing four full length PfKMO models generated by I-TASSER. 
Each is orientated similarly with the back of the protein – relative to the FAD binding site – facing out. 
The models are again colour-coded from blue at the N-terminus to red at the C-terminus and show 
the variability in the prediction of the arrangement of the C-terminal residues. 
85 
For the first 372 residues most of the secondary structure was similarly arranged 
however the exact 3-D positions of individual residues was variable. For example the side 
chains of only two residues were observed to be completely solvent exposed in every 
single model. As a result of this, the exact prediction/position of key residues was 
inconclusive from the models alone. The typical buried substrate binding chamber 
seemed to be accommodated by all of the models however its access route to bulk 
solvent could not be predicted. Some of the models did though offer potential starting 
templates for structure solution once suitable X-ray diffraction data had been obtained.  
 
3.2.5 Summary 
Bioinformatic analysis of simply the amino acid sequence of PfKMO has revealed hidden 
structural information. Commonly used sequence analysis tools including XtalPred 
suggested that the enzyme’s biophysical properties are suited to potentially favour 
successful crystallization. The combination of sequence alignments with known FAH 
structural information selected a refined pool of conserved KMO residues with potential 
functional relevance. They provided no evidence to suggest that the overall structural 
layout of PfKMO will be significantly different from previously seen FAH structures. The 
C-terminal 60-80 residues of the enzyme appear to be arranged in a new layout though 
with an unpredictable structure relative to current FAH structures. From the alignments 
and tertiary structural models it is likely that these residues protrude from the rest of the 
structure and may form a new small domain. In all the information gained about the 
sequence of PfKMO will help guide model building and refinement during structure 
solution - particularly where the X-ray diffraction resolution is ambiguous. In addition it 
can guide mutagenic studies either towards: i) functional analysis of the role of residues 






3.3 Towards PfKMO structure solution 
3.3.1 Influence of salts on PfKMO 
Numerous KMO studies have detailed an inhibitory effect of salt anions with a potential 
effect on the flavin orientation. As salts are common additives in protein crystallisation 
screens common anions and cations were assessed for their effects on PfKMO activity. 
For this purpose, initial (pseudo-steady-state) PfKMO reaction rates were determined 
based on the assay described in section 2.5.1 in the presence of excess L-KYN and 
NADPH. The results, as a percentage of PfKMO activity measured in buffer absent of any 
added salts (relative activity = 100 x the rate observed in presence of respective 
salt/average rate observed in absence of salt), are shown in figure 3.7. The screen was 
repeated three separate times with the average values and their respective standard 
deviation (the error bars) displayed. The presence of just 25 mM salt in the reaction 
buffer showed drastic and varied consequences on the enzyme activity. The effect 
wasn’t always negative, surprisingly ammonium acetate increased NADPH consumption 
by approximately 1.5-fold. Another apparent anomaly among the cations was the 
complete inhibition caused by cobalt acetate. Apart from these examples, the remaining 
cations had little effect except a 10-15 % increase in activity seen with the monovalent 
Li+, Na+ & K+ ions. This could have possibly been due to improvement of PfKMO solubility 
rather than a direct effect on activity.  
Catalysis via flavin-dependent hydroxylases is known to be sensitive to the presence of 
small monovalent anions and PfKMO does not break the trend. Of those tested fluoride 
showed the greatest inhibition at around 75 % followed by thiocyanate at 65 % and 
chloride with around 50 % inhibition. In fact the strength of inhibition appeared to 
decrease going down group 7 as bromide and iodide showed just 10-20 % inhibition. 
Nitrate and formate showed 25-30 % inhibition whilst the larger tartrate and citrate ions 
seemed to have a slightly beneficial effect as seen with acetate salts. The divalent anions 
had little effect on activity but the slight inhibition seen with phosphate is likely to be 
due to it competing with the phosphate moiety of NADPH.  
In summary the screen particularly highlighted that salts containing Co2+, nitrate, 
formate or small monovalent anions (such as fluoride and chloride) should be avoided in 
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the crystallisation of PfKMO. Any ions that influence the dynamics of the enzyme may 
provide sources of heterogeneity within the crystal lattice. Interestingly bromide and 
iodide had only slightly inhibitory affects allowing the possibility of their use for 
anomalous dispersion and phase solution. Ammonium’s substantial positive influence on 
NADPH consumption has provided an interesting route for further study. Ammonium 
salts are very common in protein crystallisation but depending on the exact nature of the 
interaction with PfKMO they may complicate crystallization of the enzyme. 
 
The effect of ammonium and chloride ions was further investigated to determine their 
effect on the Michaelis-Menten kinetics of substrate binding in PfKMO. The results are 
summarised below in table 3.3. The normal assay buffer as suggested by Crozier-Reabe 
& Moran [1, 2] contained 10 mM NaCl and so the assay was run with and without this. 
The omission of 10 mM NaCl from the assay buffer resulted in a 33 % increase in kcat and 
around a 50 % decrease in the Km for L-Kyn. It was clear that even just this small amount 
of chloride ions hampered the efficiency of the enzyme and so it was removed from all 
subsequent PfKMO assay buffers. In addition the protein strorage buffer was altered to 
contain 10 mM Na acetate rather than NaCl to reduce possible interference with the 
substrate binding site. When 50 mM ammonium acetate was added to the assay buffer, 
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both the kcat and the Km significantly increased by 53 % and 183 % respectively. It is 
unclear how ammonium ions cause a weakened binding of substrate whilst increasing 
the rate of NADPH oxidation. This could be explained by ammonium ions stimulating the 
movement of FAD towards the out conformation, thus stimulating its reduction by 
external NADPH. More extensive analysis of the influence of ammonium ions would be 
required to provide detailed answers, however for the purpose of this investigation the 
key message learned was to avoid ammonium ions during the crystallisation of PfKMO. 
 
 Unsalted buffer + 10 mM NaCl + 10 mM NaCl  
+ 50 mM NH4OAc 
Km (M) 14.6 ± 2.2 24.2 ± 1.8 68.4 ± 6.3 
kcat (s
-1) 10.3 ± 0.6 7.5 ± 0.1 11.5 ± 0.4 
kcat/Km  (s
-1





3.3.2 Crystallisation of wt PfKMO 
To search for conditions under which PfKMO crystallised, hanging drop vapour diffusion 
screening with sparse matrix screens was set up using 5 mg/mL pure wild-type (wt) 
protein. After two days one set of conditions were observed to grow single crystals in the 
drop containing L-Kyn and clusters of microcrystals in the drop without substrate (figure 
3.8). This difference was predicted to be due to decreased conformational flexibility with 
substrate bound and therefore all further trays were set up using only L-Kyn-bound 
PfKMO. The well solution was condition 41 from the Hampton Research Crystal Screen 1 
kit, which was comprised of 0.1 M HEPES pH 7.5, 20 % (w/v) PEG 4K and 10 % (v/v) 2-
propanol. Crystals were reproduced at slightly different pH and concentration of PEG 4K 
when in-house reagents were used to make the well solution (figure 3.9). Crystals could 
be grown at both 4 oC and 17 oC but were significantly more abundant and robust when 
at 4 oC. Single crystals were flash-frozen in liquid nitrogen and tested for diffraction in-
house and at the Diamond synchrotron source in Oxford. On the in-house generator only 
Table 3.3. Summary of the Michaelis-Menten kinetic constants for PfKMO in the presence of NaCl and 
ammonium acetate.  
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minimal diffraction to 11 Å resolution was observed, whilst at the synchrotron 
reflections to around 8 Å were recorded (figure 3.10). 
   
   
 
↑ Figure 3.8. PfKMO 1:1 l crystallisation 
drops from h.d.v.d screening with (left) 
and without substrate (right). With 
substrate single crystals formed but 
without clusters of microcrystals were 
visible. 
 
← Figure 3.9. PfKMO substrate-bound 
crystals reproduced using in-house lab 
reagents. 
 
Figure 3.10. Diffraction from an initial 
substrate-bound PfKMO crystal tested at 
the Diamond synchrotron beamline I04. 
Reflections extended to around 8 Å. 
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The first step towards improving the diffraction resolution limit was to improve protein 
homogeneity by introducing a gel filtration step at the end of the protein purification 
protocol. The major monomeric protein peak was collected for further concentration. As 
a result crystals were reproducibly grown over a much broader range of PEG 
concentrations and pH, but their diffraction was not substantially improved. The second 
focus was to try and slow crystal growth to try and improve lattice homogeneity and 
resulting diffracting power. When crystal trays were set up in the 4 oC room with all 
components thoroughly equilibrated, larger crystals were observed to grow. In 
combination the reservoir solutions were supplemented with numerous viscous additive 
solutions to try and further slow crystal growth. Addition of up to 10 % (v/v) glycerol and 
xylitol supported crystal growth whereas ethylene glycol and other PEG variants 
generated showers of microcrystals. Further additive screens using small compounds 
and salts were conducted using commercial kits including the ‘silver bullets’, however no 
significant improvements were observed. Different buffer pH values were also tested 
with crystals only growing between pH 6.5-8.5 and the best diffraction consistently 
observed around pH 7.0. When all of these new factors were combined in trays with 
different types of PEG precipitant, crystals with stronger diffraction were observed. 
Interestingly the crystallisation was sensitive to the different PEG variants and crystals 
could be grown with PEG 200-4000, PEGMME 550 and MOPEG 1500. At this stage larger 
crystals were being grown with dimensions of approximately 0.2  0.1  0.1 mm3 and 
resulting diffraction extending to resolutions around 5-7 Å at the Diamond synchrotron.  
While optimisation of crystal growth was on-going the process of crystal cryoprotection 
was also investigated. Ice rings were observed on the diffraction pattern of crystals 
grown in the lower PEG concentrations. For an initial test, crystals were moved to new 
drops of different soaking solutions and left to equilibrate for 24 hours to see if they 
‘survived’. The soaking solutions tested corresponded to the respective mother liquor 
plus up to 30 % of commonly used cryoprotectants such as EG, glycerol, MPD etc. 
Following on from this, different cryoprotectant solutions were designed and tested in 
soaks of 5 s up to 24 h prior to flash-freezing, mounting and testing for diffraction on the 
in-house generator. In the end, the results showed that soaking with mother liquor 
supplemented with 20 % EG provided the best diffraction results with a resolution limit 
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of around 6 Å in house and no ice rings. Some crystals still showed strong diffraction 
after 24 hrs but 5s soaks were sufficient. With further refinement the best results were 
obtained when the cryoprotectant was introduced gradually. This was either achieved by 
transferring the crystal to a drop containing 10 % and then 20 % EG cryoprotectant or by 
adding 1 L of the 20 % EG cryoprotectant to the crystallisation drop before transferring 
the crystal directly into the 20% EG cryoprotectant. When effective cryoprotection was 
combined with the earlier improvements to the crystal growth process, crystal 
diffraction consistently extended to 4-5 Å. From the best crystal a complete dataset was 
collected to a final resolution of 4.2 Å (figure 3.11). The crystal and all previously 
diffracting substrate bound crystals belonged to the tetragonal body-centred Bravais 
lattice group (potentially the space group I4) with rough unit cell dimensions of a = b = 





At this stage the resolution was not sufficient to be able to solve the protein’s structure 
via molecular replacement and SeMet-substituted wt PfKMO crystals only diffracted to 
around 5 Å resolution. Post-crystal treatments such as annealing, crystal dehydration 
and seeding were unsuccessful. Annealing on the loop via omission of the 100 K stream 
for any length of time destroyed crystals although subtle annealing by re-freezing the 
Figure 3.11. Optimised substrate-bound PfKMO 
crystal mounted (above) and resulting X-ray 
diffraction to a resolution of 4.2 Å (right). 
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crystal and transferring back to the cryoprotectant solution did not significantly affect 
diffraction. For dehydration the cover slips containing drops with crystals were moved 
over solutions with up to 20 % higher concentrations of PEG and left to equilibrate for a 
couple of days. Mostly the crystals survived but unfortunately their weak diffraction 
power also remained. Macroseeding with whole crystals/crystal chunks was also 
unsuccessful, but microseeding did manage to generate new crystals. The resulting 2nd 
generation crystals were generally smaller than their relatives and again the X-ray 
diffraction power was not improved. To round-off a negative paragraph, attempts to 
further slow crystal growth by covering the drops with mineral oil or by adding up to 0.6 
% (w/v) low-gelling agarose were unsuccessful. This led to the conclusion that some 
physical aspect of the enzyme itself may have been prohibiting the formation of an 
ordered crystal lattice. Therefore the next approach was to investigate the effects of 
protein engineering on the crystallisation of PfKMO. 
 
3.3.3 Investigation of PfKMO truncation 
3.3.3.1 Limited proteolysis 
When trying to engineer a protein to favour effective crystallisation there have been 
numerous different successful approaches, as outlined in section 1.6.3. The aim is to 
minimise the surface entropy of the protein to favour the formation of stable crystal 
contacts that allow an ordered lattice to form. With no prior structural information, 
trying to predict and mutate individual surface residues would be a time-consuming 
process and also only a handful of specific surface residues may be involved in forming 
crystal contacts. Therefore a broader approach was needed and so first limited 
proteolysis was explored to try to remove any potentially mobile or disordered 
loops/domains. Pure PfKMO was mixed with a small concentration of bovine trypsin at a 
ratio of 50:1 and incubated at 25 oC. Prior to trypsin addition and then after specific time 
points an aliquot of the reaction was removed on to ice with PMSF (dissolved in ethanol) 
added to 2 mM final concentration. Each aliquot was immediately frozen and then all 
were thawed together and subjected to SDS-PAGE analysis in comparison with the 
undigested sample. The proteolysis experiment was run both without L-Kyn and in the 
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presence of 1 mM L-Kyn with the resulting gels displayed in figure 3.12. Firstly the 
presence of L-Kyn had no effect on the rate of digestion of PfKMO. Interestingly two 
intermediates were captured at rough sizes of 46-48 KDa and 43-45 KDa compared to 
the 50.7 kDa native protein. The first was more transient, appearing after 30-60 mins 
and then mostly disappearing 30 mins later. The fact that it mostly disappeared when 
most of the full length protein still remains suggests that this intermediate may have 
been a digestion product of a contaminant originally hidden under the full length PfKMO 
gel band. The second intermediate, however, was more stable as it started forming after 
around 60 mins and continued to accumulate 4 h later. After 24 hour exposure there was 
no full length protein visible but a small amount of the second intermediate remained. 
The next step was then to characterise the stable intermediate and determine whether it 
was worth attempting to crystallise it. 
 
                    
 
To try and isolate the stable intermediate for crystallography trials, a bigger volume of 
protein was digested and stopped as before after 4 hours of the reaction. This was then 
concentrated and subjected to size-exclusion chromatography on a 280 mL s-75 column 
to try and separate the fragment from the full size protein. Promisingly, the intermediate 
was stable throughout the chromatography and could be separated to some extent from 
the full size protein as shown in the protein gel in figure 3.13. This separation could have 
been further optimised by running the column more slowly etc. Unfortunately this was 
not necessary as it was clear that the isolated intermediate did not contain any FAD and 
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Figure 3.12. NuPAGE analysis of samples 
from limited proteolysis reaction stopped 
at various time points (hours). The uncut 
full length PfKMO is shown in the zero 
column. 
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was inactive. The fraction was concentrated as much as possible to 3 mg/mL, soaked 
with FAD and used for brief crystallography trials but with no success.    
            
 
MALDI-TOF was carried out on excised and purified gel slices of both the undigested and 
stable intermediate PfKMO bands to try and identify what section of protein had been 
removed. As part of the protocol both forms were completely digested with trypsin prior 
to fragment analysis. Each sample was run four times with an example peak spectrum 
from each form shown in figure 3.14 for the full protein and for the stable intermediate. 
The mass/charge of detected fragments was automatically correlated to predicted 
trypsin cleavage products from the PfKMO protein sequence with the results for each 






M    I     II      III                   size-exclusion fractions 
Figure 3.13. NuPAGE analysis of 
size-exclusion chromatography for 
digested PfKMO. 
M = Marker 
I = pure PfKMO 
II = digested sample 
III = concentrated digest 
remaining lanes correspond to 
fractions eluted from the size 
exclusion column. 
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                    |               |   |         |    |     | |        |          
Full length   MTATDNARQVTIIGAGLAGTLVARLLARNGWQVNLFERRPDPRIETGARGRSINLALAER   60 
Intermediate  MTATDNARQVTIIGAGLAGTLVARLLARNGWQVNLFERRPDPRIETGARGRSINLALAER   60 
 
                   |     |         | |               |          | |  |     
Full length   GAHALRLAGLEREVLAEAVMMRGRMVHVPGTPPNLQPYGRDDSEVIWSINRDRLNRILLD   120 
Intermediate  GAHALRLAGLEREVLAEAVMMRGRMVHVPGTPPNLQPYGRDDSEVIWSINRDRLNRILLD   120 
 
                                   | |         |  ||              |              
Full length   GAEAAGASIHFNLGLDSVDFARQRLTLSNVSGERLEKRFHLLIGADGCNSAVRQAMASVV   180 
Intermediate  GAEAAGASIHFNLGLDSVDFARQRLTLSNVSGERLEKRFHLLIGADGCNSAVRQAMASVV   180 
 
                           |                                    |                
Full length   DLGEHLETQPHGYKELQITPEASAQFNLEPNALHIWPHGDYMCIALPNLDRSFTVTLFLH   240 
Intermediate  DLGEHLETQPHGYKELQITPEASAQFNLEPNALHIWPHGDYMCIALPNLDRSFTVTLFLH   240 
 
                                    ||   |                      |    |     
Full length   HQSPAAQPASPCFAQLVDGHAARRFFQRQFPDLSPMLDSLEQDFEHHPTGKLATLRLTTW   300 
Intermediate  HQSPAAQPASPCFAQLVDGHAARRFFQRQFPDLSPMLDSLEQDFEHHPTGKLATLRLTTW   300 
 
                                                                    |      
Full length   HVGGQAVLLGDAAHPMVPFHGQGMNCALEDAVALAEHLQSAADNASALAAFTAQRQPDAL   360 
Intermediate  HVGGQAVLLGDAAHPMVPFHGQGMNCALEDAVALAEHLQSAADNASALAAFTAQRQPDAL   360 
 
                             |         |        |   |   |       |        | 
Full length   AIQAMALENYVEMSSKVASPTYLLERELGQIMAQRQPTRFIPRYSMVTFSRLPYAQAMAR   420 
Intermediate  AIQAMALENYVEMSSKVASPTYLLERELGQIMAQRQPTRFIPRYSMVTFSRLPYAQAMAR   420 
 
 
                      |                      |          
Full length   GQIQEQLLKFAVANHSDLTSINLDAVEHEVTRCLPPLSHLC   461 
Intermediate  GQIQEQLLKFAVANHSDLTSINLDAVEHEVTRCLPPLSHLC   461 
 
ii) Stable PfKMO 
intermediate 
i) Full length 
PfKMO  
Figure 3.15. Identification of MALDI-TOF mass spec fragments of full length and the stable 
limited proteolysis intermediate digested by trypsin. Sequence in grey represents fragments 
too small or too large to be detected in the range of mass/charge values collected. Sequence in 
green represents the fragments successfully identified for each form of the protein. 
Figure 3.14. MALDI-TOF fragment analysis displaying mass/charge peaks from i) full length undigested 
PfKMO and ii) the purified stable digest intermediate. 
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The majority but not all of the possible fragments were detected for the full length 
sequence. It was clear that the residues removed by limited proteolysis related to the C-
terminus as the N-terminal residues were detected in both protein forms. The peaks 
relating to the C-terminal segments located after K376 that were present in the full 
length protein, were absent in the stable limited proteolysis intermediate. Removal of 
the sequence after this residue would leave a protein core of 41 kDa, which roughly 
correlates to the change in position seen during gel electrophoresis. These data 
suggested that K376 is solvent exposed to be able to be cleaved during limited 
proteolysis, possibly located on a surface loop or turn. Importantly, removal of the C-
terminal residues after this point was detrimental to the function of the enzyme due to 
the loss of flavin. In addition to this, C-terminal PfKMO truncations after positions 409, 
434 and 451 were engineered and found not to express any detectably active protein. 
From the tertiary structure models and prior sequence analysis it is unlikely that this 
sequence region is directly involved in flavin binding, more likely is that its removal 
destabilises the overall structure of the enzyme.  
 
3.3.4 Cysteine mutagenesis 
Cysteines are unique residues that can form covalent disulphide bridges with each other. 
Such bonds have proved essential in maintaining the internal structure of many proteins 
but when free cysteines are exposed on the surface of proteins they can cause unwanted 
disulphide-linked aggregation. PfKMO contains six cysteine residues and has been shown 
to lose activity rapidly over time in correlation with the oxidation of two unidentified 
cysteines [2]. As mentioned in section 1.6.3, the substitution of surface cysteines for 
serines to prevent disulphide-based aggregation has improved the crystallisation success 
for several proteins. Looking at the information from sequence alignments and 
homology modelling (Sections 3.2.2 & 3.2.4) there was significant evidence that two of 
the cysteines in PfKMO, C223 and C326 were likely to be buried. This left cysteines C168, 
C252 and the C-terminal C453 and C461 as potential surface targets. These four residues 
were separately substituted by serines and each construct was expressed in BL21(DE3) E. 
coli cells. The respective Michaelis-Menten properties and stabilities of each pure 
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mutant were tested in relation to wt enzyme as summarised in table 3.4. The single 










The results showed that all four of the single mutations reduced the loss of activity over 
time, with the C252S mutation significantly providing the most protective effect. In the 
absence of reducing agent C252S had a half-life of around 54 hours – 7 greater than the 
8 hours seen with the wt protein. The presence of reducing agent boosted the half-life of 
all the proteins by around a day. In addition to this, two double mutants were created – 
dm1 (C453S/C461S) and dm2 (C252S/C461S). The double mutants were also tested for 
stability. The measured t1/2 values in the absence of reducing agent are compared to wt 
and the single mutants in figure 3.16. The half-life of dm1 was level to the values around 
30 hours seen with the single mutants C453S and C461S. For dm2 however, the half-life 
was significantly improved further to 75.2 ± 5.2 h. With the high error associated with 
the data for the C252S mutant, this strongly confirmed the implication of this residue in 
destructive aggregation of wt PfKMO. The Michaelis-Menten data for dm2 yielded a Km 
of 8.8 ± 1.5 M and a kcat of 8.9 ± 1.1 s
-1. The kinetic data confirmed that all of the 
cysteine mutations had no significant effect on the enzyme’s catalytic properties.  
 
 
Protein Km (M) kcat (s
-1) t1/2 - RA (hours) t1/2 + RA (hours) 
wt 14.5 ± 2.5 9.1 ± 1.6 7.9 ± 2.6 26.2 ± 2.0 
*C168S 21.6 ± 5.1 10.7 ± 0.2 25.0 ± 0.2 45.2 ± 16.3 
*C252S 18.7 ± 5.9 6.8 ± 0.6 53.5 ± 24.3 89.2 ± 7.9 
*C453S 19.9 ± 5.5 9.0 ± 0.8 29.4 ± 1.7 42.2 ± 8.7 
*C461S 15.5 ± 4.2 6.4 ± 0.5 31.5 ±2.3 47.3 ± 6.6 
Table 3.4. Summary of Michaelis-Menten kinetics and enzyme half life (t1/2) for wt and single 
cysteine mutant forms of PfKMO. t1/2 refers to the length of incubation at 25 
o
C required for half 
of the initial enzyme activity to be lost. RA indicates presence of reducing agent (1 mM DTT). 





The dm2 protein was subsequently purified on a large-scale and used for crystallisation 
trials. It was noted that roughly 3-4 greater yield was seen compared to with wt. The 
protein ran as a single monomeric peak in size-exclusion chromatography even with the 
exclusion of reducing agent (see figure 3.17). Crystals could be grown from similar 
conditions to the wt protein but with higher concentrations of dm2 required. A search 
with the sparse-matrix crystallisation screens unfortunately failed to find any new leads 
for alternative conditions of crystal-growth.  Crystallisation via h.d.v.d with 1 l of 12.5 
mg/ml dm2 (20 mM HEPES pH 6.8, 30 mM Na acetate, 1 mM DTT and 1 mM L-Kyn) 
mixed with 1 l of reservoir solution reproducibly and more readily yielded larger 
crystals than with wt protein. The size of crystals reached up to 0.3  0.3  0.6 mm3. 
After cryoprotection, crystals tested at the Diamond synchrotron readily diffracted 
below 4.0 Å resolution. A couple of the mounted crystals tested are shown in figure 3.18. 
The larger crystals could survive and in fact required the maximum available beam 
intensity to maximise the resolution of the reflections recorded. The best crystal 
Figure 3.16. Graphical representation of the activity half-life (t1/2) for each mutant when incubated at 
25 
o
C in the absence of reducing agent. Made using Excel. 
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diffracted to give a 100.0 % complete dataset to a resolution of 3.35 Å with an Rmerge of 
0.085 (0.676 in the highest resolution shell - HS) and a I/I of 15.8 (3.0 HS). This was 
achieved from 650 images with a rotation oscillation of 0.35 º and exposure of 0.35 
s/image. The crystal was still tetragonal (I4122) with cell dimensions of a = b = 149.5, c = 
271.9 Å and  =  =  = 90.0 º and grew from a mother liquor of 0.08 M HEPES pH 7.0, 6 










Figure 3.17. FPLC traces for size exclusion 
chromatography of dm2 PfKMO in the 
absence of reducing agent. 
Blue line = 280 nm uv trace (protein peak) 
Green line = 380 nm uv trace (FAD peak 1) 
Red line = 450 nm uv trace (FAD peak 2) 
Figure 3.18. Mounted dm2 PfKMO crystals, 
which diffracted to resolutions below 3.5 Å 
at various Diamond synchrotron beamlines. 
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3.3.5 Loop replacement for shorter homologous sequence   
As mentioned in section 3.2.1, there is a short six-residue segment of sequence in 
PfKMO that is not present in other KMOs. Considering the small size and the 
conservation seen either side of this sequence it is probable that this corresponds to a 
surface loop. A section of a sequence alignment involving the closest evolutionary 
relatives to PfKMO is displayed in figure 3.19. There is a shorter consensus sequence 
present in the homologous sequences of PNXGX (where X = any residue) that aligns to 
the residues HHQSPAAQPAS at positions 240-250 in PfKMO. Interestingly there is a KMO 
from Pseudoxanthomonas suwonensis with a sequence similarity somewhere between Pf 
and the closely related Xanthomonas species. This intermediate species had a mixed 
sequence at the aforementioned position of PNQAAPGSGD. This presented a great 
opportunity to transfer a smaller sequence like those in the Xanthomonas species in to 
replace the larger sequence found in PfKMO in the hope of minimizing the flexibility of 
this potential loop. Therefore the gene sequence corresponding to the eleven aa 
residues 240-250 in PfKMO were replaced with sequence coding for the residues PNQGD 
by overlap extension PCR (see section 2.1.4). The mutant construct created (LOOPr) also 
contained the C252S/C461S double mutation (see section 3.2.4).   
 
Sten.malt_KMO    237 LFLPNQ------GDPSFATVNTGAQAEALFAREFADTLPLIPDLRADWEQHPPGLLGTLT 293 
Stre.spec_KMO    229 LFLPNQ------GDPSFATVNTGAQAEALFAREFADTLPLIPNLRADWEQHPPGLLGTLT 285 
Xant.axon_KMO    237 LFLPNA------GEPSFATTRTGDEAFALFARDFPDALPLIPQLKEHWEEHPPGLLGTLT 293 
Xant.oryz_KMO    237 LFLPNA------GEPSFATTRNGDEAFALFARDFPDALPLIPQLKQHWEEHPPGLLGTLT 293 
Xant.gard_KMO    237 LFLPNT------GEPSFATTRTGDEALALFARDFPDALPLIPQLKEHWEEHPPGLLGTLT 293 
Xant.vesi_KMO    237 LFLPNA------GEPSFATTRTGEEAHALFARDFPDALPLIPQLEEHWEEHPPGLLGTLT 293 
Xant.Camp_KMO    238 LFLPNE------GMPSFATTRSGDEALALFARDFPDALPLIPQLKEHWEEHPPGLLGTLT 294 
Xant.albi_KMO    236 LFLPNK------GEPSFASIRNGKEAVALFARDFADVLPLMPQLAEHWEQHPPGLLGTLC 292 
Psxa.suwo_KMO    237 LFLPNQA-APGSGDPCFASVRSGAEVRALFARDFPDALPLIPDLESDWENHPPGLLGTLY 298 
Pseu.fluo_KMO    237 LFLHHQSPAAQPASPCFAQLVDGHAARRFFQRQFPDLSPMLDSLEQDFEHHPTGKLATLR 299 




LOOPr protein was produced and purified from the altered construct and comparable 
activity was seen in the crude cell extracts compared to expressed dm2 PfKMO. The 
protein was purified as normal (figure 3.20) with a final step of size-exclusion 
Figure 3.19. Section from a sequence alignment of PfKMO with its closest evolutionary homologs 
showing the potential loop insertion highlighted in red. The aligned bacterial species in full were: 
Stenotrophomonas maltophilia, Streptococcus species, Xanthomonas axonopodis, Xanthomonas 
oryzae, Xanthomonas gardneri, Xanthomonas vesicatoria, Xanthomonas campestris, 
Xanthomonas albilineans, Pseudoxanthomonas suwonensis and Pseudomonas fluorescens 
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chromatography, where the mutant ran again as a single monomeric peak. The expected 
difference in size was too small to be observed in the gel filtration and on the NuPAGE 
gel. LOOPr had Km and kcat values of 12.5 ± 3.7 M and 8.3 ± 0.4 s
-1 respectively; similar 
to those observed previously with wt and dm2 proteins. Interestingly though, in limited 
proteolysis the protein digested much more quickly than wt enzyme as most of the full 
length protein band had disappeared after just 30 mins (figure 3.21). The stable 
intermediate still formed but again had a reduced lifespan and was fully degraded 
between 3-4 hrs. Following this, crystallisation trials of LOOPr (10 mg/mL plus 1 mM L-
Kyn) using the commercial sparse-matrix screens failed to yield any crystals. Whilst the 
protein’s catalytic activity was unaffected by the replacement, it appeared that local 
external changes may have perturbed the enzyme’s resistance to trypsin digestion and 
ability to crystallise in the previously encountered form.  
 







  M      I       II       III      IV      V  
Figure 3.20. NuPAGE gel of LOOPr 
Purification.  
I = sonication supernatant 
II = Q-sepharose flow-through  
III = Q-sepharose elute  
IV = Ammonium sulphate pellet 
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M      0       ½       1      1½     2      2½      3       4       5     24h 
Figure 3.21. NuPAGE gel of LOOPr limited proteolysis 




3.3.6 Conclusions and summary 
Before any experimental work was undertaken, a lot of significant information was 
obtained from the PfKMO primary amino acid sequence alone. Evolutionary information, 
in combination with secondary and tertiary structure predictions, was analysed. The 
results of the secondary structure predictions in particular were largely consistent but 
struggled with certain potential sheets/loops. Predicted tertiary structural models were 
biased towards the respective FAH template structure used, however they may be 
relevant in this case due to the global fold relationship in all currently known FAH 
structures. In all, comparisons with other FAHs provided strong evidence that the first 
370 residues of PfKMO were structurally related to the normal two domain core shape. 
The C-terminal 90 residues were unpredictable; these being additional compared to 
some FAH enzymes, and distinctly unrelated to the C-terminal domains found on the 
others. Looking at alignments of closely related KMOs there was clearly enough 
conservation of these residues to suggest that they have a stable structural 
arrangement. The conservation broke down when considering more evolutionary distant 
KMO sequences suggesting that the structure of the C-terminus has changed over time. 
This may be of particular relevance when trying to apply any PfKMO structural 
information to other KMOs such as human KMO. Excluding the C-terminus, candidates 
for residues universally involved in substrate binding as well as those potentially on the 
enzyme’s surface have been discovered. In all the only major obvious concern regarding 
the potential crystallisation success of the enzyme was the unknown nature of the C-
terminal residues.  
Since the early elation of discovering conditions that could grow PfKMO crystals, a lot of 
work went in to trying to discern a productive direction to further the route towards 
structure determination. The diffraction limit of wt substrate bound crystals was 
significantly improved from around 8 Å to 4 Å by optimising the methods of crystal 
growth and cryoprotection. At this point a wall was hit meaning that either new growth 
conditions and/or altered protein properties were needed. Screening for new conditions 
failed to find any fresh leads and so protein engineering was explored to try to 
alter/improve crystal packing. From the varied approaches tried the only success was 
encountered with cysteine mutagenesis. In particular the C252S/C461S double mutant 
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was shown to be significantly more stable than wt PfKMO and more importantly the 
resulting crystals diffracted more strongly to give reflections below 3.50 Å. The 
resolution had now reached a stage where work towards the structure solution could 
begin, and this is described in the next chapter. Along the way though interesting 
insights have been discovered and dwelled upon below. 
Throughout the crystallisation work so far a clear trend had emerged – larger substrate 
bound crystals give stronger diffraction. This in itself was interesting because if the 
problem with PfKMO crystals was related to the malformation of a stable homogenous 
lattice than why would larger crystals help? Two possible theories could cover this: i) 
that the larger crystals had grown more slowly and so were able to form more 
homogeneous and stable lattices or ii) that the crystals were composed of significantly 
more solvent than protein meaning that larger crystals gave a greater amount of protein 
and thus diffraction power. Tests of dehydration and annealing which would have 
reduced the solvent content had no influence on the diffraction power but also neither 
did seeding which would have promoted slow controlled crystal growth. Either way the 
protein was clearly not forming stable crystal contacts in this particular lattice 
arrangement and so protein manipulation was needed.  
The work on limited proteolysis and C-terminal truncation was itself limited by the loss 
of flavin cofactor and of activity of the enzyme. The removal of the C-terminus when 
forming the stable digestion intermediate may suggest that the protein had a similar 
arrangement of residues 1-376 to the two-domain core of other FAH enzymes. The C-
terminal ninety residues that follow appear to form a removable extension that can 
leave a stable core. This core though was inactive and unoccupied by flavin so it must be 
inferred that the C-terminal residues were involved in maintaining functional, FAD-
bound enzyme. With the location of the start of this region relative to the structures of 
other FAH enzymes, it appears unlikely that these residues could directly interact with 
the flavin. Therefore a reasonable conclusion is that the C-terminal residues may be 
largely exposed but still interact with and stabilise the main protein fold. Their removal 
could cause subtle structural rearrangements that perturb the flavin binding site without 
completely unfolding the protein which would then expose the remaining core to rapid 
trypsin digestion. Shortening of the potential loop at residues 240-250 had no effect on 
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the catalytic properties of the enzyme suggesting that this region may be on/near the 
protein surface as predicted in the homology models. The mutant was however more 
susceptible to trypsin digestion, implying some extent of local structural change to 
create greater exposure of basic residues to the trypsin. This loop may therefore as a 
result offer some shielding of K376 from exposure to the active site of trypsin. It was 
unclear though whether the proteolytic changes were a result of just a shorter loop at 
this position or whether the replacement disrupted local secondary structure and 
subsequently enhanced exposure of basic residues. Whilst some potentially useful clues 
were discovered here, no potential route towards better crystal packing was unearthed 
and true conclusions would only be reached in combination with structural data.     
This section presented a lot of computational analysis and predicted inferences that may 
only find significant relevance during structure solution, particularly considering the poor 
resolutions currently attained. With the crystal X-ray diffraction resolution now below 
3.5 Ǻ the route towards structure solution could begin. Model building by molecular 
replacement would be challenging at such resolutions when taking into account the low 
sequence identities to known structures. Therefore L-selenomethionine (SeMet) labelled 
dm2 PfKMO was generated and crystallised to directly calculate the phases and guide 
model building and refinement. 
 
3.4 Crystal structure of selenomethionine-labelled substrate 
bound PfKMO 
3.4.1 Crystal growth and data collection 
SeMet-labelled dm2 PfKMO was expressed in the methionine auxotroph B834 E.coli 
strain and the protein was purified as usual but in the presence of elevated levels of the 
reducing agent DTT. Size-exclusion chromatography was omitted from the purification to 
reduce the time of SeMet exposure to oxygen before crystallisation. The features of the 
final absorbance spectrum of the purified enzyme resembled wt PfKMO (displayed in 
figure 3.22). Moreover, it was confirmed that the SeMet-labelling also did not affect the 
Michaelis-Menten kinetics of the enzyme. The Km and kcat values were determined to be 
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7.0 ± 0.7 M and 8.5 ± 0.2 s-1 respectively compared to 8.8 ± 1.5M and 8.9 ± 1.1 s-1 for 




Crystals of the SeMet labelled protein were grown by h.d.v.d with hetero-microseeding. 
The drop contained 1.0 l of protein solution (15 mg/ml in 20 mM HEPES pH 6.8, 20 mM 
K acetate, 1 mM L-Kyn, 2 mM DTT), 1.0 l of the precipitant (0.1 M HEPES pH 7.0, 15 % 
w/v PEG 4000, 10 % v/v glycerol, 10 % v/v 2-propanol, 2 mM DTT & 1 mM L-Kyn) and 0.5 
l of hetero-seed solution. To prepare the seed solution, a native substrate bound dm2 
crystal was crushed, transferred to 100 l of stabilizing solution (0.1 M HEPES pH 7.0, 20 
% v/v PEGMME 550, 10 % v/v 2-propanol) and micro-centrifuged. Chunky crystals 
resembling an octagonal prism but cut in half (see figure 3.23) with rough dimensions of 
0.2 x 0.2 x 0.2 mm3 grew in 3-5 days and were harvested for data collection after three 
weeks. Prior to flash-freezing in liquid nitrogen, 1 l of 100 % (v/v) ethylene glycol was 
added directly to the drop and left to equilibrate for an hour.  
The crystals were screened for diffraction quality at the Diamond synchrotron beamline 
I04 with several crystals diffracting to a resolution below 4.0 Å. Multi-wavelength 
anomalous dispersion (MAD) X-ray diffraction data were recorded with each dataset 
collected from a different area of a single crystal. The mounted crystal is shown in figure 
3.23. Following a fluorescence scan each dataset was collected using X-ray wavelengths 
Figure 3.22. Absorbance spectrum for pure SeMet dm2 PfKMO protein. 
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of 0.97950 (Peak), 0.97965 (Inflection), 0.96860 (High Energy Remote) & 0.98730 Å (Low 
Energy Remote). Using an exposure of 0.5 s/frame of data, 220 frames were recorded 
with rotation increments of 0.5 º to yield complete data sets. The crystal was tetrahedral, 
space group I4122, with averaged unit cell parameters of a = b = 150.0 Å, c = 273.4 Å, α = 
β = γ = 90.0 º. Indexing and integration of reflections was carried out in Mosflm before 
scaling in Scala with anomalous pairs separated. The four datasets were 98.8-99.9 % 
complete to a resolution of 3.40 Å with respective Rmerge = 0.140, 0.137, 0.137 & 0.113 
(highest resolution shell = 0.580-0.680). The full data collection statistics are tabulated in 
appendix section 3.1. The phases were calculated using the Phenix program suite, which 
was able to locate all but the N-terminal SeMet residue.  
 
       
 
3.4.2 Structure solution and refinement 
A homology model of PfKMO containing residues 7-380 produced by the Phyre server 
from a template structure of PhzS monooxygenase (pdb code 3C96) was selected to 
input as a starting scaffold to fit the phase-solved electron density map generated from 
Phenix. The cell displayed a high solvent content of 83.8 % with just one protein 
molecule in the asymmetric unit, which explained the need to grow large crystals to 
strengthen X-ray diffraction. The model was exhaustively rebuilt and extended by 
numerous rounds of manual editing in Coot [237] and restrained refinement with 
Refmac5 [255]. Guided by the positions of the thirteen SeMet residues and information 
from sequence and structural alignments, a suitable model was obtained containing 
residues 7-461 (figure 3.24). This revealed clear unfilled density for one molecule each of 
Figure 3.23. Mounted substrate-bound 
SeMet dm2 PfKMO crystal used for four-
wavelength MAD data collection. The scale is 
shown in the top-right corner. 
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non-covalently bound FAD and substrate L-Kyn to be included. The density for the 
substrate (figure 3.25) was slightly ambiguous but the final placement showed 
significantly the best geometric and structural fit to the data. Strong density was evident 
for the placement of the carboxyl tail but at this resolution density for the 2-
aminobenzene ring was weak. The final model was refined with the addition of TLS to 
give R and Rfree values of 0.248 and 0.281 respectively with a figure of merit of 0.854 and 
overall mean B factor of 75.7 Å2 for 20381 significant reflections in the range of 77.86-
3.40 Å. The root means square deviation (rmsd) of bond lengths and angles from the 
ideal are 0.005 Å and 0.95 º and all the residues are present in the most favoured or 
additionally allowed regions of a Ramachandran plot as determined using the Molprobity 
server [256]. Full refinement statistics are tabulated in appendix section 3.1. 
 
 
 Figure 3.24. Representation of the fit of the final substrate-bound model to the refined  
2Fo-Fc map in purple (contoured at 1.8 ) with anomalous difference map peaks – relating 








3.4.3 Overall structure of PfKMO 
The protein can be split into three structural domains as shown in figure 3.26. Domain 1 
is mainly involved in coordinating FAD binding with an N-terminal Rossmann-like fold 
and contains residues 7-78, 106-190 & 290-376. This fold consists of five parallel β-
strands (β1, β2, β8, β12 & β19) flanked on top by three anti-parallel β-strands (β9, β10 & 
β11) and a single α-helix (α5), and below by a bundle of five α-helices (α1, α2, α3, α4 & 
α12) and two anti-parallel β-strands (β3 & β7). Domain 1 also contains two anti-parallel 
β-strands (β13 & β18) that link domains 1 and 2. Domain 2 at the bottom of the protein 
contains most of the substrate interactions. Here a platform of two anti-parallel β-
strands (β5 & β6) parallel to a further four anti-parallel β-strands (β14, β15, β16 & β17) 
sits on top of four α-helices (α6, α8, α9 & α10). 
Figure 3.25. Diagram of the substrate-binding pocket with the refined 2Fo-Fc map in 
purple (contoured at 1.5 ) with the Fo-Fc map, calculated in the absence of L-Kyn, 
shown in green/red (contoured at 3.5 ). Figure created in Coot. 
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The long, kinked α-helix α13 forms the spine of the protein through domains 1 & 2 and 
precedes the extension into domain 3. Domain 3 then extends out into four C-terminal 
α-helices (α14-17) which form a solvent-exposed bundle that caps the substrate pocket 
on the opposite side to the flavin. Domain 3 returns to contact Domain 2 of the protein 
at a patch involving helix α15 and the start of α16 which partially covers the back of the 
roof of the substrate binding pocket. At this patch, the highly conserved residues I362, 
V407, F409 & Y414 form hydrophobic contacts to anchor domain 3 to the main protein 






The first 330-360 residues of the protein – effectively the entirety of domains 1 and 2 – 
align well with the structures of other flavin-dependent enzymes as shown in table 3.5. 
Of the most similar structures, all are confirmed or thought to belong to the FAH class. 
No conservation exists for the mobile domain 3 however, which appears to be 
completely novel. Where present, the third domain of other FAH enzymes is of varied 
size and structure with an external thioredoxin fold common to some cases. The FAH C-
Figure 3.26. Two views of a cartoon representation of the final substrate-bound structure with domains 1-3 
coloured blue, purple and red respectively. The substrate and FAD are shown as sticks, coloured cyan and 
yellow respectively. Figure created using PyMol. 
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terminal regions have been implicated in oligomerisation, simply capping the back of the 
substrate binding pocket or have unknown function. Figure 3.27 shows the PfKMO 
structure in comparison with a few of the most similar FAH structures. The substrate is 
bound in a similar buried chamber beneath the isoalloxazine ring of FAD as in the 
displayed FAH structures. The flavin itself has previously been seen to occupy multiple 
conformations as described in section 3.1. In substrate bound PfKMO, the cofactor is 
present in the ‘in’ conformation with a very similar local structural arrangement to the 
displayed structures of MHPCO, HpxO and p-HBH. 
  
         Figure 3.27. Cartoon representation of the final substrate-bound structure alongside the FAH 
structures of MHPCO (pdb code 3gmc), Reb C (3rp7) and p-HBH (1pbe). The relative sequence of 
domains 1-3 are coloured blue, purple and red respectively. The substrate and FAD are shown as 










A Dali server [257] alignment search using just the C-terminal eighty residues of PfKMO 
revealed some structural resemblance to regions of a large number and variety of 
unrelated proteins. The C-terminus shows some relation to part of type I K homology 
(KH) domains, which are present in a variety of nucleic-acid binding proteins [258]. 
Figure 3.28 below shows a resulting alignment between the C-terminal domain of PfKMO 
and the archaeal exosome RNA binding protein RRP4. The sequence identity for the 
alignment is only 10 % for 59 residues however there are conserved helical structural 
elements. The KH domain is however intertwined with additional -sheets that are 
absent in the C-terminal domain of PfKMO. It is possible that this is just a case of 
convergent evolution regarding PfKMO whereby the different proteins have evolved 
towards similar arrangements for structural purposes. The C-terminal domain is 
essentially just a small four-helical barrel and such formations are likely to be commonly 














3ALJ MHPCO 35.6 2.5 342 23 
3RP8 HpxO 32.7 2.8 349 17 
2X3N PQSL 32.0 3.1 334 22 
2Y6R TetX 32.0 3.0 337 22 
1CC4 p-HBH 31.4 3.5 359 19 
2RGJ PhzS 31.0 2.7 331 22 
2VOU DHPH 30.6 2.9 340 16 
Table 3.5. Results of a search of the pdb for similar structures to substrate-bound 
dm2 PfKMO using the Dali server [257]. 
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3.4.4 The substrate binding pocket 
The substrate L-Kyn is tightly bound in between domains 1 and 2 with possible solvent 
access at the interface with domain 3. The binding site (see figure 3.29) forms a split 
hydrophobic and hydrophilic environment to meet the mixed demands of the substrate. 
The benzyl ring of L-Kyn is packed in a hydrophobic pocket below the isoalloxazine ring 
of FAD, lined with the side-chains of L213, I215, MSE222, I224, L226, F238, F319 & 
MSE373. On the other side its zwitterionic tail is surrounded by hydrophilic side chains 
including R84, Y98, H320, N369 & Y404. With the resolution of 3.4 Å one might typically 
expect around a 10 % positional error of 0.3-0.4 Å and so this was taken into account to 
filter plausible hydrogen bond distances. With this in mind, substrate specific binding 
may be coordinated by several hydrogen bonds (See figure 3.30). The majority position 
the carboxylate group of L-Kyn with potential hydrogen bonds to the side chains of R84 
(2.5 & 3.5 Å), Y98 (2.6 Å) and N369 (3.2 Å) respectively. Additionally the tail ammonium 
group is well positioned to hydrogen bond with the backbone carbonyl of H320 (3.1 Å) 
and/or possibly with the backbone carbonyl of F319 (3.6 Å). Finally the 2-amino group of 
the phenyl ring appears to directly hydrogen bond with O4 of the isoalloxazine ring of 
FAD (2.7 Å). The distance between C4a of the FAD isoalloxazine ring – which forms the 
Figure 3.28. Stereo cartoon representation of the C-terminus of PfKMO in red aligned with the 




catalytic hydroperoxy intermediate - and the hydroxylation site of L-Kyn is approximately 
5.0 Å. This distance is feasible to allow the addition of molecular oxygen and subsequent 





(Top) Figure 3.29. The mixed substrate-binding environment in the dm2 PfKMO structure. 
L-Kyn (cyan), FAD (yellow) and key residues lining the pocket are shown in sticks. 
 
(Bottom) Figure 3.30. Interatomic distances (excluding hydrogens) that could potentially 
represent hydrogen bonds involved in substrate binding. L-Kyn (cyan), FAD (yellow) and 
key interacting residues are shown in sticks. Figures made in PyMol. 
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3.5 Crystal structure of substrate-free PfKMO 
3.5.1 Crystal growth and data collection 
With wt PfKMO, only microcrystals of substrate-free enzyme could be grown which were 
unsuitable for further study. After introduction of the double cysteine mutation, single 
crystals grew under similar conditions to those used with the enzyme co-crystallized with 
substrate. A salt additives screen (10 mM final salt concentration) established that larger 
crystals more reproducibly formed with tartrate or chloride ions. The morphology of the 
crystals was subtly different from those grown with substrate as can be seen with a 
substrate-free crystal displayed in figure 3.31. The drops contained 1.0 l of protein 
solution (11.5 mg/ml in 20 mM HEPES pH 6.8, 20 mM K acetate) and 1.0 l of the 
precipitant (0.1 M HEPES pH 7.0, 10 % w/v PEG 4000, 10 % v/v glycerol, 10 % v/v 2-
propanol & 10 mM K tartrate or KCl). Crystals with a rounded wedge appearance and 
rough dimensions of 0.10 x 0.15 x 0.20 mm3 grew in 3-7 days and were harvested for 
data collection after three weeks. Prior to flash-freezing in liquid nitrogen, 1 l of 
cryoprotectant, mother liquor 20 % in EG, was added to the drop before the crystals 
were transferred directly into 2 l of the cryoprotectant.  
 
    
 
Figure 3.31. Mounted substrate-free 
crystal from the tartrate crystallisation 
drop which was used for data 
collection. The scale is labelled in the 
bottom right corner. The beam size 
(square box with a cross-hair in) was 50 
x 50 m. 
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Diffraction data were collected for each crystal at the Diamond synchrotron beamline I24 
with an X-ray wavelength of 0.978 Å. All substrate-free crystals showed significantly 
stronger diffraction extending to below 2.5 Å as seen in figure 3.32. Using an exposure of 
0.2 s and oscillation of 0.2 º, reflections were recorded over a wedge of 120 º. The 
crystals were packed in a new, orthorhombic space group - P21221. The crystals had 
mean unit cell parameters of around a = 105.0, b = 134.0, c = 188.5 Å, α = β = γ = 90.0 º. 
Indexing and integration of reflections was carried out in Mosflm before scaling in Scala. 
The tartrate crystal dataset was 99.4 % complete to a resolution of 2.26 Å with Rmerge = 
0.055 overall (0.652 in the highest resolution shell) and average signal to noise of 13.5 
(2.0). Similarly the chloride crystal dataset was 97.8 % complete to a resolution of 2.45 Å 
with Rmerge = 0.063 overall (0.597) and average signal to noise of 12.4 (2.0). Full data 
collection statistics are tabulated in appendix section 3.2. Based on the influence of salt 
ions on the reaction catalysed by PfKMO described in section 3.3.1, the data from the 






Figure 3.32. Diffraction image from a substrate-free crystal with reflections extending below 2.5 Å. 
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3.5.2 Refinement and overall structure 
For the calculation of structure factors, a suitable model was generated using molecular 
replacement (Molrep) with the previously solved monomeric substrate bound structure 
(see section 3.3). A definitive solution emerged with four protein molecules present in 
the asymmetric unit (see figure 3.33) yielding a solvent content of 62.9 %. The model 
was cycled through manual editing in Coot and restrained refinement in Refmac. For the 
first few cycles NCS restraints for each chain were applied in refinement. There was clear 
density for one FAD cofactor for each chain and only solvent in the substrate binding 
sites. For all four chains the residues 6-461 were included, except for two loop regions. 
For the loop involving residues 42-52 in front of the FAD binding site there was only 
partial density with additional density for a new, more solvent exposed loop position. 
Therefore these residues were removed from each chain in the structure. In addition, in 
chain D there was insufficient density to clearly place residues 375-378, which precede 
the C-terminal domain. Towards the end of refinement, coot was used to manually place 
431 waters in the model.  
 
Figure 3.33. Arrangement of the four 
substrate-free protein chains in the 
asymmetric unit. Each chain is coloured 
differently as cartoons with FAD shown 
in spheres. Created using PyMol. 
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The final model was refined with the addition of TLS to give R and Rfree values of 0.219 
and 0.232 respectively with an overall mean B factor of 49.4 Å2 for 117656 significant 
reflections in the range of 50.0-2.26 Å. The root means square deviation (rmsd) of bond 
lengths and angles from the ideal were 0.0050 Å and 0.94 º with all the residues present 
in the most favoured or additionally allowed regions of a Ramachandran plot. The 
Molprobity server was used to validate the final model. Full refinement statistics are 





The arrangement of the substrate-free structure showed a similar layout to substrate 
bound PfKMO with the same residues forming three structural domains (See figure 3.34). 
Each polypeptide chain showed a rmsd of 1.4-1.5 Å2 (for protein C atoms) when 
separately superimposed on to the substrate bound structure by the DaliLite pairwise 
server. Looking at an alignment of the two structures (see figure 3.35), it was clear that 
there was little to differentiate the first two domains bar the absence of substrate. The 
FAD cofactor was located in virtually the same position and the active site itself showed 
no clear differences. This was not the case for the whole protein though, as a clear 
Figure 3.34. Two views of the cartoon layout of chain A of the substrate-free structure with the sequence 
representing each of the three domains coloured blue, purple and red. FAD is shown in yellow sticks. 
Figure created using PyMol. 
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displacement of the novel C-terminal domain 3 is apparent. The helix 15remains 
anchored to the back of domain 1 and acts as a pivot on which the helices 
1416&17swing away from the unfilled substrate binding pocket. In particular, the 
Cα backbone of helix α14 swings out by up to 6.1 Å at residue 381 in the substrate-free 
structure compared to with substrate bound. The two structures appear to display two 
conformations, a ‘closed’ conformation with substrate bound and an ‘open’ 
conformation in its absence. A different view of the movement in the structures (figure 
3.36) shows that the open conformation creates a solvent-exposed tunnel leading 






Figure 3.35. Alignment of chain A of the substrate-free (violet) and the substrate-bound dm2 PfKMO 
structures. The overall alignment is shown on the left with a close-up of just the C-terminal domains 








3.5.3 Structural differences in the presence of Cl- ions 
The presence of chloride ions in the crystal mother liquor caused subtle structural 
differences compared to the above tartrate-grown substrate-free structure. The final 
model possessed R/Rfree values of 0.218/0.244 and a B factor of 46.2 Å
2 for 91114 
significant reflections in the range 35.00-2.45 Å. It contained residues 6-461 and a 
molecule of FAD in the same four-chain arrangement as displayed above. On all four 
chains, a chloride ion was placed above the active site in a cleft adjacent to the flavin’s 
isoalloxazine moiety as displayed in figure 3.37. 
 
Figure 3.36. View of the translocation of the C-terminal domain which opens up a potential entry/exit 
tunnel to the substrate binding site. A surface view of the back of the substrate-bound structure (green) 
on the left adjacent to the corresponding surface view of the substrate-free structure (violet) on the right. 
The substrate (cyan sticks) is modelled into the substrate-free structure to illustrate the location of the 






Overall the structural elements of each domain align well with the tartrate structure and 
with the C-terminal domain again in the open conformation. The average rmsd of the 
backbone C atoms of each chain to those in the tartrate structure ranges from 0.7-0.9 
Å2. Significant differences were evident in two distinct interlinking loop regions. Firstly 
the aforementioned external loop involving residues 45-53 showed strong density for 
just a single conformation – that of the substrate bound enzyme. This is shown in 
comparison to the tartrate structure in figure 3.38. Secondly the C-terminal end of the 
long helix α-13 and the adjoining loop into the start of domain 3 were pulled in to be 
more like the substrate bound structure. The two loop positions described for the 
tartrate and chloride structures are displayed in figure 3.39. This meant that the 
substrate-free ‘chloride’ structure provided a new mixed C-terminal conformation with 
elements of both the substrate bound and unbound ‘tartrate’ forms.  
 
Figure 3.37. Binding site of a chloride ion (grey) in the chloride-bound structure above 
the substrate-binding pocket. The refined 2Fo-Fc map is shown in orange (contoured at 
1.5 σ) with the Fo-Fc map calculated in the absence of the ion shown in green (contoured 










Figure 3.39. 2Fo-Fc density maps for different positions of the loop preceding the 
C-terminal domain in the chloride (orange) and tartrate (blue) substrate-free 
structures.  
In the chloride structure the loop is pulled in towards the back of the substrate 
binding pocket as seen in the L-Kyn bound structure. Created using Coot with 
contouring at 1.5 σ. 
Figure 3.38. Loop involving residues 42-52 without density in the tartrate substrate-free structure (left, 
blue) but is clearly visible in the density for the chloride substrate-free structure (right, orange). The refined 
2Fo-Fc density is contoured at 1.5 σ with the figures created using Coot. 
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At this stage the structural variations could either be dependent upon substrate binding, 
the influence of the respective salt ions or the packing of the crystal lattice. It is well 
known that small anions including chlorides strongly inhibit FAH enzymes such as pHBH 
(see section 1.2.3), and have directly been shown to inhibit both PfKMO and human 
KMO (see section 1.3). Either way an interesting glimpse into the possible dynamics of 
the enzyme was developing. From this point onwards the tartrate substrate-free form is 
labelled as the unbound structure and the chloride form as the chloride-bound structure. 
 
3.6 The cofactor binding site 
As previously mentioned, the enzyme utilises a Rossmann-like fold to form the non-
covalent FAD binding site. The cofactor density in the unbound and the chloride bound 
structures is very clear with average B-factors of 35.9 and 40.1 Å2 respectively. In the 
lower resolution substrate bound structure the FAD B-factor is naturally higher at 104.2 
Å2. Comparing all the structures there are no significant differences in the orientation of 
the FAD or in the local protein environment. The high resolution unbound structure 
provides a detailed view of the interactions that govern flavin binding. The refined 
electron density calculated with and without FAD are highlighted below in figure 3.40. 
            
Figure 3.40. Fit of the FAD cofactor into the refined 2Fo-Fc (blue) and Fo-Fc 
(green/red) density (calculated in the absence of FAD in the model) in the 
unbound (tartrate) structure with contouring at 2.0 and 4.0 σ respectively. 
Created using Coot. 
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The many potential hydrogen bonds associated with FAD binding in the unbound PfKMO 
structure are summarized in figure 3.41. The adenine nucleotide is stabilised by 
interactions with the main-chain amide CO of L135 (3.3 Å), the amide NH of L135 (2.9 Å) 
and a water molecule (2.9 Å). Also the side chain of R38 stacks above the nucleotide 
partially shielding it from solvent. More extensive H-bonds are found with the sugar 2 
and 3-OH groups and the perpendicularly stacked, highly conserved side-chains of E37 
(2.5 & 2.7 Å) and R39 (2.8 & 3.1 Å). The glutamate interactions in particular are also 
highly conserved among other published FAH structures. Moving down, the di-
phosphates form H-bonds with the amide backbone NH of residues A18 and D311 (both 
2.9 Å) as well as with a few molecules of solvent. The side-chains of R111 (2.8 & 3.1 Å) 
and D311 (2.7 Å) H-bond with the next moiety – the ribityl chain. D311 is part of the 
strictly conserved GD motif among FAH enzymes. Finally, the flavin isoalloxazine ring is 
present in the ‘in’ conformation in all structures with substantial interactions with 
residues G321 and G323-N325. All the residues discussed are highly conserved in 
alignments of KMO sequences.  
As mentioned in section 1.2.3.1, FAH enzymes utilize a dynamic cofactor isoalloxazine 
ring to accommodate the different solvent requirements of flavin reduction and of 
hydroxylation of the substrate [148]. In all the PfKMO structures in this section, the flavin 
cofactor is present in the in position in the buried active site. FAD captured in the out 
position in the structure of unbound m-HBH [175] was modelled into the structure of 
PfKMO as displayed in figure 3.42. The loop involving residues 42-52, highlighted in 
green, clashes with the out conformation of the isoalloxazine ring. This loop is disordered 
in the unbound PfKMO structure and so may be flexible enough to undergo the small 
displacement required to allow the predicted flavin movement. Counter intuitively to 
this, the B-factors for the residues in the loop are not that high in the substrate bound 
structure. It is possible that this loop is involved in forming the NADPH docking site but 






Figure 3.41. An overview of the interactions surrounding the non-covalent binding of the FAD cofactor in 
the unbound dm2 PfKMO structure. Part of the FAD pocket is shown in surface view with key protein 
residues labelled and shown as sticks. Figure created with PyMol shown in stereo. 
Figure 3.42. Potential clash observed between loop 42-52 (green) and FAD when it is modelled into the 
substrate-bound structure in the out position (orange) as taken from the m-HBH structure with pdb code 
2dkh. On the left is the substrate-bound PfKMO structure with FAD shown in yellow. Created using PyMol. 
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There is one FAH crystal structure that contains bound NADPH, which was obtained with 
an R220Q mutant version of p-HBH [163]. The mutation causes a slight displacement of 
the substrate binding domain, which reduces affinity for the substrate and destabilizes 
the flavin’s in position. The orientation of the external NADPH cofactor in the structure 
results in an unrealistically large distance between the transferrable hydrogen atom and 
the flavin isoalloxazine ring. The authors proposed that for flavin reduction, NADPH 
adjusts into a folded conformation to bring the nicotinamide moiety towards the flavin 
isoalloxazine ring. The bound NADPH from this mutant p-HBH structure is aligned onto 
the structure of substrate bound PfKMO below in figure 3.43. The modelled NADPH fits 
well onto the surface of the enzyme even with the 42-52 loop present. Also, residues 
conserved in all KMO sequences can be seen to cluster around the site of flavin 






Figure 3.43. NADPH (purple spheres) docking into the substrate-bound PfKMO structure (white). On the left 
loop 42-52 is highlighted green and on the right conserved residues among KMO sequences are highlighted 
green which appear to surround the modelled NADPH molecule. NADPH modelled based on the relative 
position in the structure of a p-HBH mutant structure (pdb code 1k0j). Created using PyMol. 
126 
3.7 Discussion and conclusions     
In this investigation the first ever KMO structures have been solved of substrate-free and 
substrate-bound PfKMO. The road to the substrate bound structure was long but 
progressive as the complex only crystallized in a lattice consisting of over 80 % solvent, 
resulting in very weak diffraction. Conditions were optimised to slowly grow larger 
crystals to give stronger diffracting power and with the additional mutagenesis of two 
cysteines to serines, resolutions of around 3.50 Å were reached. The substrate-bound 
structure was subsequently solved to a resolution of 3.40 Å using SeMet-labelled 
protein. Thirteen of the fourteen SeMet residues (missing the N-terminal residue) were 
found and whilst some were present in the vicinity of the active site, there was no 
obvious differences when the structure was modelled into data from unlabelled 
substrate-bound dm2 PfKMO (data not shown). With the double mutation single crystals 
of unbound PfKMO could be grown and without much optimisation showed significantly 
stronger diffraction despite growing from similar conditions and reaching much smaller 
sizes to those of the substrate bound enzyme. All unbound crystals were packed 
substantially differently in a new space group with a lower solvent content of around 60 
%. Therefore these crystals were readily able to diffract to high resolutions, around 2.30 
– 2.50 Å and add confidence and quality to the initial low resolution substrate bound 
model. The structures confirmed that both residues (252 and 461 respectively) are 
solvent exposed on the surface of the protein. 
The two resulting structures revealed a three-domain structure with the first two 
domains arranged with a similar overall fold to all other published FAH structures. Also 
positioned in similar respective locations were the non-covalently bound FAD cofactor 
and substrate L-Kyn. The three-helical bundle of the C-terminal domain 3, however, is 
completely new to this class of enzyme. The domain extends out from the back of the 
substrate binding pocket and revealed an interesting translocation between the two 
structures, which appears to control the opening/closing of an access route to the 
substrate-binding pocket. 
A substantial patch of free electon density was present in the active site to place L-Kyn 
into the substrate bound model. At 3.40 Å resolution the exact position of the functional 
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groups was not definitive however the side-chains of residues R84, Y98, N369 and 
possibly Y404 appear well positioned to interact with the bound substrate. It appears 
that the substrate’s carboxyl group is involved in the majority of the interactions and 
could be critical to substrate recognition. As seen in other FAH structures, the substrate 
is directly below the isoalloxazine ring of the FAD in a large buried pocket. A similar 
distance of approximately 5.0 Å separates the catalytic C4a of the flavin from the 
hydroxylated carbon of the substrate, fitting in with previous evidence that the reaction 
proceeds via a C4a-hydroperoxyflavin intermediate. All of the residues that are located 
within 6 Å of the substrate are highly conserved among all KMO homologs including 
hKMO. The only residue in the active site that is not identical in a sequence alignment 
between PfKMO and hKMO is H320, which is a phenylalanine in the human enzyme. This 
histidine is located directly above the carboxyl group of L-Kyn with its side-chain pointing 
out towards the possible route of substrate entry. There is over 5 Å separating this side-
chain from L-Kyn suggesting that it does not directly interact with the substrate once 
bound. Looking at rat KMO, which has been the model for the synthesis of several 
published KMO inhibitors, there is one slight additional variation to both PfKMO and 
hKMO. The residue relative to T408 of the bacterial enzyme is an alanine in the rat 
enzyme. The side-chain of T408 lines the substrate binding pocket at the opposite side to 
FAD, around 6 Å from the tail of L-Kyn.                  
Looking at other substrate bound FAH structures the orientation of the substrate itself 
seems to give away its route of entry in to the active site. Typically, as would be 
expected, the hydrophobic portion of the molecule is first to enter the buried site to 
evade interactions with solvent, leaving the hydrophilic end to point out towards 
solvent. L-Kyn can be clearly separated into a hydrophobic benzene ring and a 
hydrophilic zwitterionic tail as reflected in the split nature of the surrounding active site 
residues. The logical route of entry of the substrate into its buried binding site appears to 
be through a tunnel that leads to the back of the pocket opposite to the flavin. This 
tunnel is sandwiched between the structural elements β-6 of domain 2 and α-14 of 
domain 3. Interestingly the route to solvent is closed off in the substrate bound structure 
due to the closed conformation of domain 3. The apparent opening of this domain and 
subsequently of the tunnel in the unbound structure suggests a regulatory role of this 
128 
novel domain in substrate binding. At this stage of course it can’t be established whether 
the change is directly dependent upon substrate binding or upon crystal lattice packing. 
The dynamics of domain 3 are investigated further in the next chapter. 
In addition to unbound and substrate-bound forms, a chloride-bound structure was 
obtained. It had a similar crystal lattice and overall structural properties to unbound 
PfKMO but presented a couple of loop elements that resembled the substrate bound 
structure. A chloride ion was found bound adjacent to N10 of the isoalloxazine moiety on 
the si side above the substrate binding pocket. The ion was positioned quite far from the 
two respective loop alterations though, raising questions as to its significance. Previously 
in p-HBH structures the binding of a bromide ion on the re side of the flavin was linked to 
the observed conformation of the flavin. In the case of PfKMO the flavin conformation 
was not observed to be dependent on the presence/absence of the aforementioned 
chloride ion. In all the structures the FAD was positioned in the buried in position and 
additionally was shielded from solvent by loop 42-52 in the substrate bound structure. 
This loop would partially block flavin movement to the out position based on other FAH 
structures. Using NADPH bound in the structure of a p-HBH mutant [163], the coenzyme 
is able to dock in a similar location in PfKMO. From analysis of the model and the KMO 
structures a possible hypothesis to explain the logistics of flavin reduction involves:  
i) Flavin is positioned in the in position regardless of substrate binding. 
ii) Substrate binding stimulates formation of the NADPH docking site which includes 
residues 42-52. 
iii) Once NADPH docks it changes conformation and drives local movement to allow 
the FAD to swing to the out position. 
iv) NADPH reduces FAD. 
v) NADP+ rapidly dissociates and the reduced flavin swings back to the active site to 
react with molecular oxygen. 
 
In summary, the presented structures detail the environment of the active site of 
PfKMO. With high sequence conservation of all the surrounding residues the structures 
should provide a suitable model to base investigations of the active site of human KMO. 
In particular this should be able to facilitate rational inhibitor design and screening for 
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the first time to enhance the discovery of therapeutically relevant compounds. 
Homology models for the human enzyme based on the presented PfKMO structures can 
be found in the appendix section 2. Sequence alignments and the structural models 
further suggest that the first two domains of the enzyme may be a relevant scaffold for 
those of human KMO. The predictions are of course biased by the template structure but 
it is important that there is no evidence in the primary sequences that KMO has 
undergone significant structural changes during the course of evolutionary divergence 
between the bacterial and mammalian enzymes. This sadly is not the case for the whole 
sequence of the enzyme though. Difficulties are encountered trying to predict the C-
terminal domain of the human enzyme as the secondary structure prediction breaks 
down around residue 425 where mammalian KMOs have evolved a transmembrane 
helix.  
The C-terminus, and particularly the apparent conformational changes of PfKMO, will be 
explored further in the next chapter to try and see just how much information can be 





Chapter 4 – Investigation of the dynamic, novel domain 3 
4.1 Introduction 
In chapter 3, the structures of substrate bound and substrate free PfKMO were 
described, and revealed the presence of a novel dynamic C-terminal domain. Upon 
aligning the structures, a 7 Å swing of this domain from the back of the substrate-binding 
pocket was apparent between an in/closed and out/open conformation. This movement 
revealed the most obvious route of substrate entry/product release from the active site. 
Figure 4.1 shows the two structures with each residue colour-coded depending on their 
relative B-factor values. Looking at the unbound structure on the left, the section in red 
between the bottom of the vertical kinked -helix and the first helix of the C-terminal 
domain (which includes the sequence with the greatest positional displacement between 
the two structures) has relatively very high B-factors. The corresponding, translated 
region of the substrate bound structure shows relatively lower B-factors indicating that 
the presence of the substrate stabilises the residues in the in/closed conformation. 
Moreover it should be kept in mind that the substrate bound structure was solved at a 




Figure 4.1. Cartoon representation of unbound (left) and substrate-bound (right) PfKMO structures with    
B-factors coloured low-high as a spectrum of blue-red. The highly flexible C-terminal section in the unbound 
structure is highlighted by a black circle. 
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Looking at the structures from chapter 3 in more detail reveals that the side-chains of 
R84, E372, Y382 & R386 are well positioned to link the substrate to the closed helix α-14 
- possibly via a hydrogen bond network. The network finishes with R386 linking domain 3 
back to the main protein scaffold with a potential hydrogen bond to the backbone 
carbonyl of P97. In the open conformation observed in the unbound structure, Y382 and 
R386 are clearly moved away and the link breaks down (See figure 4.2). Therefore it is 
plausible that once the substrate has passed into the substrate binding pocket, it pulls 
domain 3 in behind via the aforementioned network. Whilst R84 and E372 are invariant 
among KMO sequences, Y382 and R386 are conserved but also present as F and K 
respectively - as is the case in human KMO. The interchanging of Y382 for a F, which 
would not be able to participate in the described hydrogen-bond network, is an 







Importantly the substrate-bound and substrate free enzyme forms displayed radically 
different lattices and crystal packing. As a result, the C-terminal differences described so 
far could have simply been an artefact caused by the different crystalline protein 
arrangements. C-terminal mutants (E372T, Y382F, R386K and R386T) were studied to 
Figure 4.2. Cartoon representation of substrate binding pocket and start of C-terminal domain for 
substrate-bound (left) and substrate-free (right) PfKMO structures.  
Key residues that may be involved in the movement of domain 3 are shown in sticks in addition to FAD 
(yellow) and the substrate (cyan). Distances relating to the discussed potential hydrogen bond network 
are labelled in each structure. 
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further characterize and validate the potential dynamics of domain 3 in PfKMO, with the 
additional aim of determining whether a similar system could operate in human KMO. 
 
4.2 Results 
4.2.1 Crystallisation of Y382F dm2 
The Y382F dm2 PfKMO protein was expressed and purified as normal and used for 
h.d.v.d crystallization trials with L-Kyn bound. Crystals of substrate-free Y382F dm2 could 
not be obtained within the time constraints of the project. Large, hexagonal prism 
shaped substrate-bound crystals with rough dimensions of 0.2 x 0.2 x 0.5 mm3 grew in 3 
days and were immediately harvested for data collection. The final drop contained 1.0 l 
of protein solution (15 mg/ml in 20 mM HEPES, 30 mM Na acetate, 1 mM DTT and 1 mM 
L-Kyn) with 1.0 l of the precipitant solution (0.1 M HEPES pH 7.0, 10 % w/v PEG 4000, 
10 mM KCl, 6 % v/v glycerol, 10 % v/v 2-propanol, 1 mM L-Kyn). Prior to flash-freezing in 
liquid nitrogen, 1 L of cryoprotectant (mother liquor plus 20 % EG) was added to the 
drop before the crystal was transferred into a drop containing just the cryoprotectant for 
a few seconds.  
 
   
Crystals were screened for diffraction quality at the Diamond synchrotron beamline I04-
1, with several diffracting to a resolution around 3.4 Å. X-ray diffraction data were 
collected using an X-ray wavelength of 0.920 Å, a beam intensity of 90 % and an 
Figure 4.3. Close-up picture of the 
mounted Y382F crystal used for 
collection of the highest resolution 
dataset. The beam size and position 
is represented by the red circle and 
cross-hair. 
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exposure of 0.3 s with 0.3 º oscillations over a wedge of 180 º. The crystal (shown in 
figure 4.3) had similar lattice properties to native substrate bound crystals; space group 
I4122 with mean unit cell parameters of a = b = 150.2, c = 273.6 Å, α = β = γ = 90.0 º. The 
dataset was 99.7 % complete to a resolution of 3.36 Å with Rmerge = 0.095 overall (0.599 
HS) and mean I/I = 14.4 (3.6 HS). The full data collection statistics are tabulated in 
appendix section 3.3. 
For the calculation of structure factors, a suitable model was generated using molecular 
replacement (Molrep) with the previously solved monomeric substrate bound dm2 
structure (see section 3.3). Similarly, the Y382F mutant structure also contained one 
protein molecule in the asymmetric unit and a high solvent content of 83.8 %. A large 
displacement in the C-terminal domain was however evident and so the domain was 
rebuilt in a more open conformation as depicted in figure 4.4. The model was cycled 
through manual editing/building in Coot and TLS and restrained refinement in Refmac. 
There was clear density to place one molecule of FAD and one molecule of the substrate 
L-Kyn – both in the same position as seen before. The final model included residues 7-
461 and is displayed in figure 4.5. It had R and Rfree values of 0.247 and 0.277 respectively 
and an overall mean B factor of 103.1 Å2 for 21461 significant reflections in the range of 
65.93-3.36 Å. The rmsd of bond lengths and angles from the ideal were 0.005 Å and 
0.900 o and all the residues were present in the most favoured or additionally allowed 
regions of a Ramachandran plot as determined using the Molprobity server. Full 
refinement statistics are tabulated in appendix section 3.3. 
   
 
 
            
Figure 4.4. Y382F substrate bound 2Fo-Fc density (blue) and Fo-Fc map (green/red) for C-terminal domain 
calculated: (left) with dm2 substrate bound model (green) and (right) with rebuilt more open loop 






The first two domains of the Y382F substrate-bound structure, including the substrate 
and FAD-binding pockets, were identical to the original substrate-bound structure 
described in chapter 3.4. The novel third domain however showed a relative 
displacement to a more open conformation reminiscent of the unbound PfKMO 
structure from chapter 3.5. Aligning the structure with the dm2 substrate-bound, 
chloride-bound and substrate-free structures revealed rmsd values of 0.8, 0.8 and 1.1 Å 
respectively (for protein C atoms). The overall substrate-bound structural alignment is 
displayed in figure 4.5, with a close-up section of the C-terminus including the original 
unbound structure shown in figure 4.6. The Y382F mutant C-terminal domain 3 displayed 
a mixed conformation similar to the dm2 chloride-bound structure described in section 
3.5.3. The bottom of the long -helix -13 is pulled in towards the tail of the substrate 
but the C-terminus, from helix -14 onwards, is swung out similar to the unbound 
structure. The extent of the swing (based on the position of the T381 C atom) is reduced 
at 3.8 Å compared to 6.1 Å in the fully open substrate-free conformation. The putative 
hydrogen-bond network described in figure 4.2 was speculated to link substrate binding 
to the closing of the C-terminal domain. Looking at the respective residue positions in 
the mutant substrate-bound structure in figure 4.7, this network is disrupted by the 
mutation of one its members leaving R386 out of hydrogen-bonding reach from E372 
Figure 4.5. Cartoon representation of 
the superposed substrate-bound Y382F 
mutant (orange) and original dm2 
(green) structures. FAD and the 
substrate L-Kyn are shown in sticks. 
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and P97. This may account for the observed opening of the C-terminal domain in the 







To complement the structural data, the Michaelis-Menten kinetic constants were 
determined for the Y382F dm2 mutant enzyme. The Km and kcat values were 17.1 ± 1.0 
M and 12.7 ± 0.2 s-1 compared to 8.8 ± 1.5 M and 8.9 ± 1.1 s-1 for dm2. Therefore the 
mutation did not have a massive effect on substrate binding and catalysis, despite the 






Figure 4.6. Representation of the mixed C-
terminal conformation seen with the Y382F 
mutant. Includes a cartoon alignment of the 
Y382F substrate-bound structure (orange) with 
the dm2 substrate-bound (green) and 
substrate-free (violet) structures. The substrate 
L-Kyn is shown in sticks.  
 
Figure 4.7. Altered positions of the residues 
previously implicated in a hydrogen-bonding 
network. The mutated residue Y382F is 
labelled along with the new distances between 
the residues.  
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4.2.2 Crystallisation of R386K dm2 
The R386K dm2 PfKMO protein was expressed and purified as normal and used for 
h.d.v.d crystallization trials with L-Kyn bound. The final drop contained 1.0 l of protein 
solution (15 mg/ml in 20 mM HEPES, 30 mM Na acetate, 1 mM DTT and 1 mM L-Kyn) 
with 1.0 l of the precipitant solution (0.08 M HEPES pH 7.0, 8 % w/v PEG 4000, 10 mM 
NaCl, 6 % v/v glycerol, 10 % v/v 2-propanol). Crystals shaped like hexagonal prisms with 
rough dimensions of 0.2 x 0.3 x 0.6 mm3 grew in 2-3 days and were harvested for data 
collection after 10 days. Prior to flash-freezing in liquid nitrogen, 1.5 l of cryoprotectant 
(mother liquor + 20 % EG) was added to the crystallisation drop for a couple of mins. The 
crystal was then transferred into a 2 l drop of cryoprotectant for a few seconds. 
Crystals were screened for diffraction quality at the Diamond synchrotron beamline I02 
with several diffracting to a resolution around 3.4 Å. X-ray diffraction data were collected 
using an X-ray wavelength of 0.979 Å, a beam intensity of 80 % and an exposure of 0.3 
s/frame of data, with 0.3 o oscillations over a rotation of 210 o. The crystal (displayed in 
figure 4.8) again had similar lattice properties to substrate bound wild type crystals; 
space group I4122 with mean unit cell parameters of a = b = 149.7, c = 273.5 Å, α = β = γ 
= 90.0 o. The dataset was 100.0 % complete to a resolution of 3.30 Å with Rmerge = 0.070 
overall and 0.545 in the highest resolution shell. The full data collection statistics are 
tabulated in appendix section 3.3. 
         
Figure 4.8. Close-up picture of the 
mounted R386K crystal used for 
collection of the highest resolution 
dataset. The beam size (100 x 25 
m) and position is represented by 
the red circle and cross-hair. 
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For the calculation of structure factors, a suitable model was generated using molecular 
replacement (Molrep) with the previously solved monomeric substrate bound structure 
(see section 3.3). Few differences emerged with one protein molecule present in the 
asymmetric unit and a solvent content of 83.7 %. The residues at the start of domain 3 
were again clearly displaced and rebuilt in a more open conformation (see figure 4.9). 
The model was cycled through manual editing/building in Coot and TLS and restrained 
refinement in Refmac. There was clear density to place one molecule of FAD and one 
molecule of the substrate L-Kyn – both in the same position as seen before. The final 
model included residues 7-461 with R and Rfree values of 0.247 and 0.259 respectively 
and an overall mean B factor of 108.3 for 22568 significant reflections in the range of 
53.96-3.30 Å. The rmsd of bond lengths and angles from the ideal were 0.005 Å and 
0.953 o and all the residues were present in the most favoured or additionally allowed 
regions of a Ramachandran plot as determined using the Molprobity server. Full 
refinement statistics are tabulated in appendix section 3.3. 
 
 
Figure 4.9. R386K substrate bound 2Fo-Fc density (blue) and Fo-Fc map (green/red) for C-terminal domain 
calculated: (left) with dm2 substrate bound model (green) and (right) with rebuilt more open loop 




The R386K structure was very similar to that of Y382F with unchanged domains 1 and 2 
and the same mixed C-terminal conformation. The rmsd of the substrate-bound 
structure superposed with that of Y382F, dm2, chloride-bound dm2 and substrate-free 
dm2 is: 0.2, 0.8, 0.7 and 1.0 Å respectively (for protein C atoms). The global 
superposition of the original substrate-bound dm2 structure is displayed in figure 4.10. 
The mixed C-terminal conformation is displayed more closely in figure 4.11 with the 
respective positions of the hydrogen-bond network residues indicated in figure 4.12. It is 
clear that the lysine residue introduced could not maintain the interactions involving 
R386 that closed the C-terminal domain upon substrate binding. Looking back to figure 
4.2 showing the proposed native hydrogen-bond network, the R386K structure suggests 
that the interactions described from the low-resolution structure may be accurate. Lys is 
unable to coordinate the two separate hydrogen bonds predicted with the side-chain of 
Y382 and with the backbone carbonyl of P97. As a result the residue is left stranded in 
the structure at around 5.0 and 6.7 Å from Y382 and P97 respectively. The Michaelis-
Menten kinetic constants were determined to be slightly elevated compared to the dm2 
protein and were essentially identical to those for the Y382F mutant within the error 
limits (see table 4.1 for a complete summary of the data). 
Figure 4.10. Cartoon representation of 
the aligned substrate-bound R386K 
mutant (cyan) and original dm2 (green) 
structures. FAD and the substrate L-Kyn 








For a negative control, crystals of unbound R386K were generated from a 1:1 l h.d.v.d 
drop of protein solution (12 mg/ml in 20 mM HEPES pH 6.8, 150 mM Na acetate, 1 mM 
DTT) and reservoir solution containing: 0.1 M HEPES pH 7.0, 12 % w/v PEG 4K, 10 % v/v 
glycerol, 10 mM Na tartrate, 10 % v/v 2-propanol. The crystal of rough dimensions 0.1 x 
0.1 x 0.3 mm3 grew in 3-5 days and was harvested after 6 days. Cryoprotection involved 
addition of 1.5 l cryoprotectant (mother liquor plus 20 % EG) prior to transfer into the 
cryoprotectant for a few seconds. Diffraction data were collected with an exposure of 
0.3 s per 0.3 o rotation over a total of 135 o at beamline I04 using a wavelength of 0.980 Å 
and beam intensity of 35 %. The averaged unit cell had dimensions of a = 105.2, b = 
133.9 and c = 188.5 Å packed in the orthorhombic space group P21221. Full data 
collection and refinement statistics are displayed in appendix section 3.4. The structure 
was solved using molecular replacement with the dm2 unbound structure from section 
3.5.2. As previously seen there were four molecules in the asymmetric unit each with 
one molecule of FAD bound. Key refinement values include: Resolution = 45.00-2.63 Å, 
Figure 4.11. Representation of the mixed C-terminal 
conformation seen with the R386K mutant. Includes 
a cartoon alignment of the R386K substrate-bound 
structure (cyan) with the dm2 substrate-bound 
(green) and substrate-free (violet) structures. The 
substrate L-Kyn is shown in sticks.  
 
Figure 4.12. Altered positions of the residues 
previously implicated in a hydrogen-bonding 
network. The mutated residue R386K is labelled 




R/Rfree = 0.225/0.241, mean B-factor = 40.6 Å
2 and no Ramachandran plot outliers. The 
structure was virtually identical to the dm2 unbound structure with an overall rmsd of 
0.1 Å, therefore confirming that the R386K mutation did not alter the general protein 
structure. 
 
4.2.3 Crystallisation of R386T dm2 
The R386T dm PfKMO protein was expressed and purified as normal and used for h.d.v.d 
crystallization trials with L-Kyn bound. The final drop contained 1.0 l of protein solution 
(13 mg/ml in 20 mM HEPES pH 6.8, 20 mM Na acetate, 1 mM DTT and 1.5 mM L-Kyn) 
with 1.0 l of the precipitant solution (0.1 M HEPES pH 7.0, 6 % w/v PEG 4000, 10 mM 
NaCl, 6 % v/v glycerol, 10 % v/v 2-propanol, 1 mM L-Kyn). Crystals shaped like hexagonal 
prisms with rough dimensions of 0.1 x 0.2 x 0.3 mm3 grew in 2-3 days and were 
harvested for data collection after 12 days. Prior to flash-freezing in liquid nitrogen, 
crystals were briefly soaked in successive drops of 10 % cryoprotectant (mother liquor 
plus 10 % EG) and then 20 % cryoprotectant (mother liquor plus 20 % EG). 
 
               
 
Crystals were screened for diffraction quality at the Diamond synchrotron beamline I03 
with several diffracting to a resolution of around 3.4 Å. X-ray diffraction data were 
collected using: an X-ray wavelength of 0.976 Å, a beam intensity of 50 % and an 
exposure of 0.25 s/frame, with 0.25 o oscillations over a wedge of 87.5 o. The crystal 
again had similar lattice properties to substrate bound wild type crystals; space group 
I4122 with mean unit cell parameters of a = b = 149.7, c = 272.1 Å, α = β = γ = 90.0 
o. The 
Figure 4.12. Close-up picture of the 
mounted R386T crystal used for 
collection of the highest resolution 
dataset. The beam size (50 х 50 m) 
and position is represented by the 
red circle and cross-hair. 
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dataset was 99.9 % complete to a resolution of 3.40 Å with Rmerge = 0.088 overall (0.644 
HS) and mean I/I = 9.9 (2.3 HS). The full data collection statistics are tabulated in 
appendix section 3.3. 
For the calculation of structure factors, a suitable model was generated using molecular 
replacement (Molrep) with the previously solved monomeric substrate bound structure 
(see section 3.3). Few differences emerged with one protein molecule present in the 
asymmetric unit and a solvent content of 83.6 %. The residues at the start of domain 3 
were again clearly displaced and removed from the initial model. The model was cycled 
through manual editing/building in Coot and TLS and restrained refinement in Refmac. 
There was significant density to place one molecule of FAD and one molecule of L-Kyn 
into the structure. The final model included residues 7-461 with R and Rfree values of 
0.260 and 0.270 respectively, a figure of merit of 0.721 and an overall mean B-factor of 
135.0 Å2 for 20512 significant reflections in the range of 65.68-3.40 Å. The rmsd of bond 
lengths and angles from the ideal were 0.005 Å and 0.981 o and all the residues were 
present in the most favoured or additionally allowed regions of a Ramachandran plot as 
determined using the Molprobity server. Full refinement statistics are tabulated in 
appendix section 3.3. 
 
 
Figure 4.13. R386T substrate bound 2Fo-Fc density (blue) and Fo-Fc map (green/red) for C-terminal 
domain calculated: (left) with dm2 substrate bound model (green) and (right) with rebuilt more open 




An alignment of the R386T substrate-bound structure with the original dm2 substrate-
bound structure is displayed in figure 4.14. The R386T mutant showed a similar mixed 
structural conformation to the previous Y382F and R386K substrate-bound structures as 
well as to the dm2 chloride-bound structure with rmsd values of 0.2, 0.2 and 0.8 Å 
respectively (for protein C atoms). The mixed C-terminal conformation is shown in 
comparison with the previously solved dm2 substrate-bound and substrate-free 
structures in figure 4.15. As expected, the R386T mutation disrupted the putative C-
terminal hydrogen-bonding network, with the adjusted positions of the participating 
residue displayed in figure 4.16. The mutation caused no further changes to those seen 
with the R386K substitution. Despite this the Michaelis-Menten kinetic constants were 
found to reveal a slightly less efficient enzyme. The Km and kcat values for R386T were 







Figure 4.14. Cartoon representation 
of the aligned substrate-bound R386T 
mutant (blue) and original dm2 
(green) structures. FAD and the 







To confirm that the structural differences caused by the R386T mutation were specific to 
the binding of the substrate L-Kyn, a substrate-free structure was solved. Due to time 
constraints, only the chloride-bound crystal form could be obtained. Crystals with rough 
dimensions of 0.1 x 0.1 x 0.3 mm3 grew in 3-5 days and were harvested after 6 days. 
They were generated from a 2.0:2.5 l h.d.v.d drop of protein solution (14 mg/ml in 20 
mM HEPES pH 6.8, 20 mM Na acetate, 1 mM DTT) and reservoir solution containing: 0.1 
M HEPES pH 7.0, 9 % w/v PEG 4K, 10 % v/v glycerol, 10 mM NaCl, 10 % v/v 2-propanol. 
For cryoprotection 1.0 l of cryoprotectant (mother liquor plus 20 % EG) was added to 
the crystal drop prior to transfer into cryoprotectant for a few seconds. A complete 
dataset was collected with an exposure of 0.3 s per 0.3 o rotation over a total of 150 o at 
beamline I03 using a wavelength of 0.976 Å and beam intensity of 35 %. The averaged 
unit cell had dimensions of 105.4, 134.0 and 189.5 Å packed in the orthorhombic space 
group P21221. Full data collection and refinement statistics are displayed in appendix 
section 3.4. The data was solved using molecular replacement with the dm2 chloride-
bound structure from section 3.5.3. As previously seen there were four molecules in the 
Figure 4.15. Representation of the mixed C-terminal 
conformation seen with the R386T mutant. Includes 
a cartoon alignment of the R386T substrate-bound 
structure (blue) with the dm2 substrate-bound 
(green) and substrate-free (violet) structures. The 
substrate L-Kyn is shown in sticks.  
 
Figure 4.16. Altered positions of the residues 
previously implicated in a hydrogen-bonding 
network. The mutated residue R386T is labelled 




asymmetric unit each with one molecule of FAD bound. Key refinement values include: 
Resolution = 44.71-2.52 Å, R/Rfree = 0.223/0.241, mean B-factor = 43.7 Å2 and there 
were no Ramachandran plot outliers. The structure was identical to the corresponding 
dm2 structure confirming that the mutation did not affect the overall enzyme structure 
in the absence of substrate. The rmsd of the superimposed R386T and original dm2 
chloride-bound structures is 0.1 Å for aligned C atoms. 
 
4.2.4 Crystallisation of E372T dm2 
The E372T mutation was also successfully introduced however unfortunately an 
additional unwanted mutation was gained of L367R. There was not enough time to 
repeat the cloning procedure so, as the site of the mutation seemed to be a relatively 
innocuous surface location in the previously solved structures, the mutant was 
characterised and crystallised. The E372T (L367R) dm2 PfKMO protein was expressed 
and purified as normal, although precipitation during the final concentration step 
required the salt concentration to be increased. The Michaelis-Menten kinetic constants 
Km and kcat were determined to be very similar to those for dm2 at 10.3 ± 0.7 M and 8.7 
± 0.1 s-1 respectively. Therefore it was likely that the additional L367R mutation did not 
cause any significant structural changes to the enzyme. 
The pure protein was used for h.d.v.d crystallization trials with L-Kyn bound. The final 
drop contained 1.00 l of protein solution (10 mg/ml in 20 mM HEPES, 50 mM Na 
acetate, 1 mM DTT and 1 mM L-Kyn) with 0.75 l of the precipitant solution (0.1 M 
HEPES pH 7.0, 7 % w/v PEG 4000, 10 mM NaCl, 10 % v/v glycerol, 10 % v/v 2-propanol, 2 
mM L-Kyn). Hexagonal prism shaped crystals with rough dimensions of 0.1 x 0.1 x 0.2 
mm3 grew in 3 days and were harvested for data collection after 1 week. Prior to flash-
freezing in liquid nitrogen, 1 L of cryoprotectant (mother liquor plus 20 % EG) was 
added to the drop before the crystal was transferred into the cryoprotectant solution for 





Crystals were screened for diffraction quality at the Diamond synchrotron beamline I03 
and several diffracted to a resolution around 3.3 Å. With an X-ray wavelength of 0.976 Å, 
the best diffraction dataset was collected with a beam intensity of 50 % and an exposure 
of 0.3 s per 0.3 º oscillation over a 150 º wedge. The crystal (shown in figure 4.17) had 
similar lattice properties to native substrate bound crystals; space group I4122 with 
mean unit cell parameters of a = b = 149.6, c = 270.7 Å, α = β = γ = 90.0 º. With the best 
resolution for substrate-bound data obtained to date of 3.24 Å, the dataset was 99.9 % 
complete with Rmerge = 0.088 overall (0.691 in the highest resolution shell, HS) and mean 
I/I = 14.2 (2.8 HS). The full data collection statistics are tabulated in appendix section 
3.3. 
 
The structure was solved by molecular replacement using the previously solved 
monomeric substrate bound dm2 structure (see section 3.3) as the template model. The 
E372T (L367R) mutant structure also contained one protein molecule in the asymmetric 
unit giving a high solvent content of 83.5 %. A large displacement in the C-terminal 
domain was however evident and so the domain was rebuilt in a more open 
conformation as depicted in figure 4.18. The model was cycled through manual 
editing/building in Coot and TLS and restrained refinement in Refmac. There was clear 
density to place one molecule of FAD and one molecule of the substrate L-Kyn – both in 
the same position as seen before. The final model displayed in figure 4.19 includes 
residues 7-461 with R and Rfree values of 0.230 and 0.256 respectively for 23527 
Figure 4.17. Close-up picture of 
the mounted crystal used for 
collection of the best resolution 
dataset. The beam size and 
position is represented by the 
red circle and cross-hair. 
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significant reflections in the range of 44.70-3.24 Å. In addition, the FOM was 0.786 and 
there was an overall mean B-factor of 96.7 Å2. The rmsd of bond lengths and angles from 
the ideal were 0.005 Å and 0.966 º and all the residues were present in the most 
favoured or additionally allowed regions of a Ramachandran plot as determined using 






↑ Figure 4.18. 2Fo-Fc density (blue) for E372T (L367R) and Fo-Fc (green/red) calculated based on model 
the of substrate-bound dm2 structure (left, green ribbon) and of the final E372T (L367R) substrate-bound 
structure (right, magenta ribbon) with translocated C-terminal domain. Contouring, = 1.5, 3.0 σ 
← Figure 4.19. Cartoon representation of 
final E372T (L367R) model (magenta) 
aligned with that of substrate bound dm2 
PfKMO (green). FAD and the substrate L-
Kyn are shown in sticks. 
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Mutation of the highly conserved E372 to a T caused similar structural changes seen with 
the other C-terminal mutations in the presence of the substrate. The rmsd of the 
backbone C atoms compared to dm2, Y382F, R386K, R386T, chloride-bound dm2 and 
unbound dm2 (substrate-bound unless otherwise stated) are 0.8, 0.3, 0.3, 0.3, 0.7 and 
1.1 Å respectively. As can be seen in figure 4.20, the C-terminus adopts the mixed 
conformation in the presence of L-Kyn with a relative swing of around 3.7 Å. As seen 
previously, the proposed hydrogen-bond network breaks down as shown in figure 4.21 
providing further evidence for its role linking substrate-binding to the movement of the 
C-terminal domain. For this mutant however, it cannot be ruled that the additional 
L367R mutation by itself may have contributed to the uncoupling of C-terminal closing 







Interestingly, despite generally possessing smaller crystal dimensions than the previously 
seen strongest diffracting substrate-bound crystals, crystals of substrate-bound E372T 
(L367R) PfKMO showed relatively stronger diffraction power. Looking at the structure in 
Figure 4.20. Cartoon structural representation of the 
mixed C-terminal conformation observed in the 
E372T (L367R) substrate-bound structure (magenta). 
The original dm2 substrate-bound and substrate-
free structures are shown in green and violet with 
the substrate represented by sticks. 
Figure 4.21. Breakdown of the putative C-
terminal hydrogen-bond network in the E372T 
(L367R) mutant structure. The new distances 
between the participating residues as well as 
the mutated residue are labelled. 
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more detail it is clear that the additional L367R mutation occurred in the heart of a 
crystal contact in the substrate-bound lattice arrangements. A comparison of this site in 
the mutant shown next to that in the original dm2 structure is shown in figure 4.22. The 
new arginyl side-chain fills a gap in the centre of the contact, which was presumably 
filled by solvent. Moreover this addition significantly displaced the side chain of R296 to 
a new conformation where it planar stacks with H185 and forms a hydrogen bond with 






Due to the non-specific introduction of the L367R mutation, a substrate-free structure 
was also solved to act as a negative control. Due to time constraints, only the chloride-
bound crystal form could be obtained. Crystals with rough dimensions of 0.1 x 0.1 x 0.2 
mm3 grew in 3-5 days and were harvested after 9 days. They were generated from a 
2.0:1.5 l h.d.v.d drop of protein solution (14 mg/ml in 20 mM HEPES pH 6.8, 20 mM Na 
acetate, 1 mM DTT) and reservoir solution containing: 0.1 M HEPES pH 7.0, 8 % w/v PEG 
4K, 10 % v/v glycerol, 10 mM NaCl, 10 % v/v 2-propanol. For cryoprotection, the crystal 
was briefly soaked in successive drops of 10 % cryoprotectant (mother liquor plus 10 % 
EG) and 20 % cryoprotectant (mother liquor plus 20 % EG). A 99.9 % complete dataset 
Figure 4.22. Improved crystal contact caused by the unintended L367R mutation. Left, crystal contact 
in substrate-bound dm2 PfKMO structure and right, corresponding contact in substrate-bound E372T 
(L367R) mutant structure. Refined 2Fo-Fc electron density shown in blue was contoured at 1.5 σ. 
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was collected from a 150 o segment at beamline I03. An exposure of 0.25 s per 0.25 o 
oscillation using a wavelength of 0.976 Å and beam intensity of 30 % were used. The 
averaged unit cell had dimensions of 104.7, 133.9 and 189.1 Å packed in the 
orthorhombic space group P21221. Full data collection and refinement statistics are 
displayed in appendix section 3.4. The data was solved using molecular replacement with 
the dm2 chloride-bound structure from section 3.5.3. As previously seen there were four 
molecules in the asymmetric unit each with one molecule of FAD bound. Key refinement 
values include: Resolution = 50.51-2.32 Å, R/Rfree = 0.221/0.242, mean B-factor = 45.4 Å
2 
and there were no Ramachandran plot outliers. The structure was identical to the 
corresponding dm2 structure confirming that the mutation did not affect the overall 
enzyme structure other than the small localised alterations surrounding the L367R 
mutation. The average chain rmsd of the superimposed E372T (L367R) and original dm2 
chloride-bound structures is 0.3 Å. 
 
4.3 Discussion and conclusions 
In chapter 3 the substrate-bound, chloride-bound and substrate-free dm2 PfKMO 
structures were solved revealing a novel C-terminal domain present in three different 
conformations – in, mixed and out respectively. From the substrate-bound structure a 
hydrogen bond network appeared to link the bound substrate to the closed ‘in’ C-
terminal conformation (see figure 4.2). This involved the carboxyl of the substrate, the 
side chains of R84, E372, Y382 and R386 as well as the backbone carbonyl of P97. Due to 
the poor resolution of this structure however, the exact positions of the participating 
residues is questionable. Therefore in this chapter mutants involving these residues were 
generated and tested to assess the accuracy/validity of the proposed hydrogen-bond 
network mechanism in the domain movement. 
Each mutant was briefly characterised and crystallised with the results summarised in 
table 4.1. Each substrate-bound mutant structure revealed a mixed C-terminal 
conformation reminiscent of the chloride-bound dm2 structure from chapter 3.5.3. 
Despite this the mutants all crystallised in the same high solvent tetragonal form as 
native substrate-bound crystals. This confirmed the relevance of the different C-terminal 
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structural conformations observed showing they were dependent solely on the protein 
rather than the crystal packing. The structures showed that mutation of each residue 
disrupted the interactions that closed the C-terminal domain after substrate binding with 
the native enzyme. These results correlate well to the putative hydrogen-bond network 
described in section 4.1 as the mutated residues would be unable to fulfil the precise 
interactions speculated in the native substrate-bound structure. This includes position 
386 where the substituted lysine would be unable to coordinate both the two 
interactions involving the native arginine residue with Y382 and the backbone carbonyl 
of P97. Therefore whilst the exact mechanism that closes the C-terminal domain after 
substrate-binding may not be detailed without a high-resolution substrate-bound 







Barring E372T, the other mutations all caused the values of Km and kcat to increase by 
varying extents. The Y382F and R386K mutants both displayed a two-fold increase in the 
Km compared to dm2, whereas the less conservative R386T mutant showed around a 
seven-fold increase. With the large distance separating the residues from the substrate 
binding site, these changes indicated that the native residues were in some way linked to 
the process of substrate binding. Thus, taking the structural evidence into account, the 
more open C-terminal conformations seen in all four mutant structures could account 
for the weakened Km values. The ability of the C-terminus to shut after substrate binding 











C-term. swing (Å)  




dm2 8.8 ± 1.5 8.9 ± 1.1 1.0 IN/MIXED/OUT 0.0/5.1/6.1 
E372T dm2* 10.3 ± 0.7 8.7 ± 0.1 0.8 MIXED/MIXED/n.d 3.7/4.9/n.d 
Y382F dm2 17.1 ± 1.0 12.7 ± 0.2 0.7 MIXED/n.d/n.d 3.8/n.d/n.d 
R386K dm2 17.0 ± 1.4 12.0 ± 0.9 0.7 MIXED/n.d/OUT 4.2/n.d/6.1 
R386T dm2 63.9 ± 2.4 15.2 ± 1.3 0.2 MIXED/MIXED/n.d 4.3/5.2/n.d 
Table 4.1. Summary of the kinetic and structural observations from each of the C-terminal mutants compared 
to the ‘native’ dm2 PfKMO enzyme.  
*E372T also contained an additional L367R mutation. 
1
 C-terminal conformations observed for the substrate-
bound (+L-Kyn), chloride-bound (+Cl) and unbound structures based on those observed with dm2 in chapter 3. 
2
 Swing distances represented the separation of the C atoms of T381 from aligned structures of the respective 
mutant and the original substrate-bound dm2 structure. 
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would prevent leakage back out to bulk solvent and help to keep the equilibrium 
towards binding into the enzyme. The further raised Km seen with the R386T mutant 
comes despite a similar structural arrangement and C-terminal swing to the other 
mutants. This value can be accounted for by the following theories about the residue at 
position 386:  
I) The long arginine or lysine side-chains provided a steric block preventing 
substrate egress after binding. 
II) A basic residue may be involved in initially attracting the substrate into the entry 
tunnel preceding the binding pocket, specifically by interacting with the carboxyl 
group of L-Kyn. 
As was previously mentioned the mutants also displayed increased kcat values with Y382F 
and R386K slightly higher at around 12-13 s-1 and R386T 1.7-times higher at 15 s-1. 
Interestingly Crozier-Reabe et al., reported that product release was the rate-limiting 
step in the reaction catalysed by PfKMO [1]. This suggested that the more open C-
terminal positions seen with the mutants allowed faster release of the product to cause 
the increased reaction rate. The exception to the rule was the E372T mutant, which 
despite a more open C-terminus had a similar kcat to dm2 of around 9 s
-1. Firstly it could 
be possible that the lower than expected reaction rate was caused by the additional 
L367R mutation. A more complex hypothesis could be that the negative E372 plays some 
part in ejecting the product – possibly by electrostatic repulsion of the substrate’s 
carboxylic group – and so its removal may have slightly slowed the rate of product 
release to compensate the effects of the more open C-terminal domain. The same 
hypothesis but in reverse could apply to the stronger than expected Km of the mutant for 
substrate binding, which again was similar to dm2 within the limits of error. Future work 
interrogating the separate catalytic steps by stopped-flow spectrophotometry would 
help to further elucidate the effects of the mutations. 
Understanding of the dynamics of the C-terminus and substrate binding in PfKMO seems 
to be developing well, however how does this translate to other KMOs including the 
human enzyme? As was previously mentioned R84 and E372 are strongly conserved 
across all KMO sequences, however Y382 and R386 are found as a mixture of Y/F and of 
R/K respectively. Interestingly human KMO possesses both the F and the K variations at 
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the two positions. This creates a problem as the data from the PfKMO C-terminal 
mutants suggested that either of the Y382F or the R386K mutations separately 
suppressed the conformational change that closed the back of the substrate-binding 
pocket. These observations clearly cast doubt over the relevance of the C-terminal 
closing mechanism to the human enzyme.  
Models of the structure of human KMO constructed based on the dm2 PfKMO structures 
are shown in appendix section 2. These show that from its primary sequence the human 
C-terminus may initially form the same structural domain to the novel C-terminus 
displayed by the bacterial enzyme. The similarity breaks down at around residue 330 
located at the bottom of the penultimate helix (-16) where the human sequence 
contains the predicted trans-membrane region. In addition key hydrophobic residues 
that maintain the C-terminal fold and link it to the main protein scaffold appear to be 
conserved in human KMO. Although the models are largely biased towards the template, 
they show that it is possible that human KMO may have a similar entry tunnel enclosed 
by the C-terminus before it breaks into the trans-membrane helix. Therefore it could still 
be possible that different interactions have evolved to drive the same type of substrate-










5.1.1 KMO Inhibition by substrate analogues 
The first type of potent KMO inhibitors discovered were analogues of the substrate L-
Kyn. Whilst they were indeed effective at preventing the formation of a hydroxylated 
product, it was recently shown that the binding of such compounds stimulates 
uncoupled NADPH oxidation [1]. This led to flavin reduction, reaction with oxygen and 
then decomposition to release cytotoxic hydrogen peroxide and return the flavin to its 
oxidized state. Consequently substrate analogues have been re-classified as non-
substrate effectors and have no potential for therapeutic use. Despite this their study 
was still of significance as it revealed critical information about the substrate binding 
environment and the potential functional groups that would be useful for designing true 
inhibitors of KMO. 
Two very potent substrate analogues emerged early on in the shape of 3,4-CBA [207] 
and m-NBA [206], which had IC50 values of 0.2 M and 0.9 M respectively against KMO 
from rat organ homogenates. From this Giordani et al. continued their exploration of the 
compounds by studying the effect on rat liver and brain KMO inhibition of varying the 
functional groups of 3,4-CBA [208]. Initially they found that the carboxylic acid group was 
crucial to inhibition as its removal increased the IC50 to millimolar levels. This fitted in 
with the observations from the substrate bound structure presented in chapter 3 where 
the carboxyl group of L-Kyn facilitates the majority of its interactions with the residues 
lining the substrate binding site. Removal of the tail amine group also reduced the 
inhibition strength but to a significantly lesser extent, with an IC50 of 3.9 M and 0.9 M 
on liver and brain KMO respectively. They then synthesized a 4-phenyl-4-oxo-butanoic 
acid backbone (figure 5.1) from which the R, R’ and X functional groups were varied. The 





    
Rat liver KMO 
(IC50 ± SEM, M) 
Rat brain KMO 
(IC50 ± SEM, M) 
    
Entry R R’ X 
2 H H 3,4-diCl 3.9 ± 0.2 0.9 ± 0.1 
4 CH3 H 3,4-diCl 6.9 ± 1.2 3.5 ± 0.2 
5 OCH3 H 3,4-diCl 6.9 ± 3.7 1.2 ± 0.1 
6 =CH2 3,4-diCl 36.0 ± 8.3 nt 
7 Cl H 3,4-diCl 14.8 ± 2.4 2.2 ± 0.2 
8 OH H 3,4-diCl 1.4 ± 0.3 0.30 ± 0.06 
9 Ph H 3,4-diCl 19.5 ± 1.8 nt 
10 CH2Ph H 3,4-diCl 2.9 ± 1.2 0.18 ± 0.01 
11 CH3 CH3 3,4-diCl 21 % @ 100 M nt 
12 CH3 NH2 3,4-diCl 35 % @ 100 M nt 
13 CH3 OH 3,4-diCl 43 % @ 100 M nt 
14 Cyclopropyl 3,4-diCl 20 % @ 100 M nt 
20 OH H 3-Cl 1.10 ± 0.3 0.48 ± 0.02 
21 OH H 3-F 9.1 ± 1.1 5.6 ± 0.9 
22 OH H 3-NO2 11.5 ± 4.0 1.95 ± 0.15 
23 OH H 3,4-diF 3.0 ± 0.2 1.45 ± 0.08 
24 OH H OCH3 7 % @ 100 M nt 
 
At the R position originally occupied by an amine group in the substrate and 3,4-CBA, 
quite varied changes could be introduced without causing a substantially large reduction 
in the strength of inhibition. However, significantly reduced potency was experienced 
when hydrophobic or large bulky groups were present. No drastic change was observed 
upon substitution with a hydroxyl group, on the other hand, suggesting that a hydrogen 
bond donor/acceptor may be required at this position. Indeed from the substrate bound 
structure solved in chapter 3, it appeared that the corresponding amine group of L-Kyn 
was involved as an H-bond donor to the backbone carbonyl of H320. The addition of 
functional groups at the R’ position greatly diminished the strength of inhibition of the 
Figure 5.1. Structures of the substrate L-Kyn, the substrate analogue 3,4-CBA and the 4-phenyl-4-
oxo-butanoic acid scaffold. 
Table 5.1. Inhibition data from 4-phenyl-4-oxo-butanoic acid 
compounds based on scaffold in figure 5.1. Giordani et al., [208] 
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compounds in keeping with the fact that D-Kyn does not effectively bind to KMO. Finally, 
introduction of a substituent at the 3’-position of the aromatic ring showed that a 
hydrophobic OMe group abolished KMO inhibition leaving the order of inhibition 
strength as 3-Cl>3-F>3-NO2. The importance of an added group at the 4’ position was 
inconclusive as it improved the inhibition strength with the 3,4-difluoro but did not 
effect it with the 3,4-dichloro analogue.  
A similar study was conducted in 2000 using 2-hydroxy- and 2-amino-4-aryl-4-oxo-
butanoic acids and esters [209]. The results of inhibition assays using rat liver 
mitochondrial suspensions for the various compounds are detailed in tables 5.2 and 5.3. 
The results were quite inconsistent, particularly regarding differences between the 2-
amino and their respective 2-hydroxy compounds (for example comparing compounds 
3b to 5b and 2k to 4k). There was however strong evidence that substitution at the 2’ 
position of the aromatic ring was largely ineffective compared to the inhibition potency 
achieved with substitutions at the 3’ and 4’ positions. In addition, the acid analogues 
showed significantly greater KMO inhibition than their ester analogues in the majority of 
cases. There was no clear evidence that the but-2-enoic chain produced stronger or 
weaker inhibitors than the previously used butanoic chain. Taken together, these studies 
highlighted some of the key features required for strong binding in the active site, the 








                                   







5.1.2 KMO inhibition by novel organic compounds 
Shortly after the discovery of substrate analogue inhibitors, the search for more specific 
and more potent KMO inhibitors moved on to novel and more complex compounds. In 
1997, screening of a chemical library based on bioisosters of the L-Kyn carboxyl group 
rapidly identified a sulphonamide as a good starting scaffold [4]. Subsequently a series of 
N-(4-phenylthiazol-2-yl)benzenesulphonamides were synthesized and shown to be 
promising high-affinity competitive inhibitors of KMO. The inhibition results are 
summarised in table 5.4. Of those tested in vitro on KMO from rat kidney mitochondria, 
Tables 5.2 (left) & 5.3 (right). Rat KMO liver Inhibition results for compounds based on the 
structural scaffolds depicted above each respective table (taken from Drysdale et al 2000 [209]).          
a
 IC50 values taken as averages from multiple runs. 
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the strongest compounds had IC50 values of 20-40 nM, up to 10 times lower than the 
substrate analogues. Within error there was little difference to discriminate between 
lots of the compounds, however a few patterns were clear. On the R’ (‘head’) ring the 
addition of functional groups at the 3-, the 4-, or both positions improved the strength of 
inhibition of the compound. Of the functional groups tested, hydrophilic groups were 
favoured over hydrophobic groups to provide the strongest KMO inhibition. As a result 
the order of potency ranged from H<OMe<Me<Cl/NO2. Again the presence of functional 
groups at position 4-, or at 3- and 4- on the R’’ (‘tail’) ring improved the inhibition 
strength, but here Cl groups were less effective than NH2, Me or OMe. Compound 16, 
known as Ro 61-8048, was taken forward for potential therapeutic inhibition of human 
KMO. Whilst the inhibitor was an effective therapeutic tool in several in vivo and ex vivo 
disease models (see section 1.4.2) it never went past pre-clinical trials as it failed the 
Ames mutagenic test.  
 
    
 
The aim of the work described in this chapter was to build on screening findings and use 
co-crystallisation to reveal information regarding the mechanism/interactions involved in 
the binding of non-substrate effectors and inhibitors. Part of this involves efforts to 
understand what causes the differential recognition of the two types of compound by 
KMO. With this information novel inhibitors could be rationally designed without the 
side-effect of uncoupled NADPH oxidation. As part of this the design and synthesis of a 
novel series of potential KMO inhibitors was carried out by Gavin Milne (PhD, St. 
Table 5.4. Summary of inhibition results for 
series of benzenesulphonamides based around 
the displayed molecule scaffold. FCE 28833 is 
another name for 3,4-CBA. Taken from Rover et 
al., 1997 []. 
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Andrews University). Using in vitro screening with pure recombinant PfKMO, these 
compounds were rationally modified with the aim of increasing their potency. Novel 
potent inhibitors were co-crystallised with PfKMO to obtain crucial structural 
information regarding the nature of inhibitor binding. Structural information obtained 
would rapidly speed up the development of targeted inhibitors of human KMO for 
potential therapeutic exploitation. 
 
5.2 Binding of substrate analogues 
5.2.1 Inhibition data 
Substrate analogues may themselves be unsuitable as therapeutic tools, however a lot of 
useful information could still be gained from their study. The changes that these cause to 
the flavin spectrum upon binding, and their competition with L-Kyn binding indicate that 
it is likely that these compounds bind in the same specific location and orientation as the 
substrate itself. Therefore investigating the PfKMO inhibition strength of different 
analogue compounds could aid the rational design of novel KMO inhibitors. The 
published substrate analogues benzoylalanine (BA), m-nitrobenzoylalanine (m-NBA) and 
3,4-dichlorobenzoylalanine (3,4-CBA), as well as some additional compounds (labelled 
c39-c43), were synthesized by Gavin Milne (PhD, St Andrews University). The 
compounds, which are displayed in figure 5.2, were screened and partially characterized 




















The published substrate analogues BA, m-NBA and 3,4-CBA were shown to be 
competitive inhibitors of L-Kyn binding of varying strength. The Ki values measured 
correlated well with the published IC50 values determined in assays with rat KMO. The 
unsubstituted BA had a moderate Ki of 7.0 ± 3.6 M whereas addition of an m-nitro or 
3,4-dichloro functional group dramatically increased the potency with Ki values of 42.0 ± 
3.0 nM and 5.3 ± 1.0 nM respectively. For 3,4-CBA the inhibition constant was so low 
that it could not be accurately determined within the error of each individual Ki assay, 
however it was evidently in the very low nanomolar region. Example inhibition plots 
from one run with each compound m-NBA and 3,4-CBA are shown in figure 5.3. It was 
previously reported that the binding of these compounds stimulated uncoupled NADPH 
Figure 5.2. Molecular structures of the substrate L-Kyn, the 
published substrate analogues BA, m-NBA and 3,4-CBA and 
the novel substrate analogue compounds. Where known 
published rat liver IC50 values are labelled as determined in 
previously discussed studies. Pictures created using 
ChemDraw. 
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oxidation leading to degradation of the reduced flavin to release the free radical 
generator hydrogen peroxide [1]. To confirm this each substrate analogue was tested for 
NADPH oxidation in the absence of substrate. It was observed that BA and m-NBA 
stimulated NADPH oxidation confirming them to be substrates or non-substrate 
effectors rather than inhibitors. However, in the presence of up to 100 M of the 
compound 3,4-CBA there was no sign of background NADPH oxidation. With the 
incredibly low Ki value for this compound it seems likely that 3,4-CBA in fact acts as a 
competitive PfKMO inhibitor. The Ki assays were all proportionally background corrected 
to remove the contribution of NADPH oxidation caused by BA and m-NBA binding from 
the measured rate readings    
         
 










Figure 5.3. Inhibition plots for m-NBA and 3,4-CBA. The Ki is estimated from the average intersection point on 
the graph of 1/v against concentration of inhibitor (left) and competitive inhibition is shown by the parrellel 
best-fit lines on the graph of [S]/v (where [S] = concentration of L-Kyn) against concentration of inhibitor 
(right). Data plotted using Origin 8.0. 
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All of the novel substrate analogues tested had reduced potency of L-Kyn inhibition but 
to varying extents. The conversion of BA’s phenyl ring into a fully saturated cyclohexyl 
ring in c39 reduced the inhibition potency by around five-fold. On the other hand 
conversion into a naphthalene ring in c40 only had no effect on the strength of 
inhibition. This was interesting as it suggested that there was a large hydrophobic pocket 
that could be filled at this end of the binding site. Additionally the pocket must have 
enough room to allow addition of functional groups at the 3’ and 4’ positions of the 
phenyl ring as seen with m-NBA and 3,4-CBA. These observations match with the nature 
of the substrate binding environment discovered in section 3. A large hydrophobic 
pocket surrounds the substrate’s phenylamine ring but at with a relatively tight fit as the 
separation distance is only around 4.5 Å. Certainly if c40 was to bind in a similar location 
there would have to be a reasonable amount of local positional adjustments. 
The other three compounds synthesized – c41, c42 and c43 – were very ineffective as 
PfKMO inhibitors. This was to be expected if the compounds did bind in the substrate 
binding pocket due to the conformation of the substrate L-Kyn adopted in the bound 
structure. In particular c42 and c43 with their greatly reduced flexibility would be 
hindered in trying to position the amino and carboxyl groups to coordinate the key 
hydrogen bonds observed in the substrate binding pocket. With the weak binding of 
these compounds it was difficult to observe any stimulation of NADPH oxidation in the 
absence of substrate for the concentrations tested. The aforementioned compound c39 
clearly showed background NADPH oxidation and so could be considered as either a 
substrate or a non-substrate effector similar to BA and m-NBA. The extent of uncoupling 
of NADPH oxidation with c40 needs to be tested further. All the substrate analogues 
tested showed competitive inhibition in plots of [S]/v against [analogue]. The full 









5.2.2 The Structure of PfKMO with m-NBA bound 
Given the strong binding affinity of m-NBA and 3,4-CBA for PfKMO, these compounds 
could be readily co-crystallized with the enzyme. As such crystals of PfKMO with m-NBA 
bound were grown using hanging drop vapour diffusion (h.d.v.d) with a 1:1 L drop 
composed of protein solution (14 mg/ml in 20 mM HEPES pH 6.8, 30 mM Na acetate, 1 
mM DTT) and reservoir solution supplemented with the substrate analogue (0.08 M 
HEPES pH7.0, 6 % PEG 4K, 8 % glycerol, 8 mM NaCl, 10 % 2-propanol and 1 mM m-NBA). 
Large, hexagonal prism shaped crystals with rough dimensions of 0.2  0.3  0.5 mm3 
grew in 2-3 days and were harvested for data collection after 9 days. Prior to flash-
freezing crystals in liquid nitrogen, 1.5 l of cryoprotectant (mother liquor plus 20 % EG) 
was added to the crystallisation drop and then the crystal was briefly soaked in a drop of 
cryoprotectant.  
The crystals were screened for diffraction quality at the Diamond synchrotron beamline 
I02 with several diffracting to a resolution around 3.5 Å. X-ray diffraction data were 
collected using an X-ray wavelength of 0.979 Å, exposure of 0.3 s/frame of data and 
beam intensity of 100 % with 0.3 º oscillations over a total of wedge of 67.2 º. The crystal 
 % Inhibition with x M inhibitor 
Compound 10 30 100 *BG turnover Ki (M) IC50 (M) 
c39 6.3 10.0 17.1 10.2 % 35  18  
c40 n.d n.d n.d n.d 10.3  2.3  
c41 0 0 4.1 0.0 %   
c42 0 5.7 8.9 0.0 %   
c43 1.0 6.3 9.0 2.9 %   
BA 25.6 46.2 71.2 13.5 % 7.0  3.6 50 
m-NBA 92.1 96.1 96.5 13.0 % 0.042  0.003 0.9 
3,4-CBA 97.2 100.0 100.0 0.4 % 0.0053  0.0010 0.2 
Table 5.5. Summary table of the inhibition data measured for the substrate-analogue compounds. 
Screen values represent the % inhibition of the rate of NADPH oxidation with 50 M L-Kyn for the 
stated analogue concentrations compared to uninhibited controls. n.d = no data.                             
*BG turnover relates to the measured background NADPH oxidation in absence of substrate as a 
percentage of the normal rate of turnover with 50 M L-Kyn, recorded in the presence of 100 M of 
each compound. The BG was subtracted from screen values and in Ki measurements. Ki values are 
shown as average values from multiple runs. 
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lattice was similar to substrate bound crystals; space group I4122 with mean unit cell 
parameters of a = b = 149.7, c = 273.0 Å, α = β = γ = 90.0 º. The dataset was 96.1 % 
complete to a resolution of 3.55 Å with Rmerge = 0.096 overall and 0.799 in the highest 
resolution shell. The crystal used for data collection is displayed in figure 5.4 with full 




The structure was solved by molecular replacement using Molrep [reference], with the 
previously solved monomeric substrate bound structure used as the molecular 
replacement model (see section 3.3). There was one protein molecule present in the 
asymmetric unit with a solvent content of 83.7 %. The model was cycled through manual 
editing in Coot and TLS and restrained refinement in Refmac. There was clear density to 
place one molecule of FAD and one molecule of the substrate analogue m-NBA. Refined 
electron density maps calculated in the presence and absence of m-NBA are shown in 
figure 5.5. The final model included residues 7-461 with R and Rfree values of 0.247 and 
0.254 respectively, a figure of merit of 0.776 and an overall mean B-factor of 133.4 Å2 for 
17259 significant reflections in the range of 44.76-3.55 Å. The root means square 
deviation (rmsd) of bond lengths and angles from the ideal were 0.005 Å and 0.919 º and 
all the residues were present in the most favoured or additionally allowed regions of a 
Figure 5.4. Close-up picture of 
the mounted m-NBA bound 
PfKMO dm2 crystal used for 
data collection with scale and 
beam size labelled. 
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Ramachandran plot as determined using the Molprobity server. Full refinement statistics 
are tabulated in appendix section 3.5. 
 
 
   
 
 
Overall the structure of m-NBA bound PfKMO was visually indistinguishable from the 
previously described substrate bound structure. As can be seen in figure 5.6, the 
substrate analogue was bound in the same site as the substrate L-Kyn with the C-
terminal domain also in the same closed conformation. This structural snapshot suggests 
that non-substrate effectors like m-NBA are initially recognised and bound as substrates, 
which presumably leads to the observed uncoupled NADPH oxidation and hydrogen 
peroxide release. Interestingly the m-nitro group is not orientated to directly block 
hydroxylation by a C4a-hydroperoxyflavin. Instead it points away from the flavin and into 
the hydrophobic pocket lined by residues M222, I224, F238, F319 and M373. Therefore 
the failure of these compounds to act as substrates is likely to be due to the loss of the 2’ 
Figure 5.5. Electron density for the bound substrate-analogue m-NBA in the final model. The 2Fo-Fc 
density map from the final round of refinement is shown in blue. The Fo-Fc map after refinement in 
the absence of m-NBA is shown in green/red. Created with Coot with contouring of 1.5 and 3.0 σ. 
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amine group compared to L-Kyn rather than due to steric hindrance from the 3’ nitro 
group. At the resolution observed it is difficult to accurately compare the exact 
positions/orientations of the substrate and m-NBA. Therefore it is difficult to 
conclusively pinpoint the cause of the differential hydroxylation patterns. From the 
structures, however, it is plausible that either: i) the m-nitro goup slightly distorts the 
position of the substrate phenyl ring or ii) the missing 2’-amine group is directly involved 
in directing the flavin intermediate towards efficient hydroxylation over the uncoupled 








5.2.3 The Structure of PfKMO with 3,4-CBA bound 
Crystals of PfKMO with 3,4-CBA bound were grown using h.d.v.d with a 1:1 L drop 
composed of protein solution (11.5 mg/ml in 20 mM HEPES pH 6.8, 20 mM K acetate) 
and reservoir solution supplemented with the substrate analogue (0.1 M HEPES pH 7.0, 9 
% PEG 4K, 8 % glycerol, 10 mM NaCl, 10 % 2-propanol, 1 mM 3,4-CBA). Large crystals 
Figure 5.6. Comparison of the structures of 
m-NBA (yellow) and substrate (green) 
bound dm2 PfKMO. Left overall carton 
alignment with ligands shown in sticks. 
Below close-up of the active site 
environments with residues lining the 
substrate-binding pocket shown in sticks. 
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shaped like hexagonal prisms (see figure 5.7) with rough dimensions of 0.2  0.2  0.6 
mm3 grew in 2-4 days and were harvested for data collection after 7 days. Crystals were 
flash-frozen after brief sequential soaks in mother liquor supplemented with 10 % and 
then 20 % EG. The crystals were screened for diffraction quality at the Diamond 
synchrotron beamline I24 with several of them diffracting to a resolution around 3.4 Å. 
X-ray diffraction data were collected using an X-ray wavelength of 0.978 Å, exposure of 
0.2 s/frame of data and beam intensity of 60 % with 0.2 º oscillations over a total of 
wedge of 120 º. The crystal lattice was similar to substrate bound crystals; space group 
I4122 with mean unit cell parameters of a = b = 149.4, c = 273.8 Å, α = β = γ = 90.0 º. The 
dataset was 96.4 % complete to a resolution of 3.37 Å with Rmerge = 0.099 overall (0.651 
HS) and a mean intensity of 11.2 (2.8 HS). The full data collection statistics are tabulated 




The structure was solved by molecular replacement using Molrep, with the previously 
solved monomeric substrate bound structure used as the molecular replacement model 
(see section 3.3). As expected, there was found to be one protein molecule present in 
the asymmetric unit and a solvent content of 83.7 %. The model was cycled through 
manual editing in Coot and TLS and restrained refinement in Refmac. There was clear 
density to place one molecule of FAD and one molecule of the substrate analogue 3,4-
CBA – both in the same position as seen before. Due to the low resolution of the data, it 
Figure 5.7. Close-up picture of one 
the mounted 3,4-CBA-bound PfKMO 
crystals tested for diffraction with 
scale and beamsize are labelled 
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was not conclusively clear which orientation of the compound’s 3,4-chloro groups was 
correct. After refining both variations, one option was selected with a significantly better 
fit - as can be seen in the density maps in figures 5.8 and 5.9. At this resolution though, 
the multiple occupancy of both conformations cannot be ruled out. The final model 
included residues 7-461 with R and Rfree values of 0.237 and 0.239 respectively, a figure 
of merit of 0.773 and an overall mean B-factor of 112.3 for 20256 significant reflections 
in the range of 34.56-3.37 Å. The rmsd of bond lengths and angles from the ideal were 
0.004 Å and 0.882 º and all the residues were present in the most favoured or 
additionally allowed regions of a Ramachandran plot as determined using the Molprobity 
server. Full refinement statistics are tabulated in appendix section 3.5. 
 
 
Figure 5.8. Refined 2Fo-Fc (blue) and Fo-Fc (green/red) density for the final model of 
3,4-CBA in the substrate-binding site. The Fo-Fc map was calculated after 
refinement without 3,4-CBA in the model. Created with Coot with contouring of 
1.5 and 3.0 σ. 
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The overall structure of 3,4-CBA bound PfKMO was again virtually indistinguishable from 
the previously described substrate bound structure. As can be seen in figure 5.10, the 
substrate analogue was bound in the same site as the substrate L-Kyn with the C-
terminal domain also in the same closed conformation. As with m-NBA the additional 
functional groups of the analogue – in this case the 3,4-dichloro groups – were not 
orientated to directly block hydroxylation by a C4a-hydroperoxyflavin. Instead they point 
away from the flavin and into the same hydrophobic pocket as mentioned before. 
Therefore the documented failure of these compounds to act as substrates is likely to be 
due to the loss of the 2’ amine group compared to L-Kyn rather than due to direct steric 
hindrance from the added 3’ functional groups. Interestingly the inhibition results 
suggested that 3,4-CBA was a competitive PfKMO inhibitor rather than a substrate 
analogue like m-NBA. No obvious differences are evident between the structures and the 
binding nature of the two compounds. Instead their differing natures regarding 
uncoupled NADPH oxidation may be down to the addition of a functional group at the 4’-
position of the phenyl ring in 3,4-CBA. Whether or not this position is critical for 
distinguishing substrate analogues that do and do not stimulate uncoupled NADPH 
oxidation, with 3,4-CBA bound the process of flavin reduction must be restricted. From 
Figure 5.9. Refined 2Fo-Fc density (blue) and Fo-Fc density (green/red) for the two orientations of 3,4-CBA in 
the substrate-binding site. Pictures created with Coot with contouring of 1.5 and 3.0 σ. 
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this it could be possible that either the movement of the flavin isoalloxazine moiety or 
the movement/formation of the NADPH docking site is prohibited. 
 








5.3 Binding of a novel inhibitor series 
5.3.1 A novel series of PfKMO inhibitors based on the ‘Rover’ 
compounds 
The most successful KMO inhibitors discovered so far were the compounds synthesized 
by Rover et al. [4] , as discussed in section 5.1.2. These compounds were therefore 
selected to provide both an initial design scaffold and a comparative level for a novel 
series of potential inhibitors. Gavin Milne (PhD, University of St Andrews) synthesized 
Rover compounds 16 (Ro 61-8048) and 19, which were subsequently tested for in vitro 
Figure 5.10. Comparison of the structures of 3,4-CBA (cyan) and substrate (green) bound dm2 PfKMO. 
Left overall carton alignment with ligands shown in sticks. Below close-up of the active site 
environments with residues lining the substrate-binding pocket shown in sticks. Created using PyMol. 
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PfKMO inhibition. Both were shown to be reasonably strong competitive inhibitors with 
respect to L-Kyn with Ki values of 1.03  0.27 M and 1.67  0.23 M respectively. 
Inhibition plots for one of the runs with Rover 16 is shown in figure 5.11. With each 
compound, NADPH oxidation in the absence of substrate was not detected. The 
compounds were however very insoluble, and initial solid stocks were dissolved in 100 % 
DMSO and diluted to give up to a 2 % DMSO final assay concentration. The aim was to 
use a similar scaffold to that of the potent Rover compounds but with varied functional 
groups to improve the efficacy and safety of the compounds for potential therapeutic 
use. As Rover 16 was found to be slightly more potent than Rover 19, the m-nitro 
functional group was initially used in conjunction with a novel scaffold depicted in figure 
5.12 to investigate the effect of varying the R1 groups on the strength of KMO inhibition. 







Figure 5.11. Inhibition plots for Rover 16 (Ro 61-8048). The Ki is estimated from the average intersection point 
on the graph of 1/v against concentration of inhibitor (left) and competitive inhibition is shown by the parrellel 
best-fit lines on the graph of [S]/v (where [S] = concentration of L-Kyn) against concentration of inhibitor (right). 
Data plotted using Origin 8.0. 
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  % Inhibition with x M inhibitor 
Compound R1 group 5 10 15 Screen Ki (M) 
GM283 COOH 0.0 0.0 0.0   
GM57 CH2-CH2NH2 0.0 0.0 0.0   
GM42 CH2-CHNH2COOH 0.0 0.0 0.0   
GM41 CH2-CH2-CHNH2COOH 0.0 0.0 0.0   
GM73 CH2-CH2-C6H5 1.6 8.4 16.2   
GM107 CH2-CH2-C6H3(3,4-diOMe) 2.5 6.1 12.8   
GM88 CH=CH-C6H3(3,4-diOMe) ppt ppt ppt   
GM155 *CH-(O)-CH-C6H3(3,4-diOMe) 4.9 14.1 26.4  2.88  0.18 
GM213 CH=CNH2-C6H3(3,4-diOMe)    20.3 ± 7.1  
GM266 CHOH-CHNH2-C6H3(3,4-diOMe)    13.6 ± 8.2  
GM395 CHOH-CHNH2-C6H3(3,4-diOMe)    5.1 ± 5.5  
GM511 Cis CHOH-CHOH-C6H3(3,4-diOMe)    0.0 ± 2.1  
GM512 Trans CHOH-CHOH-C6H3(3,4-diOMe)    4.5 ± 5.4  
GM229 CH2-CO-C6H3(3,4-diOMe)    13.5 ± 4.2  
GM141 NH-CO-C6H3(3,4-diOMe) 17.9 19.2 31.8 37.4 ± 9.9 1.30  0.21 
GM195 NH-CO-CH2-C6H3(3,4-diOMe)    32.0 ± 11.2 1.82  0.38 
GM289 CH2-NH-CO-C6H3(3,4-diOMe)    10.1 ± 11.0  
GM444 CH2-NH-SO2-C6H5    1.5 ± 2.9  
GM473.1 2,2-diMe,4-C6H3(3,4-diOMe)-1,3-dioxolane    6.5 ± 11.3  
GM473.2 2,2-diMe,4-C6H3(3,4-diOMe)-1,3-dioxolane    0.0 ± 6.6  
Rover 16 NH-SO2-C6H3(3,4-diOMe) 12.1 26.3 32.7 43.6 ± 14.4 1.03  0.27 
Figure 5.12. Molecular structures of Rover compound 16 as well as the initial scaffold for 
the novel inhibitor series synthesised. Created using ChemDraw. 
Table 5.6. Summary of PfKMO inhibition data for initial set of compounds compared to Rover 16. The % 
inhibition values were measured relative to uninhibited enzyme in 1 ml cuvette assays. ppt indicates that the 
compound precipitated during the assay. For the screen values, the % inhibition represents an average value 
plus or minus the standard deviation from 3-6 readings in 96-well plate screens. Ki values were determined an 
average values plus or minus the standard deviation from multiple separate assays. More detailed 
experimental details are available in section 2.5.  
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The first compounds tested did not yield any strong inhibitors of PfKMO. All compounds 
with hydrophilic R groups, including GM283, GM42, GM57 and GM41, showed no 
inhibition at the concentrations tested. Some inhibition was seen where the R group 
contained a phenyl group, as in compounds GM73 and GM107. Compounds GM73, 
GM88 and GM107 had low solubility in the final assay mixture. GM73 and GM107 were 
kept soluble with the addition of 5-10 % DMSO but GM88 continued to precipitate. As a 
result of this finding it was presumed that a hydrophobic R group was required for 
inhibition, as is the case in the Rover compounds. This hydrophobic nature does though 
lead the compounds towards insolubility – another major feature of the Rover 
compounds. It was decided to fix the two phenyl ends of the molecule and investigate 
the positions in the adjoining alkyl chain with particular emphasis towards the addition 
of solubilizing hydrophilic functional groups. 
When different organic linker chains were tested, different potencies of PfKMO 
inhibition were detected. Levels of inhibition similar to the published KMO inhibitor 
Rover 16 were seen with a couple of the compounds that contained an amide linker 
group. GM141 was the most potent of the compounds tested with a Ki of 1.30  0.21 
M. GM195, with an extra CH2 spacer in the R1 linker showed a slightly weaker Ki of 1.82 
 0.38 M. The position of the amide group was critical to the potency of the compound 
as GM289 – in which the amide was shifted along the chain by one place – showed 
significantly weaker PfKMO inhibition. The carbonyl group by itself could not account for 
the increased potency over the previous round of compounds, as GM229 was not as 
effective during screening. The conservation of the backbone NH adjacent to the 5-
membered heterocycle in the strongest inhibitors may implicate its involvement in a 
hydrogen bonding interaction with PfKMO. The compounds with the amide linker were 
clearly more soluble than their predecessors, but still some DMSO was required. This 
round of refinement significantly furthered understanding in the development of this 
particular series of KMO inhibitors. At this point, no opportunity for significant deviation 
from the structure of the Rover compounds had been unearthed. In the final round of 
compound synthesis the attention turned towards varying the functional groups 





The last round of compounds synthesized by Gavin Milne yielded an array of potent 
PfKMO inhibitors as summarised in table 5.7. Substitution on the R2 ring had the most 
significant impact on the potency of the compounds. From screening it appeared that 
inhibition strength increased with the following order of functional groups at the 3’ 
position: H<Me<OMe<CF3<F/NO2<Cl/Br. The effect of swapping the NO2 group of GM141 
for a Cl or Br group was to slightly increase the potency of PfKMO inhibition from 1.3 to 
around 0.8 M. This increase was significantly amplified when a second Cl group was 
added at the 4’ position in GM303 and GM347, which had nanomolar Ki values of 115.3  
10.7 nM and 65.0  20.0 nM respectively. Monobromination at the 4’ position in GM307 
and GM469 yielded a similar level of inhibition to the same substituent in the 3’ position. 
These findings lead to the suggestion that the presence of an electronegative/electron-
withdrawing group at both positions is responsible for the potency of the strongest 
PfKMO inhibitors.  
 
Figure 5.13. Molecular structures GM141 as well as the final compound scaffold for the synthesis of the 







Substitution on the R3 ring also influenced the strength of PfKMO inhibition, although to 
a lesser extent than on the R2 ring. As can be seen from the screening results, all the 
compounds with the 3,4-diOMe substitution showed greater inhibition than their 
respective unsubstituted counterparts. For example, the Ki of GM347 was around two-
fold lower than GM303, and the Ki of GM466 was three to four-fold lower than that of 
GM340. All of the compounds with the 3,4-diOMe substitution were observed to be less 
soluble than those that were unsubstituted. Consequently some other R3 functional 
   % Inhibition with x M inhibitor  
Comp. R2  R3  0.5 5 20 50 Screen Ki (M) 
GM302 H H - 11.6 4.6 20.8 10.3  9.5 - 
GM339 3-Me H - 19.2 45.7 - 8.4  9.6 - 
GM348 3-OMe H - 23.8 49.1 - 7.0  5.1 - 
GM342 3-F H - 25.0 50.0 - 1.3  8.0 - 
GM304 3-CF3 H - 22.9 41.6 62.8 22.6  12.1 - 
GM307 4-Br H - 20.9 49.2 62.1 21.3  10.9 - 
GM340 3-Cl H - 29.9 57.2 - 22.0  3.6 2.770  0.430  
GM308 3-Br H - 38.9 66.1 84.3 13.0  9.2 1.581  0.197 
GM303 3,4-diCl H 37.0 87.0 95.6 96.6 95.0  3.2 0.115  0.011  
GM328 H 3,4-diOMe - - - - 5.4  4.6 - 
GM366 3-Me 3,4-diOMe - - - - 2.2  7.7 - 
GM467 3-OMe 3,4-diOMe - - - - 20.3 ± 5.1 - 
GM367 3-F 3,4-diOMe - - - - 17.7  9.1 - 
GM457 3-CF3 3,4-diOMe - 30.0 - - 39.7 ± 13.6 - 
GM469 4-Br 3,4-diOMe - 44.0 - - 44.3 ± 13.6 - 
GM466 3-Cl 3,4-diOMe - 50.0 - - 56.4 ± 9.6 0.782  0.054  
GM440 3-Br 3,4-diOMe - 58.3 - - 62.4 ± 10.9 - 
GM347 3,4-diCl 3,4-diOMe 50.9 95.9 96.9 - 94.4  1.9 0.065  0.020  
GM729 3,4-diCl 3,4-diOH 37.9 90.3 - - 93.4 ± 2.2 - 
GM760 3,4-diCl 3-PO2(OEt)2, 4-OMe 78.4 99.7 - - 91.6 ± 6.7 0.020  0.004  
GM769 3,4-diCl 3-OMe, 4-PO2(OEt)2 75.1 97.2 - - 97.6 ± 0.1 0.017  0.002  
GM141 3-NO2 3,4-diOMe - - - - 37.4  9.9 1.30  0.21 
Rover 16 3-NO2 3,4-diOMe - 29.9 64.7 87.3 43.6 ± 14.4 1.03  0.27 
Table 5.7. Summary of PfKMO inhibition data for the final set of novel compounds compared to Rover 16. The 
% inhibition values were measured relative to uninhibited enzyme in 1 ml cuvette assays. For the screen 
values, the % inhibition represents an average value plus or minus the standard deviation from 3-6 readings in 
96-well plate screens. Ki values were determined an average values plus or minus the standard deviation from 
multiple separate assays. For a selection of inhibition plots for novel compounds see appendix section 4. 
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groups were introduced to try and improve the solubility of the most potent inhibitors 
GM303 and GM347. The 3,4-dihydroxy substituted compound (GM729) was more 
soluble and showed similar inhibition levels to GM303. It was the addition of a 
diethylphosphate group at either the 3’ or 4’ position that proved most exciting though. 
GM760 and GM769 both had very low Ki values of around 20 nM but also possessed 
improved solubility. The four nanomolar PfKMO inhibitors synthesised as a result of 
these rounds of design, screening and refinement are displayed in figure 5.14. These 
compounds were ten to fifty-times as potent as Rover 16 (Ro 61-8048) in our assays with 




Initial attempts to solve the structure of dm2 PfKMO bound with the novel inhibitors 
synthesised by Gavin Milne were unsuccessful. The protein was mixed 1:1 L with well 
solutions containing a number of different inhibitors at 1-2 mM. Crystals grew in the 
presence of several of the compounds (GM303, GM307, GM469) in the I4122 space 
group with similar cell dimensions to those obtained for substrate bound PfKMO crystals, 
but in every case the quality of the electron density was insufficient in order to 
confidently model the respective inhibitors. Some crystals also grew in the space group 
P21221 in the presence of GM347 and GM443 but were similar to unbound enzyme in 
Figure 5.14. Molecular structures of the four most potent PfKMO inhibitors tested. Created using ChemDraw. 
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every sense. Attempted sparse-matrix screening to search for alternate crystal growth 
conditions in the presence of GM347 were fruitless. A happy conclusion was reached 
though when the compounds were added directly to the thawed aliquot of enzyme for 
5-20 mins (room temperature) or 15-30 mins (on ice) prior to the setting up of crystal 
trays. The inhibitors were added to 1 mM from a 20-50 mM stock that was made in 100 
% DMSO. Concomitant with inhibitor addition 1.0 M HEPES pH 8.0 was added to 20 mM 
final concentration, as the compounds were found to be more soluble with a raised pH. 
Finally, a move to sitting drop vapour diffusion (s.d.v.d) reproducibly produced more and 
thicker crystals. All crystals of inhibitor-bound protein grew as needles of varying 
thickness as typified by the crystallisation drop shown in figure 5.15. Despite numerous 







Figure 5.15. Picture of a s.d.v.d crystallisation drop containing optimised GM303-bound dm2 
PfKMO crystals. 
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5.3.2 The Structure of PfKMO with GM303 bound 
 
Crystals of GM303 bound dm2 PfKMO were grown by the s.d.v.d. The drop contained 1.0 
l of GM303 soaked protein solution (13 mg/ml in 20 mM HEPES pH  7.5, 30 mM Na 
acetate, 1 mM DTT and 1 mM GM303 – from an inhibitor stock of 20 mM in 100 % 
DMSO) and 1.0 l of the precipitant solution (0.1 M HEPES pH 7.0, 12 % w/v PEG 4K, 5 % 
v/v glycerol, 10 mM Na tartrate 10 % v/v 2-propanol). The crystals were much thinner 
than the substrate-bound crystals, still with a hexagonal prism shape but with a different 
orientation. The hexagonal face represented the smallest surface whereas it was 
previously the largest face. The crystals with maximum dimensions of up to 0.05  0.05  
0.4 mm3 grew in 3-7 days and were harvested for data collection after 6 weeks. Prior to 
flash-freezing in liquid nitrogen, 3 l of cryoprotectant containing mother liquor 
supplemented with 20 % (v/v) ethylene glycol and 1 mM GM303, was added directly to 
the crystallisation drop.  
 
 
The crystals (as shown in figure 5.16) were screened for diffraction quality at the 
Diamond synchrotron beamline I03 with several diffracting to a resolution below 2.5 Å 
with a new set of lattice properties. X-ray diffraction data were collected using an X-ray 
wavelength of 0.9763 Å, exposure of 0.5 s/frame of data and beam intensity of 80 % with 
0.5 º oscillations over a total of 250 frames. The crystal was found to be hexagonal - 
space group P6122 (after testing different point groups with Molrep) - with mean unit 
cell parameters of a = b = 117.2, c = 418.2 Å, α = β = 90.0, γ = 120.0 º. Due to the large 
unit cell dimensions on the crystal’s c-axis, reflections were very close together which 
caused difficulties with automatic indexing in Mosflm. To overcome this, the mosaicity 
Figure 5.16. Picture of 
one of the  mounted 
GM303-bound crystals 
tested with diffraction 
below 2.5 Å. 
The scale and beam size 
are displayed. 
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and spot separation were entered manually. The dataset was 100.0 % complete to a 
resolution of 2.18 Å with Rmerge = 0.136 overall and 0.547 in the highest resolution shell. 
The full data collection statistics are tabulated in appendix section 3.6. 
For the calculation of structure factors, a suitable model was generated using molecular 
replacement (Molrep) with the previously solved substrate bound structure (see section 
3.3). A definitive solution emerged with three protein molecules present in the 
asymmetric unit yielding a solvent content of 54.9 %. The model was cycled through 
manual editing in Coot and restrained refinement in Refmac. For the first few cycles NCS 
restraints for each chain were applied in refinement. There was clear density for one 
molecule of FAD and one molecule of the inhibitor GM303 for each chain. The electron 
density for the inhibitor is shown in figure 5.17 and with the relatively high resolution of 
the data it was possible to establish the correct orientation of the molecule with 
confidence. On all three chains the residues 6-461 were included, except that there was 
insufficient clear density to unambiguously place residues 378-381 which precedes the 
C-terminal domain in chain A. Towards the end of refinement, Coot was used to 
manually place 783 waters in the model. The final model was refined with the addition 
of TLS to give R and Rfree values of 0.197 and 0.238 respectively, a figure of merit of 0.862 
and an overall mean B factor of 29.5 for 85024 significant reflections in the range of 
46.5-2.18 Å. The rmsd of bond lengths and angles from the ideal were 0.005 Å and 1.10 º 
and all the residues were present in the most favoured or additionally allowed regions of 
a Ramachandran plot as determined using the Molprobity server. Full refinement 





   
 
Figure 5.17. Fit of the bound molecule of GM303 in the active site of the structure. The refined      
2 Fo-Fc density (contoured at 1.5 σ) for the final position of the molecule is shown in blue with the 
Fo-Fc map, calculated after refinement without the inhibitor (contoured at 3.5 σ), shown in green. 
Figure made using Coot. 
Figure 5.18. Two views of a cartoon overlay of the structures of substrate-bound (green) and GM303-
bound (blue) dm2 PfKMO with FAD and the ligands shown in sticks. Made using PyMol. 
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The GM303-bound PfKMO structure is displayed aligned with the substrate-bound 
structure in figure 5.18. The average rmsd of C atoms of the chains from the GM303 
bound structure was 1.8 Å compared to substrate (and substrate analogue) bound KMO 
and 0.8 Å compared to unbound PfKMO. Therefore the structure in fact appeared to 
more strongly resemble the unbound structure from section 3.5. Whilst the inhibitor was 
bound in the same pocket as the substrate/substrate analogues, the polypeptide chain 
had undergone several major alterations. Firstly the C-terminal domain was in the open, 
substrate-free conformation with a swing of 6.4 Å (comparing the C atoms of aligned 
T381 residues) relative to the original substrate bound conformation. The second major 
change was that the long external loop including residues 42-52 was clearly fixed in a 
more expansive conformation in all three chains. Density for such a conformation was 
also seen to exist in two of the four chains from the solved unbound structure (see 
section 3.5). It is possible though that in the inhibitor bound structure the expansive 
conformation may have been an artefact of its new arrangement in terms of crystal 
lattice packing. As can be seen in figure 5.18, domain 2 at the bottom of the enzyme is 
slightly displaced relative to all the PfKMO structures solved to date. It is possible that 
this change may have stabilized the loop in the second conformation. 
 
Figure 5.19. Comparison of the aligned active site environment from the substrate-bound (green) and 
GM303-bound (blue) structures. Ligands and key residues are shown in sticks. A glimpse of the more open 
C-terminus can be seen by the helix displacement on the left of the picture. Figure created using PyMol. 
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With a resolution of 2.18 Å the electron density was sufficient to accurately position the 
inhibitor and its functional groups. The 3,4-dichloro ring of GM303 was positioned and 
oriented just as was seen when 3,4-CBA was bound with the two chloro groups pointing 
away from the flavin. The carbon atom of GM303 corresponding to the hydroxylation 
site of L-Kyn is 4.1 Å away from the C4a of the flavin isoalloxazine ring. All of the 
potential hydrogen bonds that stabilize GM303 binding appear to involve the amide 
group that proved pivotal to compound inhibition during screening. The amide nitrogen 
shares a hydrogen bond (2.6 Å) with the hydroxyl of the side chain of Y404, which was 
previously not utilized when substrate was bound. The side chain of N369, which is 
involved in positioning the carbonyl group of L-Kyn, hydrogen bonds with the amide 
oxygen of GM303 via a water molecule (2.7 Å and 2.6 Å). GM303’s unsubstituted phenyl 
ring then sits where the guanidinium group of R84 was located in the substrate bound 
structure. As can be seen in figure 5.19, R84 is pushed aside by around 3.5 Å leaving the 
phenyl ring of GM303 stacked between the side chains of R84 and Y404. This obstruction 
by the protruding end of GM303 may hinder the formation of the network of 
interactions that was responsible for closing domain 3 in the presence of substrate. With 
few other significant changes observed in the active site it may be this displacement of 
R84 that causes the other structural changes observed upon GM303 binding. Therefore 
it appeared from the structural features of the GM303-bound structure that the inhibitor 
was not recognized as a substrate as suggested by the lack of observable uncoupling of 
NADPH oxidation. 
 
5.3.3 The Structure of PfKMO with GM347 bound 
Crystals of GM347 bound dm2 PfKMO were grown by s.d.v.d. The drop contained 1.0 l 
of GM347 soaked protein solution (13 mg/ml in 20 mM HEPES pH  7.5, 30 mM Na 
acetate, 1 mM DTT and 1 mM GM347 – from an inhibitor stock of 20 mM in 100 % 
DMSO) and 1.0 l of the precipitant solution (0.1 M HEPES pH 7.0, 12 % w/v PEG 4K, 8 % 
v/v glycerol, 20 mM Na Tartrate, 10 % v/v 2-propanol). Thin, hexagonal prism crystals 
(similar to with GM303-bound) with rough dimensions of up to 0.05  0.05  0.40 mm3 
grew in 3-7 days and were harvested for data collection after 10 days. Prior to flash-
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freezing in liquid nitrogen, 1.5 l of cryoprotectant containing mother liquor 
supplemented with 33 % (v/v) ethylene glycol and 2 mM GM347, was added directly to 
the drop.  
The crystals were screened for diffraction quality at the Diamond synchrotron beamline 
I04-1 with several diffracting to a resolution below 2.3 Å with similar lattice properties to 
the GM303 bound KMO crystals. An example crystal is shown in figure 5.20. X-ray 
diffraction data were collected using an X-ray wavelength of 0.920 Å, exposure of 0.3 
s/frame of data with 0.3 º oscillations over a total of 131.1 º. The crystal was found to 
belong to the hexagonal space group P6122 with mean unit cell parameters of a = b = 
117.7, c = 420.1 Å, α = β = 90.0, γ = 120.0 º. The data were indexed and integrated in 
Mosflm and scaled in Scala as before. The dataset was 99.9 % complete to a resolution of 
2.15 Å with Rmerge = 0.137 overall (0.549 HS) and an intensity of 11.0 (2.7). The full data 
collection statistics are tabulated in appendix section 3.6. 
        
 
For the calculation of structure factors, a suitable model was generated using molecular 
replacement (Molrep) with the previously solved GM303 bound structure. A definitive 
solution emerged again with three protein molecules present in the asymmetric unit, 
yielding a solvent content of 55.4 %. The model was cycled through manual editing in 
Coot and restrained refinement in Refmac. For the first few cycles NCS restraints for 
each chain were applied in refinement. There was clear density for one molecule of FAD 
for each chain. There was also clear density to place the 3,4-dichloro R2 ring, the 5-
Figure 5.20. Picture of a mounted 
GM347-bound crystal, which diffracted 
to a resolution around 2.25 Å. 
Beam-size = 20  20 m. 
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membered heterocycle ring and the amide linker of GM347 in a similar location to that 
seen with GM303. Unfortunately the density for the 3,4-OMe R3 ring was weak and 
ambiguous meaning that it could not be accurately modelled. Several datasets of similar 
resolution from different crystals harvested from different drops were processed, but 
still the same problem consistently remained. Therefore the R3 ring was excluded from 
the final model and the refined electron density maps calculated in the presence and 
absence of this truncated inhibitor are shown in figure 5.21. On all three chains the 
residues 6-461 were included except that there was insufficiently clear density to 
unambiguously place residues 378-379, 375-378 and 377-381 in chains B, A and C 
respectively. Towards the end of refinement, Coot was used to manually place 816 
waters in the model. The final model (shown in figure 5.22) was refined with the addition 
of TLS to give R and Rfree values of 0.208 and 0.234 respectively and an overall mean B-
factor of 31.4 Å2 for 89610 significant reflections in the range of 45.00-2.15 Å. The rmsd 
of bond lengths and angles from the ideal were 0.005 Å and 1.12 º and all the residues 
were present in the most favoured or additionally allowed regions of a Ramachandran 
plot as determined using the Molprobity server. Full refinement statistics are tabulated 
in appendix section 3.6. 
 
Figure 5.21. Fit of the truncated molecule of GM347 in the active site of the structure. The refined   
2Fo-Fc density (contoured at 1.5 σ) for the final position of the molecule is shown in blue with the Fo-Fc 
map calculated after refinement withouth the inhibitor present (contoured at 3.5 σ) shown in green. 




The overall structure of GM347 bound PfKMO was very similar to the previous GM303 
bound structure, which had structural features that more resembled unbound over 
substrate bound PfKMO. The average rmsd of C atoms for all three chains of the GM347 
bound structure was: 0.4 Å compared to GM303 bound, 1.8 Å compared to substrate 
(and substrate analogue) bound and 0.9 Å compared to unbound PfKMO. As previously 
detailed with the GM303 bound structure, the C-terminal domain 3 and external 42-52 
loop were both present in their respective open conformations. The parts of GM347 that 
could be unambiguously positioned were found to adopt the same orientation as 
observed for GM303, with the 3,4-dichloro groups clearly pointing out away from the 
flavin. It is unclear why the 3,4-OMe R3 ring could not be located by clear density given 
the high resolution of the datasets tested. It is possible that either the compound started 
to decompose or that the ring occupied multiple conformations upon binding. The latter 
is more likely as the density for the neighbouring side-chain of Y404 was also relatively 
weak and no deterioration in the inhibition strength was noticed over time during 
inhibition assays and screening. With the basic R84 side-chain nearby it was hoped that 
binding of the two strongest inhibitors, which contained R3 PO2(OEt)2 groups, would be 
more stable. 
Figure 5.22. Side and front views of a cartoon overlay of the structures of substrate-bound (green) and 
GM347-bound (grey) dm2 PfKMO with FAD and the ligands shown in sticks. Made using PyMol. 
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5.3.4 The Structure of PfKMO with GM760 bound 
Crystals of GM760 bound dm2 PfKMO were grown by s.d.v.d. The drop contained 1.0 l 
of GM760 soaked protein solution (13 mg/ml in 20 mM HEPES pH  7.5, 30 mM Na 
acetate, 1 mM DTT and 1 mM GM760 – from an inhibitor stock of 50 mM in 100 % 
DMSO) and 1.0 l of the precipitant solution (0.1 M HEPES pH 7.0, 13 % w/v PEG 4K, 6 % 
v/v glycerol, 10 mM Na tartrate, 10 % v/v 2-propanol). Thin, hexagonal prism crystals 
(similar to with GM303-bound) with rough dimensions of 0.04  0.04  0.80 mm3 grew in 
3-7 days and were harvested for data collection after 10 days. Prior to flash-freezing in 




The crystals were screened for diffraction quality at the Diamond synchrotron beamline 
I02 with several diffracting to a resolution below 2.5 Å with similar lattice properties to 
the GM303 bound crystals. X-ray diffraction data were collected using an X-ray 
wavelength of 0.979 Å, exposure of 0.3 s/frame of data and beam intensity of 50 % with 
0.3 º oscillations over a total of 117 º. The crystal (displayed in figure 5.23) belonged to 
space group P6122 with mean unit cell parameters of a = b = 117.3, c = 418.1 Å, α = β = 
90.0, γ = 120.0 º. The data were indexed and integrated in Mosflm and scaled in Scala as 
Figure 5.23. Picture of 
the mounted GM760-
bound crystal used for 
data collection. 
The scale and beam 
size are labelled. 
186 
before. The dataset was 100.0 % complete to a resolution of 2.40 Å with Rmerge = 0.156 
overall (0.682 HS) and intensity 11.0 (2.6 HS). The full data collection statistics are 
tabulated in appendix section 3.6. 
The GM303 bound structure was used as a model to start refinement. The model was 
cycled through manual editing in Coot and restrained refinement in Refmac. For the first 
few cycles NCS restraints for each chain were applied in refinement. There was clear 
density for one molecule of FAD and one molecule of the inhibitor GM760 for each 
chain. The refined density with and withouth the inhibitor is shown in figure 5.24 and 
with the relatively high resolution of the data the position of the functional groups was 
established. The positions of the oxygen and OEt groups on the phosphate though could 
not be differentiated with 100 % confidence and may be interchangeable. On all three 
chains the residues 6-461 were included except that there was insufficient density to 
clearly place residues 376-382, which precede the C-terminal domain in chain A. Towards 
the end of refinement, Coot was used to manually place 940 waters in the model. The 
final model was refined with the addition of TLS to give R and Rfree values of 0.203 and 
0.248 respectively and an overall mean B-factor of 44.4 for 64181 significant reflections 
in the range of 50.0-2.40 Å. The rmsd of bond lengths and angles from the ideal were 
0.005 Å and 1.08 º and all the residues were present in the most favoured or additionally 
allowed regions of a Ramachandran plot as determined using the Molprobity server. Full 





The overall structure of GM760 
bound PfKMO was very similar to the previous inhibitor bound structures, which had 
Figure 5.24. Fit of the bound molecule of GM760 in the active site of the structure. The refined 2Fo-Fc 
(contoured at 1.5 σ) for the final position of the molecule is shown in blue with the Fo-Fc map 
(contoured at 3.5 σ) in the absence of inhibitor shown in green. Figure made using Coot. 
Figure 5.25. Side and front views of a cartoon overlay of the structures of substrate-bound (green) and 
GM760-bound (violet) dm2 PfKMO with FAD and the ligands shown in sticks. Made using PyMol. 
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structural features that more resembled unbound over substrate bound PfKMO. The 
rmsd of C atoms of a chain of the GM760 bound structure was: 0.5 Å compared to 
GM303 bound, 1.8 Å compared to substrate (and substrate analogue) bound and 0.9 Å 
compared to unbound PfKMO. As previously detailed with the GM303 and GM347 
bound structures, the C-terminal domain 3 and external 42-52 loop were both present in 
their respective open conformations. The inhibitor was again bound in the same pocket 







Interestingly, with the large 3’-PO2(OEt)2 group added to the R3 ring of GM760, a couple 
of significant local changes were enforced compared to with GM303 bound. The 3’-
PO2(OEt)2 group pointed out of the binding pocket to be adjacent to the imidazole group 
of R84 at a distance of Å. This pushed the R3 ring deeper into the buried pocket, which 
presumably caused the observed out-swing of the side chain of Y404 by around 120 o 
relative to the substrate/substrate analogue bound, unbound and GM303 bound 
Figure 5.26. Comparison of the aligned active site environment from the substrate-bound (green) 
and GM760-bound (violet) structures. Ligands and key residues are shown in sticks. A glimpse of the 
more open C-terminus can be seen by the helix displacement on the left of the picture. Figure 
created using PyMol. 
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structures. Therefore in the GM760 bound structure Y404 sits in the plane above the R3 
ring with a possible π-stacking interaction. To accommodate this translocation, the 
inhibitor’s amide linker is rotated by around 150 o relative to GM303 and GM347 to 
point in to the hydrophobic pocket below the side chain of H320. The carbonyl oxygen 
atom now formed potential hydrogen bonds with the hydroxyl of T408 (2.6 Å) and a 
water molecule (3.0 Å). In addition two water molecules formed potential hydrogen 
bonds with the amide nitrogen atom (both at around 2.7 Å). 
 
5.3.5 The Structure of PfKMO with GM769 bound 
Crystals of GM769 bound dm2 PfKMO were grown by s.d.v.d. The drop contained 1.0 l 
of GM769 soaked protein solution (13 mg/ml in 20 mM HEPES pH  7.5, 30 mM Na 
acetate, 1 mM DTT and GM769 – from an inhibitor stock of 50 mM in 100 % DMSO) and 
1.0 l of the precipitant solution (0.1 M HEPES pH 7.0, 11 % w/v PEG 4K, 6 % v/v glycerol, 
10 mM Na tartrate, 10 % v/v 2-propanol). Long, thin, hexagonal prism crystals (similar to 
with GM303-bound) with rough dimensions of 0.05  0.05  0.50 mm3 grew in 3-7 days 
and were harvested for data collection after 3-4 weeks. Prior to flash-freezing in liquid 
nitrogen, 3 l of cryoprotectant containing well solution supplemented with 20 % (v/v) 
ethylene glycol and 1 mM GM769, was added directly to the drop.  
 
           
Figure 5.27. Picture of the 
mounted GM769-bound crystal 
used for data collection.  
The beam size was 20  20 m. 
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The crystals were screened for diffraction quality at the Diamond synchrotron beamline 
I02 with several diffracting to a resolution below 2.5 Å with similar lattice properties to 
the previous inhibitor bound crystals. X-ray diffraction data were collected from the 
crystal displayed in figure 5.27. An X-ray wavelength of 0.979 Å, exposure of 0.35 
s/frame of data and beam intensity of 55 % with 0.3 º oscillations over a total of 153.6 º 
was used. The crystal was monoclinic, space group P6122 with mean unit cell parameters 
of a = b = 117.5, c = 417.8 Å, α = β = 90.0, γ = 120.0 º. The data were indexed and 
integrated in Mosflm and scaled in Scala as before. The dataset was 99.9 % complete to 
a resolution of 2.30 Å with Rmerge = 0.157 overall (0.675 HS) and I/I 12.5 (3.2 HS). The full 
data collection statistics are tabulated in appendix section 3.6. 
The previously solved GM303 bound structure was again used to start refinement. The 
model was developed as described previously. There was clear density for one molecule 
of FAD and one molecule of the inhibitor GM769 for each chain. The refined density in 
the presence and absence of the inhibitor is shown in figure 5.28 and with the relatively 
high resolution of the data the position of the functional groups was established. The 
positions of the oxygen and OEt groups on the phosphate again could not be 
differentiated with 100 % confidence and may be interchangeable. On all three chains 
the residues 6-461 were included except that there was insufficient density to clearly 
place residues 377-379, 378-380 and 375-377 in chains B, A and C. Towards the end of 
refinement, Coot was used to manually place 820 waters in the model. The final model 
was refined with the addition of TLS to give R and Rfree values of 0.202 and 0.230 
respectively and an overall mean B-factor of 37.0 for 72900 significant reflections in the 
range of 38.80-2.30 Å. The rmsd of bond lengths and angles from the ideal were 0.005 Å 
and 1.05 º and all the residues were present in the most favoured or additionally allowed 
regions of a Ramachandran plot as determined using the Molprobity server. Full 





Figure 5.28. Fit of the bound molecule of GM769 in the active site of the structure. The refined 2Fo-Fc 
density (contoured at 1.5 σ) for the final position of the molecule is shown in blue with the Fo-Fc map 
(contoured at 3.5 σ) calculated in the absence of GM769 shown in green. Figure made using Coot. 
Figure 5.29. Side and front views of a cartoon overlay of the structures of substrate-bound (green) and 
GM769-bound (purple) dm2 PfKMO with FAD and the ligands shown in sticks. Made using PyMol. 
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The overall structure of GM769 bound dm2 PfKMO is aligned to the substrate-bound 
form in figure 5.29. The structure was very similar to the previous inhibitor bound 
structures, which had structural features that more resembled unbound over substrate 
bound PfKMO. As discussed before with the other inhibitor bound structures, the C-
terminal domain 3 and external 42-52 loop were both present in their respective open 
conformations. The rmsd of C atoms of a chain of the GM769 bound structure was: 0.4 
Å compared to GM303 bound, 0.5 Å compared to GM760 bound, 1.8 Å compared to 
substrate (and substrate analogue) bound and 0.9 Å compared to unbound PfKMO. The 








Interestingly, with the PO2(OEt)2 group on the 4’ rather than the 3’ position in GM760, 
the amide linker flips by 180 ˚ to resume the orientation occupied in bound GM303 (and 
Figure 5.30. Comparison of the aligned active site environment from the substrate-bound (green) and 
GM769-bound (purple) structures. Ligands and key residues are shown in sticks. A glimpse of the 
more open C-terminus can be seen by the helix displacement on the left of the picture. Figure created 
using PyMol. 
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possibly GM347). Moreover a novel third conformation for the side-chain of Y404 is seen 
with a rotation of around -120 ˚ relative to the substrate/substrate analogue bound, 
unbound and GM303 bound structures. R84 is again displaced but now it was the 4’-
PO2(OEt)2 group that was sandwiched between the side chains of R84 and Y404. The 3’-
OMe group of GM769 points in to the vacant space left by the side-chain of Y404. This 
demonstrates the flexibility of the residues lining the active site to accommodate various 
alterations to the functional groups of the novel inhibitors. 
 
5.4 Discussion and conclusions 
In section 5.2 the binding characteristics of substrate analogues was investigated. 
Background NADPH oxidation in the absence of L-Kyn confirmed the analogues were 
non-substrate effectors rather than inhibitors as first discussed by Crozier-Reabe [1]. 
From in vitro assays with pure PfKMO, it was found the addition of electronegative 
functional groups to the compound’s phenyl ring drastically improved its binding affinity. 
Interestingly, little effect was seen upon conversion into a naphthalene ring system 
showing that there was a large hydrophobic pocket to be filled. This is consistent with 
the spacious hydrophobic pocket seen adjacent to the outer side of the benzene ring of 
the substrate in the previously described crystal structures. Crystal structures with the 
tight binding published substrate analogues m-NBA and 3,4-CBA bound revealed that the 
compounds bound in the same location and orientation as the substrate L-Kyn. The C-
terminal domain 3 was positioned in the closed, substrate-bound position suggesting 
that the compounds were initially recognized as potential substrates upon binding. It is 
therefore possible that the apparent uncoupling of NADPH oxidation was due to either: 
i) the loss of an interaction from the amine group on L-Kyn with the catalytic flavin-
intermediate and/or ii) a slight displacement in the position of the target benzene ring. 
The key information for taking on to the search for novel PfKMO inhibitors was that the 
addition of functional groups such as m-nitro and 3,4-dichloro to the benzene ring 
greatly improved the strength of binding. 
Following this information, a novel series of PfKMO inhibitors was successfully 
discovered and refined. The compounds were based on the structure of the published 
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potent KMO inhibitor Ro 61-8048, synthesised by Rover et al. [4]. Ro 61-8048 initially 
showed therapeutic potential as discussed in section 1.4.2. It is however, unsuitable for 
therapeutic use as it failed the Ames test, which was probably due to the presence of a 
nitro group. Given the low published IC50 values of around 20-50 nM for the Rover 
compounds, the strength of inhibition in our assays on PfKMO was a little weaker than 
expected. The published values were determined using mitochondrial extracts from rat 
liver KMO and so there was a possibility that the differences were due to subtle 
variations between the bacterial and rat KMO active site environments. The strength of 
inhibition in PfKMO was still reasonably strong though, and enough to suggest a high 
level of similarity between the binding site in the two enzymes. Therefore, together with 
the clear conservation seen with the active site residues in the previously solved 
bacterial KMO structures, it was concluded that PfKMO presents a suitable model for 
developing potential inhibitors of human KMO. We therefore set out to generate a new 
set of compounds that could reproduce the inhibitory properties of Ro 61-8048 with 
alternative, safer functional groups. 
Subsequently, Gavin Milne (PhD, University of St Andrews) designed an initial 1,2,4-
oxadiazole-based scaffold to mimic the 4-phenylthiazol-2-yl of the Rover compounds. 
From this starting point, compound refinement and screening identified the key 
functional groups required for potent PfKMO inhibition. The combination of a tail 
benzene ring with an amide linker successfully created a novel secondary scaffold with 
similar levels of PfKMO inhibition as the Rover compounds. The inhibition constant Ki of 
the novel compound (GM141) was determined to be 1.30  0.21 M compared to 1.03  
0.27 M and 1.67  0.23 M for Rover 16 (Ro 61-8048) and 19 respectively. After this 
point the addition/variation of functional groups associated with the 3’ and 4’ positions 
of both the head R2 and tail R3 benzene rings identified even more potent inhibitors with 
nanomolar inhibition constants. On the R2 ring, the 3,4-dichloro moieties gave the 
strongest inhibition, similar to the pattern seen with the substrate analogues. At the tail 
R3 ring the addition of a 3’ or 4’-PO2(OEt)2 group further increased the inhibition 
strength. The process of screening and compound refinement finished with compounds 
GM760 and GM769, which had essentially identical Ki values of 20.2 ± 3.5 nM and 16.5 ± 
2.1 nM respectively. Importantly, both compounds were largely soluble in water unlike 
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the majority of the compounds which did not contain the 3’ or 4’-PO2(OEt)2 group. The 
plate-screening and Ki data for the majority of the compound series is summarised in the 













































































































































































































Following the successful crystallization and structure determination of dm2 PfKMO (see 
Chapter 3), co-crystallization with the more potent inhibitors was attempted. Eventually 
conditions were found from which crystals of inhibitor bound enzyme could be 
reproducibly grown leading to structures containing the four tightest binding novel 
inhibitors: GM303, GM347, GM760 and GM769. Unexpectedly a third new type of lattice 
packing was observed with three protein molecules in the asymmetric unit in the 
hexagonal space group P6122 and with strong diffraction. The final resolution of the X-
ray datasets was between 2.15 and 2.40 Å. From these structures the positions of the 
inhibitors (with the exception of GM347) could be accurately defined in the substrate-
binding pocket. The tail of the compounds extended out of the pocket, disrupting the 
Figure 5.31. Graph summarising inhibition data for novel 1,2,4-oxadiazole-based series of PfKMO 
inhibitors. Average plate-screen data with 10 M of each inhibitor is displayed with orange bars (left 
axis) with Ki values determined plotted as blue bars (right axis). See sections 2.5 and 5.3.1 for full 
assay details. Created in Excel. 
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interactions that previously linked the substrate with the C-terminal domain 3 via 
interaction with R84. As a result the inhibitor structures exhibited an open C-terminal 
conformation reminiscent of the unbound PfKMO structure. This was a significant 
difference with the substrate analogues and may explain the effect of these compounds 






A structural comparison of the inhibitor binding environments for GM303, GM760 and 
GM769 is shown in figure 5.32. In all three cases the side-chain of R84 is pushed aside 
accounting for the breakdown of interactions responsible for closing the C-terminal 
domain when substrate/substrate analogues bind (see Chapter 4). A beautiful insight 
into the rotation of the Y404 side-chain to accommodate the three different inhibitor 
tails can be seen. The side-chain occupies three separate orientations to π–stack with 
each of the inhibitors. An additional variation among the compounds is the orientation 
Figure 5.32. Structural overlay of the inhibitor binding sites for each novel compound with that of the 
substrate-bound structure (green). The inhibitor-bound structures are coloured blue, violet and purple 
for GM303, GM760 and GM769. Ligands and key protein residues are shown as sticks with the protein 
structure represented in cartoon. Figrue and alignmentcreated using PyMol. 
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of the amide linker group. In the GM303 and GM769 bound structures the carbonyl 
points out towards N369 but in GM760 – with the PO2(OEt)2 group in the 3’ position – it 
rotates to point into the hydrophobic pocket below H320. In all three cases the head 3,4-
dichlorobenzene ring is virtually identical and adopts a position similar to that occupied 
by the substrate analogue 3,4-CBA. It therefore is likely that the previously mentioned 
difference in stimulation of flavin reduction between the inhibitors and substrate 
analogues is down to the tail of the molecule. This is possibly linked to the loss of the 
carboxyl group on 3,4-CBA and the substrate, and its replacement with a much larger tail 
arrangement. 
 
In summary the aim of developing a novel series of potent PfKMO inhibitors was 
achieved with great success. Moreover, a new set of compounds with further alternative 
tail R3 groups have been synthesized by Gavin Milne ready for future testing and 
structure solution. The presented and ongoing new compounds may themselves present 
exciting therapeutic tools for the inhibition of human KMO. The only significant 
sequence difference in the predicted active site of the human enzyme is the substitution 
of H320 for a phenylalanine. As can be seen from the structures, this side chain does not 
influence inhibitor binding except with GM760. The amide carbonyl of GM760 is around 
3.0-3.5 Å from a nitrogen atom in the imidazole ring of H320 but is unlikely to be 
involved in a hydrogen bond with it. This is because the carbonyl is already fully occupied 
by two <3.0 Å hydrogen bonds, and additionally the position of the imidazole nitrogen 
doesn’t fit with either of these. Still, if the same inhibition properties do not transfer to 
clinical studies with the human enzyme, the presented inhibitor bound structures should 
still serve as a significantly useful model for the rational design and optimisation of 






Chapter 6 – Conclusions and Future Work 
 
In this investigation, the first PfKMO crystal structures were solved using an engineered 
cysteine double mutant C252S/C461S (dm2) with enhanced stability in solution. The 
mutations did not significantly affect the catalytic ability of the enzyme and the residues 
are located in surface areas of the structure distant from the substrate entry route. 
Therefore it is presumed that the structures presented and ideas discussed are 
transferable to the native enzyme. In all the structures of dm2 PfKMO obtained include 
substrate bound, substrate-free (unbound), substrate-free with chloride ions (chloride), 
substrate analogue bound (m-NBA and 3,4-CBA), novel inhibitor bound (GM303, GM760 
and GM769), Y382F substrate bound, R386K substrate bound and unbound, R386T 
substrate bound and substrate-free chloride, E372T/L367R substrate bound and 
chloride. In all cases the majority of the protein was modelled from residues 6-461 with a 
similar overall architecture which can be arbitrarily split into three structural domains. 
The first two domains (up to residue 376), comprising the FAD and substrate binding 
sites are structurally related to the fold seen with other FAH enzymes whose structures 
have been solved. The third, C-terminal domain is unrelated to anything else seen in the 
enzyme class to date and extends out from the first two domains from the back of the 
substrate binding pocket at the substrate’s carboxyl tail. This domain occupies different 
conformations in the solved PfKMO structures and this observation led to the 
investigation of its role/function. The second and main focus of the investigation as it 
developed was to quantify and characterise the nature of inhibitor binding in the 
substrate binding site.  
 
6.1 Substrate binding and role of the C-terminal domain 
The initial substrate-bound structure was solved to a resolution of 3.40 Å with SeMet-
labelled protein. Again it was evident that the SeMet residues did not significantly alter 
the catalytic ability or the structure of the enzyme. The exact position of the substrate 
and the surrounding active site residues are slightly ambiguous given the resolution of 
the data. The substrate’s orientation is strongly supported by the positioning of the 
carboxyl group within 3 Å of a guanidinium group from the highly conserved residue R84 
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and by the positioning of the phenyl ring of L-Kyn with its site of hydroxylation 
approximately 5 Å from the catalytic intermediate-forming C4a atom of the flavin. This 
specific substrate-flavin distance correlates well with the reported values seen in 
structures of other FAH enzymes [158, 170-172, 174-176, 178, 259]. In addition the 
protein residues proposed to surround the bound substrate are all highly conserved 
among KMO homologs. Building on this structure the Mowat group will look to 
substitute these potential substrate interacting residues to fully characterise the nature 
of substrate binding. 
The substrate analogue structures with 3,4-CBA and with m-NBA bound both further 
validated the substrate’s orientation and position. Whilst the resolution of the structures 
was not improved, the added functional groups provided significant density to confirm 
the position of the ligand phenyl ring. Interestingly in 2008 Crozier-Reabe et al., showed 
that BA and m-NBA acted as non-substrate effectors of PfKMO as their binding 
stimulated uncoupled flavin reduction leading to hydrogen peroxide production [1]. The 
preliminary data in this study agreed with these findings but suggested that the analogue 
3,4-CBA did not have this effect and was a true competitive inhibitor of PfKMO. There 
were no structural differences evident between the binding of 3,4-CBA and m-NBA so 
further investigation is needed to confirm and explain the difference between the 
compounds. This could be achieved by stopped-flow work with 3,4-CBA and the use of 
fluorescence resonance energy transfer (FRET) along with possible substitution of the 
FAD cofactor for fluorescently-labelled analogues.  
The solution of the structure of unbound PfKMO to a much higher resolution of 2.26 Å 
provided a more defined and detailed structural model that additionally incorporated 
solvent molecules. The crystals exhibited different lattice packing in a different space 
group to substrate bound crystals. The resulting structure was virtually indistinguishable 
from the substrate bound form over the first two domains; however the novel C-
terminal domain swung out from the rest of the enzyme by up to around 6 Å. This 
movement was shown to be dependent upon the binding of substrate rather than the 
nature of the crystal packing by the study of a series of C-terminal mutants – E372T, 
Y382F, R386T and R386K. In the substrate bound structure, with what was labelled as 
the closed C-terminal conformation, these residues appeared to be well positioned to 
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form a chain of non-covalent intermolecular interactions linking the C-terminus to the 
side-chain of a key substrate-interacting residue R84.  
In the open conformation of the unbound PfKMO structure the residues involved in this 
chain of interactions were clearly further apart from each other. A similar, partially open 
(mixed) C-terminal conformation was present in the substrate bound mutant structures. 
Whilst the resolution was unfortunately still poor in these structures at 3.24-3.40 Å, 
there was clear evidence for placing the C-terminus in a significantly more open 
conformation than with the initial substrate bound dm2 PfKMO structure. The exact 
mechanism and catalytic relevance of the C-terminal movement needs further study. For 
example the mutants could be used to validate whether the rate of product release is 
faster when the C-terminal domain is more open using stopped flow spectrophotometry. 
In addition it would be interesting to see if the mutants experience raised levels of 
uncoupled flavin reduction generating hydrogen peroxide due to leakage of bound 
substrate from the NADPH-reduced enzyme-substrate complex. Finally the exact 
mechanism of substrate entry can be studied in greater detail to visualise the nature of 
the two-step substrate binding process observed by Crozier-Reabe et al., [1]. Given the 
data presented here it is possible that the substrate could initially bind in the C-terminal 
domain – possibly involving residue R386 (as R386T possessed a four-fold raised Km in 
comparison to the other mutants) – before being guided through into the buried 
substrate binding site. If this were true it could have implications for the rational design 
of a new series of inhibitors which target the C-terminal domain rather than the active 
site itself. 
 
6.2 Inhibition and human KMO 
A novel series of 1,2,4-oxadiazole amides designed and created by Gavin Milne (PhD, 
University of St Andrews) produced four nanomolar Ki competitive inhibitors of PfKMO. 
Crystal structures with the compounds bound revealed that they filled the substrate 
binding pocket, prevented closure of the C-terminal domain and possibly disrupted the 
NADPH binding site. As previously mentioned the PfKMO active site looks like a good 
model for that of the human enzyme when looking at the sequence conservation of the 
involved residues. The only difference in residues within 5 Å of the substrate is the 
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change of H320 from PfKMO to phenylalanine in the human enzyme. To provide more 
direct evidence for this hypothesis, purified dm2 PfKMO was recently sent to 
GlaxoSmithKline plc (GSK) to directly compare the inhibition pattern observed with a set 
of compounds to the pattern observed using overexpressed human KMO from isolated 
SF9 (a eukaryotic expression strain) cell membranes. The overall correlation between the 
pIC50 results with the two enzymes was good with an R
2 value of 0.83 (see figure 6.1). 
The results, which were based on the direct measurement of 3-HK production by 
RapidFire® mass spectrometry, suggest that the bacterial active site structural features 
and inhibition results presented in this work may be relevant in the search for inhibitors 
of the human enzyme.  
 
 
With the mammalian enzyme still difficult to purify and study in vitro, the generation of 
H320F dm2 PfKMO (currently ongoing in the group) may further help to establish PfKMO 
as a useful surrogate target for the screening, characterisation and crystal structure 
solution of potential human KMO inhibitors. A more complicated approach may be to 
generate a fusion protein with the transmembrane-containing C-terminal domain of 
human KMO swapped out for those of the bacterial PfKMO. Even with the structural 
information and homology models available this task may not be straight forward. 
Different fusions could be created at different points of the human sequence to ideally 
try and start the swap at a loop and not in the middle of a secondary structural element. 
Secondary mutations may be necessary to ‘fix’ patches of the fusion where PfKMO 
residues that are different to the corresponding human residues conflict with the 
Figure 6.1. Correlation of pIC50 values 
between the PfKMO and human KMO 
RapidFire® mass spectrometry assays. Data 
is expressed as mean values, the overall 
correlation between assays gives an R
2
 
value of 0.83. 
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properties of neighbouring residues. So it would take a lot of careful designing but may 
yield a soluble active protein that can be crystallised and co-crystallised with novel 
inhibitors in the human active site.  
There are still more novel inhibitors to be tested and therefore more structures to solve. 
It would also be interesting to look into how these inhibitors prevent flavin reduction. 
The process of NADPH docking is still poorly understood so mutational studies regarding 
the mobile loop involving residues 43-52 may be a good start. It may also be worth trying 
to crystallise the substrate-free and the inhibitor bound enzyme with NADPH or NADP+ 
or to soak these compounds into substrate-free, substrate bound and inhibitor bound 
crystals. The coenzyme’s would likely have to be present at very high concentrations in 
order to fully occupy the transient docking site. In the case of the inhibitor bound 
crystals though it may be that an NADPH complex can be obtained more easily if it is the 
flavin dynamic movement presumed necessary for reaction with NADPH, rather than the 
NADPH docking site, that is perturbed. Again stopped-flow and fluorescence work with 
the inhibitors and PfKMO may also be useful to understand the differences between 
their binding and that of the substrate and substrate analogues. For example with some 
sort of fluorescent labelling near the docking site or on the NADPH itself the relative 
enzyme affinity for NADPH could be compared when different ligands are bound.  
In all there is a lot of work on the bacterial enzyme that has been started in this 
investigation and some selected areas may be more highly prioritised for further study. 
Due to the clinical interest the future of the enzyme lies with the mammalian forms and 
so it is conceivable that the discussed adaptions of PfKMO to be more like human KMO 
may be the key and highest impact route for the continued study of the enzyme. For 
now though the set of structures presented here should have an immediate impact as 
they can be used to speed up human KMO structural modelling and subsequently the 
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Appendix 1 – Amino acid sequence analysis 
 
 
1.1 Emboss needle pairwise alignment to human KMO 
 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# 
# Length: 505 
# Identity:     160/505 (31.7%) 
# Similarity:   257/505 (50.9%) 
# Gaps:          63/505 (12.5%) 
# Score: 681.0 
 
 
HumanKMO         1 ---MDSSVIQRKKVAVIGGGLVGSLQACFLAKRNFQIDVYEAREDTRVAT     47 
                      .|::    ::|.:||.||.|:|.|..||:..:|::::|.|.|.|:.| 
PfKMO            1 MTATDNA----RQVTIIGAGLAGTLVARLLARNGWQVNLFERRPDPRIET     46 
 
HumanKMO        48 FTRGRSINLALSHRGRQALKAVGLEDQIVSQGIPMRARMIHSLSGKKSAI     97 
                   ..|||||||||:.||..||:..|||.:::::.:.||.||:|......:.. 
PfKMO           47 GARGRSINLALAERGAHALRLAGLEREVLAEAVMMRGRMVHVPGTPPNLQ     96 
 
HumanKMO        98 PYG-TKSQYILSVSRENLNKDLLTAAEKYPNVKMHFNHRLLKCNPEEGMI    146 
                   ||| ..|:.|.|::|:.||:.||..||. ....:|||..|...:.....: 
PfKMO           97 PYGRDDSEVIWSINRDRLNRILLDGAEA-AGASIHFNLGLDSVDFARQRL    145 
 
HumanKMO       147 TV--LGSDKVPKDVTCDLIVGCDGAYSTVRSHLMKKPRFDYSQQYIPHGY    194 
                   |:  :..:::.|  ...|::|.||..|.||..:..........:..|||| 
PfKMO          146 TLSNVSGERLEK--RFHLLIGADGCNSAVRQAMASVVDLGEHLETQPHGY    193 
 
HumanKMO       195 MELTIPPK-NGDYAMEPNYLHIWPRNTFMMIALPNMNKSFTCTLFMPFEE    243 
                   .||.|.|: :..:.:|||.|||||...:|.|||||:::|||.|||:..:. 
PfKMO          194 KELQITPEASAQFNLEPNALHIWPHGDYMCIALPNLDRSFTVTLFLHHQS    243 
 
HumanKMO       244 ---------FEKLLTSNDVVDFFQKYFPDAIPLIGEKLLVQDFFLLPAQP    284 
                            |.:|:..:....|||:.|||..|::..  |.|||...|... 
PfKMO          244 PAAQPASPCFAQLVDGHAARRFFQRQFPDLSPMLDS--LEQDFEHHPTGK    291 
 
HumanKMO       285 MISVKCSSFHFKSHCVLLGDAAHAIVPFFGQGMNAGFEDCLVFDELMDKF    334 
                   :.:::.:::|.....||||||||.:|||.|||||...||.:...|.:... 
PfKMO          292 LATLRLTTWHVGGQAVLLGDAAHPMVPFHGQGMNCALEDAVALAEHLQSA    341 
 
HumanKMO       335 SNDLSLCLPVFSRLRIPDDHAISDLSMYNYIEMRAHVNSSWFIFQKNMER    384 
                   :::.| .|..|:..|.||..||..:::.||:||.:.|.|..::.::.:.: 
PfKMO          342 ADNAS-ALAAFTAQRQPDALAIQAMALENYVEMSSKVASPTYLLERELGQ    390 
 
HumanKMO       385 FLHAIMPSTFIPLYTMVTFSRIRYHEAVQRWHWQKKVINKGLFFLGSLIA    434 
                   .:....|:.|||.|:||||||:.|.:|:.|...|::::...:.....|.: 
PfKMO          391 IMAQRQPTRFIPRYSMVTFSRLPYAQAMARGQIQEQLLKFAVANHSDLTS    440 
 
HumanKMO       435 I---SSTYLLIHYMSPRSFLRLRRPWNWIAHFRNTTCFPAKAVDSLEQIS    481 
                   |   :..:.:...:.|.|.|.                              
PfKMO          441 INLDAVEHEVTRCLPPLSHLC-----------------------------    461 
 
HumanKMO       482 NLISR    486 
                         
PfKMO          462 -----    461 
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1.2 Multiple sequence alignment with FAH structural data 
 
Conserved residues across all KMO sequences are highlighted on the sequence of PfKMO in 
cyan. From the FAH structures residues involved in FAD-binding are highlighted yellow and in 
substrate-binding are highlighted green. Created with Clustal W2. 
 
PfKMO       -------------------------MTATDNARQVTIIGAGLAGTLVARLLARNG----- 30 
p-HBH       ------------------------------MKTQVAIIGAGPSGLLLGQLLHKAG----- 25 
PhH         ------------------------MTKYSESYCDVLIVGAGPAGLMAARVLSEYVRQKPD 36 
PQSL        ---------------------------MTDNHIDVLINGCGIGGAMLAYLLGRQG----- 28 
MHPCO       ---------------------MANVNKTPGKTRRAEVAGGGFAGLTAAIALKQNG----- 34 
RebC        --------------------------MNAPIETDVLILGGGPVGMALALDLAHRQ----- 29 
phzS        ----------------------------MSEPIDILIAGAGIGGLSCALALHQAG----I 28 
AVH         ---------------------------MNDHEVDVLVVGAGLGGLSTAMFLARQG----- 28 
m-HBH       MQFHLNGFRPGNPLIAPASPLAPAHTEAVPSQVDVLIVGCGPAGLTLAAQLAAFP----D 56 
                                                 : * *  *   .  *          
 
PfKMO       WQVNLFERRPDPRIET--GARG---RSINLALAERGAHALRLAG--LEREVLAEAVMMRG 83 
p-HBH       IDNVILERQTPDYVLGRIRAGVLEQGMVDLLREAGVDRRMARDG------LVHEGVEIAF 79 
PhH         LKVRIIDKRSTKVYNG--QADGLQCRTLESLKNLGLADKILSEANDMSTIALYNPD--EN 92 
PQSL        HRVVVVEQARRERAIN--GADLLKPAGIRVVEAAGLLAEVTRRG----GRVRHELEVYHD 82 
MHPCO       WDVRLHEKSSELRAFG--AGIYLWHNGLRVLEGLGALDDVLQGS---------HTPPTYE 83 
RebC        VGHLVVEQTDGTITHP--RVGTIGPRSMELFRRWGVAKQIRTAG-WPGDHPLDAAWVTRV 86 
phzS        GKVTLLESSSEIRPLG--VGINIQPAAVEALAELGLGPALAATA-----IPTHELRYIDQ 81 
AVH         VRVLVVERRPGLSPYP--RAAGQNPRTMELLRIGGVADEVVRADDIRGTQGDFVIRLAES 86 
m-HBH       IRTCIVEQKEGPMELG--QADGIACRTMEMFEAFEFADSILKEACWINDVTFWKPDPAQP 114 
                : :                    :           :                     
 
PfKMO       RMVHVPGTPPNLQPYGRDDSEVIWSINR-----DRLNRILLDGAEAAGASIHFNLGLDSV 138 
p-HBH       AGQRRRIDLKRLSGGKTVTVYGQTEVTR---------DLMEAREACGATTVYQAAEVRLH 130 
PhH         GHIRRTDRIPDTLPGISRYHQVVLHQGR-IERR-ILDSIAEISDTRIKVERPLIPEKMEI 150 
PQSL        GELLRYFNYSSVDARGYFILMPCESLRR---------LVLEKIDGEATVEMLFETRIEAV 133 
MHPCO       TWMHNKSVSKETFNGLPWRIMTRSHLHD----------ALVNRARALGVDISVNSEAVAA 133 
RebC        GGHEVYRIPLGTADTRATPEHTPEPDAIC-----PQHWLAPLLAEAVGERLRTRSRLDSF 141 
phzS        SGATVWSEPRGVEAGNAYPQYSIHRGEL------QMILLAAVRERLGQQAVRTGLGVERI 135 
AVH         VRGEILRTVSESFDDMVAATEPCTPAGWAMLSQDKLEPILLAQARKHGGAIRFGTRLLSF 146 
m-HBH       GRIARHGRVQDTEDGLSEFPHVILNQAR-VHDH-YLERMRNS-PSRLEPHYARRVLDVKI 171 
                                                                             
 
PfKMO       DFARQR--------LTLSNVS--------------------------------------- 151 
p-HBH       DLQGER--------PYVTFER--------------------------------------- 143 
PhH         DSSKAEDPEAYPVTMTLRYMSEDESTPLQFGHKTENGLFRSNLQTQEEEDANYRLPEGKE 210 
PQSL        QRDERH---------AIDQVR--------------------------------------- 145 
MHPCO       D--------------PVGRLT--------------------------------------- 140 
RebC        EQRDDH------VRATITDLR--------------------------------------- 156 
phzS        EERDGR--------VLIGARDG-------------------------------------- 149 
AVH         RQHDDDAG----AGVTARLAG--------------------------------------- 163 
m-HBH       DHGAAD----YPVTVTLERCD------------------------------------AAH 191 
                                                                            
 
PfKMO       -GERLEKRFHLLIGADGCNSAVRQAMAS-VVDLGEHLETQPHGYKELQITPEASAQFNLE 209 
p-HBH       DGERLRLDCDYIAGCDGFHGISRQSIP--------AERLKVFERVYPFGWLGLLADTPPV 195 
PhH         AGEIETVHCKYVIGCDGGHSWVRRTLG--FEMIG-EQTDYIWGVLD-AVPASNFPDIRSR 266 
PQSL        LNDGRVLRPRVVVGADGIASYVRRRL----LDIDVERRPYPSPMLVGTFALAPCVAERNR 201 
MHPCO       LQTGEVLEADLIVGADGVGSKVRDSIG-FKQDRWVSKDGLIRLIVPRMKKELGHGEWDNT 199 
RebC        TGATRAVHARYLVACDGASSPTRKALG--IDAPPRHRTQVFRNILFRAPELRSLLGERAA 214 
phzS        HGKPQALGADVLVGADGIHSAVRAHLHPDQRPLSHGGITMWRGVTEFDRFLDGKTMIVAN 209 
AVH         PDGEYDLRAGYLVGADGNRSLVRESLG--IGRYGHGTLTHMVGVIF-DADLSGIMEPGTT 220 
m-HBH       AGQIETVQARYVVGCDGARSNVRRAIG--RQLVG-DSANQAWGVMD-VLAVTDFPDVRYK 247 
                       : ..**  .  *  :                                   
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PfKMO       PNALHIWPHGDYMCIALPNLDRSFTVTLFLHHQSPAAQPASPCFAQLVDGHAARRFFQRQ 269 
p-HBH       SHELIYANHPRGFALCSQRSATRSRYYVQVPLTEK----------VEDWSDERFWTELKA 245 
PhH         --CAIHSAESGSIMIIPREN-NLVRFYVQLQARAE--KGGR----VDRTKFTPEVVIANA 317 
PQSL        ----LYVDSQGGLAYFYPIGFDRARLVVSFPREEA--RELM----ADTRGESLRRRLQRF 251 
MHPCO       IDMWNFWPRVQRILYSPCNENELYLGLMAPAADPR----------GSSVPIDLEVWVEMF 249 
RebC        LFFFLMLSSSLRFPLRALDGRGLYRLTVGVDD-------------------ASKSTMDSF 255 
phzS        DEHWSRLVAYPISARHAAEGKSLVNWVCMVPSAAVGQLDNEADWNRDGRLEDVLPFFADW 269 
AVH         G-WYYLHHPEFKGTFGPTDRPDRHTLFVEYDP------DEG----ERPEDFTPQRCVELI 269 
m-HBH       --VAIQSEQ-GNVLIIPREGGHLVRFYVEMDK-LD--ADER----VASRNITVEQLIATA 297 
                                                                             
 
PfKMO       FPDLSPMLDSLEQDFEHHPTGKLATLRLTTWHVGG-----------QAVLLGDAAHPMVP 318 
p-HBH       RLPAEVAEKLVTGPSLEKSIAPLRSFVVEPMQHGR------------LFLAGDAAHIVPP 293 
PhH         KKIFHPYTFDVQQLDWFTA-YHIGQRVTEKFSKDE-----------RVFIAGDACHTHSP 365 
PQSL        VGDESAEAIAAVTGTSRFKGIPIGYLNLDRYWADN------------VAMLGDAIHNVHP 299 
MHPCO       PFLEPCLIEAAKLKTARYDKYETTK--LDSWTRGK------------VALVGDAAHAMCP 295 
RebC        ELVRRAVAFDTEIEVLSDSEWHLTHRVADSFSAGR------------VFLTGDAAHTLSP 303 
phzS        DLGWFDIRDLLTRNQLILQYPMVDRDPLPHWGRGR------------ITLLGDAAHLMYP 317 
AVH         GLALDAPEVKPELVDIQG--WEMAARIAERWREGR------------VFLAGDAAKVTPP 315 
m-HBH       QRVLHPYKLDVKNVPWWSV-YEIGQRICAKYDDVADAVATPDSPLPRVFIAGDACHTHSP 356 
                                                             : *** :   * 
 
PfKMO       FHGQGMNCALEDAVALAEHLQSAADNASA----LAAFTAQRQPDALAIQAMALEN----- 369 
p-HBH       TGAKGLNLAASDVSTLYRLLLKAYREGRG--ELLERYSAICLRRIWKAERFSW------- 344 
PhH         KAGQGMNTSMMDTYNLGWKLGLVLTGRAK-RDILKTYEEERQPFAQALIDFDHQFSRLFS 424 
PQSL        ITGQGMNLAIEDASALADALDLALRDACALEDALAGYQAERFPVNQAIVSYGH------- 352 
MHPCO       ALAQGAGCAMVNAFSLSQDLEEGSSVEDA----LVAWETRIRPITDRCQALSG------- 344 
RebC        SGGFGMNTGIGSAADLGWKLAATLRGWAG-PGLLATYEEERRPVAITSLEEAN------- 355 
phzS        MGANGASQAILDGIELAAALARNADVAAA----LREYEEARRPTANKIILANR------- 366 
AVH         TGGMSGNAAVADGFDLAWKLAAVLQGQAG-AGLLDTYEDERKVAAELVVAEAL------- 367 
m-HBH       KAGQGMNFSMQDSFNLGWKLAAVLRKQCA-PELLHTYSSERQVVAQQLIDFDREWAKMFS 415 
              . . . .  .   *   *             *  :                        
 
PfKMO       -----------------YVEMSSKVASPTYLLERELG-----------------QIMAQR 395 
p-HBH       -----------------WMTSVLHRFPDTDAFSQRIQ----------------QTELEYY 371 
PhH         GRPAKDVADEMGVSMDVFKEAFVKGNEFASGTAINYDENLVTDKKSSKQELAKNCVVGTR 484 
PQSL        ----------------ALATSLEDRQRFAGVFDTALQ--------------------GSS 376 
MHPCO       ----------------------------DYAANRSLS-------------------KGNM 357 
RebC        -----------VNLRRTMDRELPPGLHDDGPRGERIR-----------------AAVAEK 387 
phzS        -----------------------EREKEEWAAASRPK----------------------T 381 
AVH         ---------------AIYAQRMAPHMAEVWDKSVGYP----------------ETLLGFR 396 
m-HBH       --DPAKEGGQGGVDPKEFQKYFEQHGRFTAGVGTHYAPSLLTG-QASHQALASGFTVGMR 472 
                                                                             
 
PfKMO       QPTRFIPRYSMVTFSRLPYAQAMARGQIQEQLLKFAVAN-HSDLTSINLDAVEHEVTRCL 454 
p-HBH       LGSEAGLATIAENYVGLPYEEIE  -  394 
PhH         FKSQPVVRHSEGLWMHFGDRLVT---DGRFRIIVFAGKATDATQMSRIKKFAAYLDSENS 541 
PQSL        RTPEALGGERSYQPVRSPAPLG  -  398 
MHPCO       FTPAALEAARYDPLRRVYSWPQ  -  379 
RebC        LERSGARREFDAPGIHFGHTYRSSIVCGEPETEVATGGWRPSARPGARAPHAWLTPTTST 447 
phzS        EKSAALEAITGSYRNQVERPR  -  402 
AVH         YRSSAVLATDDDP-ARVENPLTP---SGRPG---FRGPHVLVSRHGERLSTVDLFGDGWT 449 
m-HBH       FHSAPVVRVSDAKPLQLGHCGKA---DGRWRLYAFAGQNDLAQPESGLLALCRFLESDAA 529 
                                                                             
 
PfKMO       PPLSHLC  -  461 
PhH         -VISRYTPKGADRNSRIDVITIHSCHRDDIEMHDFPAPALHPKWQY---DFIYADCDSWH 597 
RebC        LDLFGRG-----------FVLLSFGTTDGVEAVTR---------------AFADRHVPLE 481 
AVH         LLAGELG---------ADWVAAAEAVSAELGVPVR----------------AYRVGAGLT 484 
m-HBH       SPLRRFTPSGQDIDSIFDLRAIFPQAYTEVALETLPALLLPPKGQLGMIDYEKVFSPDLK 589 
                                         :                            .       
 
PhH         HPHPKSYQAWGVDETKGAVVVVRPDGYTSLVTDLEGTAEIDRYFSGILVEPKEKSGAQTE 657 
RebC        TVTCHAPEIHALY--ERAHVLVRPDGHVAWRGD-HLPAELGGLVDKVRGAA  -  529 
AVH         DPESAVSERYGIG--KAGASLVRPDGIVAWRTD-EAAADAAQTLEGVLRRVLDR  -  535 
m-HBH       NAGQDIFELRGIDRQQGALVVVRPDQYVAQVLPLGDHAALSAYFESFMRA  -  639 
                   :  ::   . : .:****  .:        * .   .  .                                               
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1.3 Analysis of KMO sequence alignments 
 
Residues that are 100 % identical (green) and 100 % conserved (yellow) from separate KMO 
sequence alignments are highlighted on the respective representative sequences.  
H.sapiens KMO represents an alignment of mammalian KMO sequences (12 sequences). 
C.elegans KMO represents an alignment of worm and insect KMOs (37 sequences). 
S.cerevisiae KMO represents an alignment of fungi KMOs (35 sequences). 
PfKMO (All bact) represents an alignment of bacterial KMOs (43 sequences). 
PfKMO (close Hs) represents an alignment of just the most similar bacterial homologs to 
PfKMO (10 sequences). 
 
h.sapiens KMO     ------------MDSSVIQRKKVAVIGGGLVGSLQACFLAKRNFQIDVYEAREDTRVATF 48 
C.elegans KMO     ------------MPS-------VAIAGAGLVGALNACFFAQKGWDVSVYEFRKDIRTMKH 41 
S.cerevisiae KMO  ------------MSES------VAIIGAGLVGCLAALAYSKEGYNVTLFDYRQDPRLDTT 42 
PfKMO (All Bact)  -------------MTATDNARQVTIIGAGLAGTLVARLLARNGWQVNLFERRPDPRIETG 47 
PfKMO (Close Hs)  -------------MTATDNARQVTIIGAGLAGTLVARLLARNGWQVNLFERRPDPRIETG 47 
                                         
h.sapiens KMO     TRG--RSINLALSHRGRQALKAVG--LEDQIVSQGIPMRARMIHSLSGKK-SAIPYGTKS 103 
C.elegans KMO     VQG--RSINLALSQRGKSALEAVG--LKEYIVNQGVPLYARLIHNKDGKTYSRQPYGKPG 97 
S.cerevisiae KMO  KNKNLKSINLAISARGIDALKSIDPDACEHILQDMIPMKGRMIHDLKGRQ-ESQLYGLHG 101 
PfKMO (All Bact)  ARG--RSINLALAERGAHALRLAG--LEREVLAEAVMMRGRMVH-VPGTPPNLQPYGRDD 102 
PfKMO (Close Hs)  ARG--RSINLALAERGAHALRLAG--LEREVLAEAVMMRGRMVH-VPGTPPNLQPYGRDD 102 
                      
h.sapiens KMO     -QYILSVSRENLNKDLLTAAEKYPNVKMHFNHR----------LLKCNPEEGM-ITVLGS 151 
C.elegans KMO     -EHIVSINRRHLNEVMITQAEKSPNVKFFFEHKVKNVDYDKKQLVVQCTSQPSKIPTFGN 156 
S.cerevisiae KMO  -EAINSINRSVLNNSLLDELEKS-TTELKFGHK----------LVKIEWTDDKQICHFAI 149 
PfKMO (All Bact)  SEVIWSINRDRLNRILLDGAEAA-GASIHFNLG----------LDSVDFARQRLTLSNVS 151 
PfKMO (Close Hs)  SEVIWSINRDRLNRILLDGAEAA-GASIHFNLG----------LDSVDFARQRLTLSNVS 151 
 
h.sapiens KMO     DKVPK-----DVTCDLIVGCDGAYSTVRSHLMKKPRFDYSQQYIPHGYMELTIPPKN--- 203 
C.elegans KMO     KSPPQEHAEFHVEADLILACDGAYSAVRRSLMTIPRFDFSQEYIEHGYVELNIMANN--- 213 
S.cerevisiae KMO  GEDLKTP--HTEKYDFVIGCDGAYSATRSQMQRKVEMDFSQEYMNLRYIELYIPPTEEFK 207 
PfKMO (All Bact)  GERLEKR------FHLLIGADGCNSAVRQAMASVVDLGEHLETQPHGYKELQITPEAS-- 203 
PfKMO (Close Hs)  GERLEKR------FHLLIGADGCNSAVRQAMASVVDLGEHLETQPHGYKELQITPEAS-- 203 
 
h.sapiens KMO     ----GDYAMEPNYLHIWPRNTFMMIALPNMNKSFTCTLFM--------PFEEFEKLL-TS 250 
C.elegans KMO     ----NEFAFEENVFHLWPRGHFTLIALANRDKTFTVTIFA--------PFSEFEKHMSTS 261 
S.cerevisiae KMO  PNYGGNFAIAPDHLHIWPRHKFMLIALANSDGSFTSTFFG--------SKDQISDLITSK 259 
PfKMO (All Bact)  ----AQFNLEPNALHIWPHGDYMCIALPNLDRSFTVTLFLHHQSPAAQPASPCFAQLVDG 259 
PfKMO (Close Hs)  ----AQFNLEPNALHIWPHGDYMCIALPNLDRSFTVTLFLHHQSPAAQPASPCFAQLVDG 259 
 
h.sapiens KMO     NDVVDFFQKYFPDAIPLIGEKLLVQDFFLLPAQPMISVKCSSFHFKS-HCVLLGDAAHAI 309 
C.elegans KMO     EDVLSFFEENFPDAFLLLGKEHIADTFNRVKPQPLVSIKCSPHSFFD-NLVLMGDAAHAM 320 
S.cerevisiae KMO  SRVREFLIENFPDIINIMDLDDAVKRFITYPKESLVCVNCKPYDVPGGKAILLGDAAHAM 319 
PfKMO (All Bact)  HAARRFFQRQFPDLSPMLDS--LEQDFEHHPTGKLATLRLTTWHVGG-QAVLLGDAAHPM 316 
PfKMO (Close Hs)  HAARRFFQRQFPDLSPMLDS--LEQDFEHHPTGKLATLRLTTWHVGG-QAVLLGDAAHPM 316 
 
h.sapiens KMO     VPFFGQGMNAGFEDCLVFD-ELMDKFSNDLSLCLPVFSRLRIPDDHAISDLSMYNYIEMR 368 
Caen.ele_KMO      VPFYGQGMNCGFEDCLVFS-ETLEEYGNDIAKAVKVYSDGRVNDAHSINDLAMYNYEELK 379 
S.cerevisiae KMO  VPFYGQGMNCGFEDVRILM-ALLKKHSGDRSRAFTEYTQTRHKDLVSITELAKRNYKEMS 378 
PfKMO (All Bact)  VPFHGQGMNCALEDAVALA-EHLQSAA-DNASALAAFTAQRQPDALAIQAMALENYVEMS 374 
PfKMO (Close Hs)  VPFHGQGMNCALEDAVALA-EHLQSAA-DNASALAAFTAQRQPDALAIQAMALENYVEMS 374 
 
h.sapiens KMO     AHVNSSWFIFQKNMERFLHAIMPSTFIPLYTMVTF-SRIRYHEAVQRWHWQKKVINKGLF 427 
C.elegans KMO     DLVNKSSYKLRKKFDTIMNSIFPKSWIPLYSMVTF-SRIPYSEVIERRKRQDKILSR--- 435 
S.cerevisiae KMO  HDVTSKRFLLRKKLDALFSIIMKDKWIPLYTMISFRSDISYSRALERAGKQTRILKF--- 435 
PfKMO (All Bact)  SKVASPTYLLERELGQIMAQRQPTRFIPRYSMVTF-SRLPYAQAMARGQIQEQLLKFA-- 431 
PfKMO (Close Hs)  SKVASPTYLLERELGQIMAQRQPTRFIPRYSMVTF-SRLPYAQAMARGQIQEQLLKFA-- 431 
 
h.sapiens KMO     FLGSLIAISSTYLLIHYMSPRSFLRLRRPWNWIAHFRNTTCFPAKAVDSLEQISNLISR- 486 
C.elegans KMO     ----IMTTTSTLALIGAAAG------------IYVNRGKLGL------------------ 461 
S.cerevisiae KMO  -------LESLTLGMLSIGG--------------YKLFKFLTRERS-------------- 460 
PfKMO (All Bact)  -----VANHSDLTSINLDA--------------VEHEVTRCLPPLSHLC----------- 461 
PfKMO (Close Hs)  -----VANHSDLTSINLDA--------------VEHEVTRCLPPLSHLC----------- 461 
224 
1.4 Alignment to FAH sequences - secondary structure prediction 
 
CLUSTAL W2 (2.0.10) multiple sequence alignment with secondary structure information 
labelled with -sheets in yellow and -helices in red. For PfKMO the data is based on 
secondary structure predictions as described in section 3.2.3. 
 
 
3ihg           ------MNDHEVDVLVVGAGLGGLSTAMFLARQG-----VRVLVVERRPG-LSPYPRA---  46 
2qa1           AHHHHHHHRSDAAVIVVGAGPAGMMLAGELRLAG-----VEVVVLERLVE-RTGESRG---  52 
1foh           ----TKYSESYCDVLIVGAGPAGLMAARVLSEYVRQKPDLKVRIIDKRST-KVYNGQA---  53 
2x3n           -----GMTDNHIDVLINGCGIGGAMLAYLLGRQG-----HRVVVVEQARR-ERAINGA---  46 
3c96           -------MSEPIDILIAGAGIGGLSCALALHQAG----IGKVTLLESSSE-IRPLGVG---  46 
2y6r           -----MNLLSDKNVAIIGGGPVGLTMAKLLQQNG---IDVSVYERDNDRE-ARIFGGT---  49 
3gmc           MANVNKTPGKTRRAEVAGGGFAGLTAAIALKQNG-----WDVRLHEKSSE-LRAFGAG---  52 
2vou           ------MSPTTDRIAVVGGSISGLTAALMLRDAG-----VDVDVYERSPQPLSGFGTG---  48 
PfKMO          ----MTATDNARQVTIIGAGLAGTLVARLLARNG-----WQVNLFERRPDPRIETGARGRS  52 
1dod           ---------MKTQVAIIGAGPSGLLLGQLLHKAG-----IDNVILERQTPDYVLGRIR---  44 
                            . : *.:  *   .  *               :               
 
3ihg           -AGQNP-RTMELLRIGGVADEVVRADDIRGTQGDFVIRLAESVRGEILRTVSESFDDMVAA 105 
2qa1           -LGFTA-RTMEVFDQRGILPRFGEVETS--TQGHFGG-------------LPIDFGVLEGA  96 
1foh           -DGLQC-RTLESLKNLGLADKILSEANDMSTIALYNPDEN----GHIRRTDRIPDTLPGIS 108 
2x3n           -DLLKP-AGIRVVEAAGLLAEVTRRGGRVRHELEVYHD------GELLRYF--------NY  91 
3c96           -INIQP-AAVEALAELGLGPALAATAIPTHELRYIDQS------GATVWSEPR------GV  93 
2y6r           -LDLHKGSGQEAMKKAGLLQTYYDLALPMGVNIADAA-------GNILSTK--------NV  94 
3gmc           -IYLWH-NGLRVLEGLGALDDVLQGSHTPPTYETWMHN-------KSVSKE----------  94 
2vou           --IVVQPELVHYLLEQGVELDSISVPSSSMEYVDALT-------GERVGSVP---------  90 
PfKMO          INLALAERGAHALRLAGLEREVLAEAVMMRGRMVHVPGTP-------PNLQPY--------  98 
1dod           -AGVLEQGMVDLLREAGVDRRMARDGLVHEGVEIAFA-------GQRRRID---------L  87 
                           .   *                                            
 
3ihg           TEPCTPAGWAMLSQDKLEP-ILLAQARKH-GGAIRFGTRLLSFRQHD-DDAGAGVTARLAG 163 
2qa1           WQAAK-----TVPQSVTET-HLEQWATGL-GADIRRGHEVLSL-----TDDGAGVTVEVRG 145 
1foh           -RYHQVVLHQGRIERHILDSIAEISDTRIKVERPLIPEKMEIDSSKAEDPEAYPVTMTLRY 168 
2x3n           SSVDARGYFILMPCESLRRLVLEKID-GEATVEMLFETRIEAVQRDERH-----AIDQVRL 146 
3c96           EAGNAYPQYSIHRGELQMILLAAVRERLGQQAVRTGLGVERIEER------DGRVLIGARD 148 
2y6r           KPENRFDNPEINRNDLR----AILLNSLENDTVI-WDRKLVMLEP-----GKKKWTLTFEN 145 
3gmc           -TFNGLPWRIMTRSHLHDA--LVNRARAL-GVDISVNSEAVAAD--------PVGRLTL-- 141 
2vou           ------ADWRFTSYDSIYG---GLYELFG-PERYHTSKCLVGLSQ-------DSETVQMRF 134 
PfKMO          GRDDSEVIWSINRDRLNRI--LLDGAEA-AGASIHFNLGLDSVD-------FARQRLTLSN 149 
1dod           KRLSGGKTVTVYGQTEVTR-DLMEAREAC-GATTVYQAAEVRLH----DLQGERPYVTFER 143 
                                    .                                         
                
3ihg           ----------------------------------------PDGE-YDLRAGYLVGADGNRS 183 
2qa1           ----------------------------------------PEGK-HTLRAAYLVGCDGGRS 165 
1foh           MSDHESTPLQFGHKTENSLFHSNLQTQEEEDANYRLPEGKEAGEIETVHCKYVIGCDGGHS 229 
2x3n           ----------------------------------------NDGR--VLRPRVVVGADGIAS 165 
3c96           ----------------------------------------GHGKPQALGADVLVGADGIHS 169 
2y6r           ----------------------------------------KPSE----TADLVILANGGMS 162 
3gmc           ----------------------------------------QTGE--VLEADLIVGADGVGS 160 
2vou           ----------------------------------------SDGT--KAEANWVIGADGGAS 153 
PfKMO          ----------------------------------------VSGERLEKRFHLLIGADGCNS 170 
1dod           -----------------------------------------DGERLRLDCDYIAGCDGFHG 163 
                                                         :        .:. .:*  :  
 
3ihg           LVRESLGI--GRYG-HGTLTHMVGVIFDADLSGIMEPGTTGWYYLHHPEFKGTFGPTDRPD 241 
2qa1           SVRKAAGF--DFPGTAATMEMYLADIKGVELQPRMIG-------ETLPGGMVMVGPLPGGI 217 
1foh           WVRRTLGF--EMIGEQ---TDYIWGVLDAVPASNFPDIRSRCAIHSAESGSIMIIPRENNL 285 
2x3n           YVRRRLLD--IDVERRPYPSPMLVGTFALAPCVAERN----RLYVDSQGGLAYFYPIGFDR 220 
3c96           AVRAHLHP--DQRPLSHGGITMWRGVTEFDRFLDGKTMIVANDEHWSRLVAYPISARHAAE 228 
2y6r           KVRKFVTD--TEVEETGTFNIQADIHQPEINCPGFFQLCNGNRLMASHQGNLLFANPNNNG 221 
3gmc           KVRDSIGFKQDRWVSKDGLIRLIVPRMKKELGHGEWDNTIDMWNFWPRVQRILYSPCNENE 221 
2vou           VVRKRLLGIEPTYAGYVTWRGVLQPGEVADDVWNYFNDKFTYGLLDDGHLIAYPIPGRENA 214 
PfKMO          AVRQAMASVVDLGEHLETQPHGYKELQITPEASAQFNLEPNALHIWPHGDYMCIALPNLDR 231 
1dod           ISRQSIPAERLKVFERVYPFGWLGLLADTPPVSHEL-----IFANHPR-GFALCSQRSATR 218 
                .*                                                           
 
3ihg            -------RHTLFVEYDPDEG----ERPEDFTPQRCVELIG-LALDAPEVK---------P 280 
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2qa1            -------TRIIVCERGTPPQ----RRETPPSWHEVADAWK-RLTGDDIAH---------A 256 
1foh            -------VRFYVQLQARAEKGGRVDRTKFTPEVVIANAKK-IFHPYTFDV---------Q 328 
2x3n            -------ARLVVSFPREEARELMADTRGESLRRRLQRFVGDESAEAIAAV---------T 264 
3c96            -------GKSLVNWVCMVPSAAVGQLDNEADWNRDGRLEDVLPFFADWDLGWFDIRDLLT 281 
2y6r            -------ALHFGISFKTPDEWKNQTQVDFQNRNSVVDFLLKEFSDWDERYK-----ELIH 269 
3gmc            -------LYLGLMAPAADPRGSSVPIDLEVWVEMFPFLEPCLIEAAKLKT---------- 264 
2vou            ESPRLNFQWYWNVAEGPDLDELMTDVRGIRLPTSVHNNSLNPHNLRQFHSKGESLFKPFR 274 
PfKMO           ----SFTVTLFLHHQSPAAQPASPCFAQLVDGHAARRFFQRQFPDLSPMLD--------S 279 
1dod            ----------SRYYVQVPLSEKVEDWSDERFWTELKARLPSEVAEKLVTG---------- 258 
                                   
                                           
 
3ihg            ELVDIQGWEMAARIAERWREG----RVFLAGDAAKVTPPTGGMSGNAAVADGFDLAWKLA 336 
2qa1            EPVWVSAFGNATRQVTEYRRG----RVILAGDSAHIHLPAGGQGMNTSIQDAVNLGWKLG 312 
1foh            QLDWFTAYHIGQRVTEKFSKDE---RVFIAGDACHTHSPKAGQGMNTSMMDTYNLGWKLG 385 
2x3n            GTSRFKGIPIGYLNLDRYWAD----NVAMLGDAIHNVHPITGQGMNLAIEDASALADALD 320 
3c96            RNQLILQYPMVDRDPLPHWGRG---RITLLGDAAHLMYPMGANGASQAILDGIELAAALA 338 
2y6r            TTLSFVGLATRIFPLEKPWKSKRPLPITMIGDAAHLMPPFAGQGVNSGLVDALILSDNLA 329 
3gmc            -----ARYDKYETTKLDSWTRG---KVALVGDAAHAMCPALAQGAGCAMVNAFSLSQDLE 316 
2vou            DLVLNASSPFVTVVADATVDRMVHGRVLLIGDAAVTPRPHAAAGGAKASDDARTLAEVFT 334 
PfKMO           LEQDFEHHPTGKLATLRLTTWHVGGQAVLLGDAAHPMVPFHGQGMNCALEDAVALAEHLQ 339 
1dod            PSLEKSIAPLRSFVVEPMQHG----RLFLAGDAAHIVPPTGAKGLNLAASDVSTLYRLLL 314 
                                          . : **:.    *  . .   .  :   *   :  
 
3ihg            AVLQG-QAGAGLLDTYEDERKVAAELVVAEA--LAIYAQRMAPHMAEVWDKSVGYPETLL 393 
2qa1            AVVNG-TATEELLDSYHSERHAVGKRLLMNT--QAQGLLFLSGPEVQPLRDVLTELIQYG 369 
1foh            LVLTG-RAKRDILKTYEEERHAFAQALIDFD--HQFSRLFSGRPAKDVADEMGVSMDVFK 442 
2x3n            LALRDACALEDALAGYQAERFPVNQAIVSYG--HALATSLEDR------QRFAGVFDTAL 373 
3c96            RNADV----AAALREYEEARRPTANKIILAN--REREKEEWAAASRPKTEKSAALEAITG 392 
2y6r            DGKFN--SIEEAVKNYEQQMFIYGKEAQEES--TQNEIEMFKPDFTFQQLLNV - 378 
3gmc            EGSSV----EDALVAWETRIRPITDRCQALSGDYAANRSLSKGNMFTPAALEAARYDPLR 372 
2vou            KNHDL----RGSLQSWETRQLQQGHAYLNKVK-KMASRLQHGGSFEPGNPAFAFGLPKVD 389 
PfKMO           SAADN----ASALAAFTAQRQPDALAIQAMALENYVEMSSKVASPTYLLERELGQIMAQR 395 
1dod            KAYRE--GRGELLERYSAICLRRIWKAERFSWWMTSVLHRFPDTDAFSQRIQQTELEYYL 372 
                            :  :                                             
 
3ihg            GFRYRSSAVLATDDDPARVENPLTPSGRPGFRGPHVLVSRHGERLSTVDLFGDGWTLLAG 453 
2qa1            EVARHLAGMVSGLEITYDVGTGSHP--LLGKRMPALELTTATRETSSTELLHTARGVLLD 427 
1foh            EAFVKGNEFASGTAINYDENLVTDKKSSKQELAKNCVVGTRFKSQPVVRHSEGLWMHFGD 502 
2x3n            QGSSRTPEALGGERSYQPVRSPAPLG - 399 
3c96            SYRNQVERPRLE - 404 
2y6r             
3gmc            RVYSWPQ - 379 
2vou            EPSVVTNS - 397 
PfKMO           QPTRFIPRYSMVTFSRLPYAQAMARGQIQEQLLKFAVANHSDLTSINLDAVEHEVTRCLP 455 
1dod            GSEAGLATIAENYVGLPYEEIE - 394 
                                                                             
 
3ihg            ELGAD--------------------------WVAAAEAVSAELGVPVRAYRVGAGLTDPE 487 
2qa1            LADNP--------------------------RLRARAAAWSDR---------VDIVTAVP 452 
1foh            RLVTDGRFRIIVFAGKATDATQMSRIKKFSAYLDSENSVISLYTPKVSDRNSRIDVITIH 562 
PfKMO           PLSHLC - 461 
                 :                              : :  :: :              ::                                                           
 
3ihg            SAVSERYGIGK---------------------------------------AGASLVRPDG 508 
2qa1            GEVSATSGLRD---------------------------------------TTAVLIRPDG 473 
1foh            SCHRDDIEMHDFPAPALHPKWQYDFIYADCDSWHHPHPKSYQAWGVDETKGAVVVVRPDG 622 
                : .     : .                                       ..::::****           
 
3ihg            IVAWRTDEAAADAAQTLEGVLRRVLDR - 535 
2qa1            HVAWAAPGSHHDLPMALERWFGAPLTG - 500 
1foh            YTSLVTDLEGTAEIDRYFSGILVEPKEKSGAQTEADWTKSTA – 664 
                 ::: : .   .    :.  :   . 
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Appendix 2 – Structural inferences for human KMO 
 
2.1 Alignment of human KMO with PfKMO 
 
An alignment of the amino acid sequences of human KMO and PfKMO with residues within 
5, 6 and 8 Å of the substrate in the dm2 structure highlighted. The alignment shows strong 






PfKMO           -MTATDNARQVTIIGAGLAGTLVARLLARNGWQVNLFERRPDPRIETGARGRSINLALAE 59 
humanKMO        MDSSVIQRKKVAVIGGGLVGSLQACFLAKRNFQIDVYEAREDTRVATFTRGRSINLALSH 60 
                  ::. : ::*::**.**.*:* * :**:..:*::::* * *.*: * :*********:. 
                                         
PfKMO           RGAHALRLAGLEREVLAEAVMMRGRMVHVPGTPPNLQPYGRDDSEVIWSINRDRLNRILL 119 
humanKMO        RGRQALKAVGLEDQIVSQGIPMRARMIHSLSGKKSAIPYG-TKSQYILSVSRENLNKDLL 119 
                ** :**: .*** :::::.: **.**:*  .   .  ***  .*: * *:.*:.**: ** 
 
PfKMO           DGAEAAG-ASIHFNLGLDSVDFARQRLTLSNVSGERLEKRFHLLIGADGCNSAVRQAMAS 178 
humanKMO        TAAEKYPNVKMHFNHRLLKCNPEEGMITVLGSDKVPKDVTCDLIVGCDGAYSTVRSHLMK 179 
                 .**    ..:***  * . :  .  :*: . .    :   .*::*.**. *:**. : . 
 
PfKMO           VVDLGEHLETQPHGYKELQITPEASAQFNLEPNALHIWPHGDYMCIALPNLDRSFTVTLF 238 
humanKMO        KPRFDYSQQYIPHGYMELTIPPKN-GDYAMEPNYLHIWPRNTFMMIALPNMNKSFTCTLF 238 
                   :.   :  **** ** *.*:  .:: :*** *****:. :* *****:::*** *** 
 
PfKMO           LHHQSPAAQPASPCFAQLVDGHAARRFFQRQFPDLSPMLDS--LEQDFEHHPTGKLATLR 296 
humanKMO        MPFEE---------FEKLLTSNDVVDFFQKYFPDAIPLIGEKLLVQDFFLLPAQPMISVK 289 
                : .:.         * :*: .: .  ***: ***  *::..  * ***   *:  : ::: 
 
PfKMO           LTTWHVGGQAVLLGDAAHPMVPFHGQGMNCALEDAVALAEHLQSAADNAS-ALAAFTAQR 355 
humanKMO        CSSFHFKSHCVLLGDAAHAIVPFFGQGMNAGFEDCLVFDELMDKFSNDLSLCLPVFSRLR 349 
                 :::*. .:.********.:***.*****..:**.:.: * ::. ::: * .*..*:  * 
                             
PfKMO           QPDALAIQAMALENYVEMSSKVASPTYLLERELGQIMAQRQPTRFIPRYSMVTFSRLPYA 415 
humanKMO        IPDDHAISDLSMYNYIEMRAHVNSSWFIFQKNMERFLHAIMPSTFIPLYTMVTFSRIRYH 409 
                 **  **. ::: **:** ::* *. ::::::: :::    *: *** *:******: *  
                        
PfKMO           QAMARGQIQEQLLKFAVANHSDLTSIN-----------------------------LDAV 446 
humanKMO        EAVQRWHWQKKVINKGLFFLGSLIAISSTYLLIHYMSPRSFLRLRRPWNWIAHFRNTTCF 469 
                :*: * : *::::: .:   ..* :*.                               .. 
 
PfKMO           EHEVTRCLPPLSHLC-- 461 
humanKMO        PAKAVDSLEQISNLISR 486 







2.2 Homology model of human KMO tertiary structure 
 
Tertiary protein structure models for human KMO (yellow) were generated with the i.model 
online server (IBI Biosolutions pvt ltd) using the: i) substrate-bound (green) and ii) substrate-
free (mauve) dm2 PfKMO structures as templates. The resulting models are shown in figures 
A2.1 and A2.2 prepared using PyMol. The predicted trans-membrane region is highlighted in 
red and caused problems in the models. It is likely that the trans-membrane region actually 
forms a helix that extends out away from the rest of the protein. It could then span the outer 
mitochondrial membrane with the remaining C-terminal forty residues on the other side of 
the membrane, as depicted in figure A2.3. 
 
   
   
Figure A2.1 – human 
KMO model based on 
substrate-bound 
PfKMO structure 
Figure A2.2 – human 




    
 
The active site residues in the human model shown as sticks (see figure A2.4) are 
highly similar to the substrate-binding residues identified in the structures of PfKMO. 
The only difference is the labelled residue Phe-313, which relates to His-320 of the 
bacterial enzyme. FAD and L-Kyn are modelled in as green sticks. 
 
 
Figure A2.3 – Modified human substrate-bound 
model with C-terminal transmembrane extension 
(red) 
Figure A2.4 – Active site in human model 
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Appendix 3 – PfKMO X-ray data tables 
 
3.1 Selenomethionine-labelled substrate-bound dm2 PfKMO 
 
Table A3.1 – Data collection and refinement statistics for single SeMet dm2 L-Kyn-bound crystal 
 Peak Inflection HER LER 
Data collection     
Beamline I04 I04 I04 I04 
X-ray wavelength (Å) 0.9795 0.9797 0.9686 0.9873 
Space group I4122 I4122 I4122 I4122 
Average cell dimensions     
    a = b, c (Å) 149.9, 273.4 150.0, 273.4 149.9, 273.4 150.0, 273.5 
 ()  90.0 90.0 90.0 90.0 








Rmerge 0.140 (0.654) 0.137 (0.673) 0.137 (0.599) 0.114 (0.581) 
I / I 8.9 (2.7) 10.3 (2.8) 9.7 (3.1) 11.7 (3.3) 
Completeness (%) 99.9 (100.0) 98.8 (98.7) 99.7 (99.8) 98.8 (99.2) 
Redundancy 7.5 (7.7) 8.8 (9.0) 8.7 (9.0) 8.8 (9.0) 
Anomalous Redundancy 4.0 (4.1) 4.6 (4.6) 4.6 (4.6) 4.6 (4.6) 
     
Refinement     
Resolution (Å) 77.86-3.40    
No. reflections 20381    
Rwork / Rfree 0.249/0.281    
No. atoms     
    Protein     
    Ligand/ion     
    Water     
B-factors     
    Protein     
    Ligand/ion     
    Water     
rmsd     
    Bond lengths (Å) 0.005    
    Bond angles () 0.936    










3.2 Substrate-free dm2 PfKMO 
 
Table A3.2 – Data collection and refinement statistics for unbound and chloride-bound crystals 
 Unbound Chloride 
Data collection   
Beamline I24 I04 
X-ray wavelength (Å) 0.9778 0.9797 
Space group P21221 P21221 
Cell dimensions   
    a, b, c (Å) 104.9, 134.2, 188.3 105.0, 133.9, 189.1 
 ()  90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 75.59-2.26 (2.38-2.26)* 94.54-2.45 (2.58-2.45) 
Rmerge 0.055 (0.652) 0.063 (0.597) 
I / I 13.5 (2.0) 12.4 (2.0) 
Completeness (%) 99.4 (99.6) 97.8 (99.0) 
Redundancy 3.8 (3.7) 3.8 (3.6) 
   
Refinement   
Resolution (Å) 50.00-2.26 35.00-2.45 
No. reflections 117656 91114 
Rwork / Rfree 0.219/0.232 0.218/0.244 
No. atoms   
    Protein   
    Ligand/ion   
    Water   
B-factors   
    Protein   
    Ligand/ion   
    Water   
rmsd   
    Bond lengths (Å) 0.005 0.007 
    Bond angles () 0.940 1.113 












3.3 Substrate-bound C-terminal PfKMO mutants 
 
Table A3.3 – Data collection and refinement statistics for substrate-bound mutants. 
 Y382F dm2 R386K dm2 R386T dm2 E372T
 (†)
 dm2 
Data collection     
Beamline I04-1 I02 I03 I03 
X-ray wavelength (Å) 0.9200 0.9790 0.9763 0.9763 
Space group I4122 I4122 I4122 I4122 
Cell dimensions     
    a = b, c (Å) 150.2, 273.6 149.8, 273.5 149.7, 272.1 149.6, 270.7 
 ()  90.0 90.0 90.0 90.0 








Rmerge 0.095 (0.599) 0.070 (0.545) 0.088 (0.644) 0.088 (0.691) 
I / I 14.4 (3.6) 20.1 (4.9) 9.9 (2.3) 14.2 (2.8) 
Completeness (%) 99.7 (99.8) 100.0 (100.0) 99.9 (99.9) 99.9 (100.0) 
Redundancy 9.0 (9.1) 14.3 (14.8) 5.7 (5.7) 8.5 (8.8) 
     
Refinement     
Resolution (Å) 65.93-3.36 53.96-3.30 65.68-3.40 44.70-3.24 
No. reflections 21461 22568 20512 23527 
Rwork / Rfree 0.247/0.277 0.247/0.259 0.260/0.270 0.230/0.256 
No. atoms     
    Protein     
    Ligand/ion     
    Water     
B-factors     
    Protein     
    Ligand/ion     
    Water     
rmsd     
    Bond lengths (Å) 0.005 0.005 0.005 0.005 
    Bond angles () 0.900 0.953 0.981 0.966 
*Values in parentheses are for highest-resolution shell. 
(†)











3.4 Substrate-free C-terminal PfKMO mutants 
 
Table A3.4 – Data collection and refinement statistics for substrate-free mutant crystals. 








Data collection    
Beamline I04 I03 I03 
X-ray wavelength (Å) 0.9800 0.9763 0.9763 
Space group P21221 P21221 P21221 
Cell dimensions    
    a, b, c (Å) 105.2, 133.9, 188.5 105.4, 134.0, 189.5 104.7, 133.9, 189.1 
 ()  90.0 90.0 90.0 






Rmerge 0.115 (0.619) 0.106 (0.599) 0.072 (0.599) 
I / I 7.8 (2.0) 8.9 (2.6) 12.1 (2.5) 
Completeness (%) 98.3 (99.7) 97.6 (99.6) 99.8 (99.8) 
Redundancy 3.6 (3.6) 5.3 (5.1) 4.8 (4.9) 
    
Refinement    
Resolution (Å) 45.00-2.63  44.71-2.52 50.51-2.32 
No. reflections 74239 84072 109394 
Rwork / Rfree 0.225/0.241 0.223/0.241 0.221/0.242 
No. atoms    
    Protein    
    Ligand/ion    
    Water    
B-factors    
    Protein    
    Ligand/ion    
    Water    
rmsd    
    Bond lengths (Å) 0.005 0.005 0.005 
    Bond angles () 0.953 0.977 0.990 
*Values in parentheses are for highest-resolution shell. 
(†)












3.5 Substrate-analogue bound dm2 PfKMO 
 
Table A3.5 – Data collection and refinement statistics for substrate-analogue bound structures. 




Data collection   
Beamline I02 I24 
X-ray wavelength (Å) 0.9790 0.9778 
Space group I4122 I4122 
Cell dimensions   
    a = b, c (Å) 149.7, 273.0 149.4, 273.8 
 ()  90.0 90.0 




Rmerge 0.096 (0.799) 0.099 (0.651) 
I / I 7.9 (1.9) 11.2 (2.8) 
Completeness (%) 96.1 (97.9) 96.4 (97.3) 
Redundancy 4.5 (4.6) 8.0 (8.1) 
   
Refinement   
Resolution (Å) 44.76-3.55 34.56-3.37 
No. reflections 17259 20256 
Rwork / Rfree 0.247/0.254 0.237/0.239 
No. atoms   
    Protein   
    Ligand/ion   
    Water   
B-factors   
    Protein   
    Ligand/ion   
    Water   
rmsd   
    Bond lengths (Å) 0.005 0.004 
    Bond angles () 0.919 0.882 













3.6 Inhibitor-bound dm2 PfKMO 
 
Table A3.6 – Data collection and refinement statistics for inhibitor bound structures. 








Data collection     
Beamline I03 I04-1 I02 I02 
X-ray wavelength (Å) 0.9763 0.9200 0.9790 0.9790 
Space group P6122 P6122 P6122 P6122 
Cell dimensions     
    a = b, c (Å) 117.2, 418.2 117.7, 420.1 117.3, 418.1 117.5, 417.8 
= ()  90.0, 120.0 90.0, 120.0 90.0, 120.0 90.0, 120.0 








Rmerge 0.136 (0.547) 0.137 (0.549) 0.156 (0.682) 0.157 (0.675) 
I / I 12.7 (4.2) 11.0 (2.7) 11.0 (2.6) 12.5 (3.2) 
Completeness (%) 100.0 (99.9) 99.9 (99.2) 100.0 (99.9) 99.9 (99.6) 
Redundancy 10.7 (9.8) 10.1 (5.2) 11.1 (8.0) 14.9 (10.5) 
     
Refinement     
Resolution (Å) 46.52-2.18 45.00-2.15 58.12-2.40 36.00-2.30 
No. reflections 85024 89610 64181 72900 
Rwork / Rfree 0.197/0.238 0.208/0.234 0.203/0.248 0.202/0.229 
No. atoms     
    Protein     
    Ligand/ion     
    Water     
B-factors     
    Protein     
    Ligand/ion     
    Water     
rmsd     
    Bond lengths (Å) 0.005 0.006 0.005 0.005 
    Bond angles () 1.096 1.117 1.081 1.052 
*Values in parentheses are for highest-resolution shell. 
(†)












Appendix 4 – PfKMO Inhibition data 
4.1 Inhibition plots for GM141 
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4.5 Inhibition plots for GM769 
 
 
 
